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RÉSUMÉ DESTINÉ A UN LARGE PUBLIC 
Le mélanome cutané est un des cancers les plus agressifs et dont l’incidence augmente le 
plus en Suisse. Une fois métastatique, le pronostic de survie moyenne avec les thérapies 
actuelles est d’environ huit mois, avec moins de 5% de survie à cinq ans. Les récents 
progrès effectués dans la compréhension de la biologie de la cellule tumorale mais surtout 
dans l’importance du système immunitaire dans le contrôle de ce cancer ont permis le 
développement de nouveaux traitements novateurs et prometteurs. Ces thérapies, appelées 
immunothérapies, reposent sur la stimulation et l’augmentation de la réponse immunitaire à 
la tumeur. Alors que les derniers essais cliniques ont démontré l’efficacité de ces traitements 
chez les patients avec des stades avancés de la maladie, le contrôle de la maladie à long-
terme est seulement atteint chez une minorité des patients. La suppression locale et 
systémique de la réponse immunitaire spécifique anti-tumorale apparaitrait comme une des 
raisons expliquant la persistance d’un mauvais pronostic clinique chez ces patients. Des 
études sur les souris ont montré que les vaisseaux lymphatiques joueraient un rôle 
primordial dans ce processus en induisant une tolérance immune, ce qui permettrait à la 
tumeur d’échapper au contrôle du système immunitaire et métastatiser plus facilement. Ces 
excitantes découvertes n’ont pas encore été établi et prouvé chez l’homme. Dans cette 
thèse, nous montrons pour la première fois que les vaisseaux lymphatiques sont directement 
impliqués dans la modulation de la réponse immunitaire au niveau local et systémique dans 
le mélanome chez l’homme. Ces récentes découvertes montrent le potentiel de combiner 
des thérapies visant le système lymphatique avec les immunothérapies actuellement 
utilisées afin d’améliorer le pronostic des patients atteint du mélanome.  
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SUMMARY 
Cutaneous melanoma is one of the most invasive and metastatic human cancers and causes 
75% of skin cancer mortality. Current therapies such as surgery and chemotherapy fail to 
control metastatic disease, and relapse occurs frequently due to microscopic residual 
lesions. It is, thus, essential to develop and optimize novel therapeutic strategies to improve 
curative responses in these patients. In recent decades, tumor immunologists have revealed 
the development of spontaneous adaptive immune responses in melanoma patients, leading 
to the accumulation of highly differentiated tumor-specific T cells at the tumor site. This 
remains one of the most powerful prognostic markers to date. Immunotherapies that 
augment the natural function of these tumor-specific T cells have since emerged as highly 
attractive therapeutic approaches to eliminate melanoma cells. While recent clinical trials 
have demonstrated great progress in the treatment of advanced stage melanoma, long-term 
disease control is still only achieved in a minority of patients. Local and systemic immune 
suppression by the tumor appears to be responsible, in part, for this poor clinical evolution. 
These facts underscore the need for a better analysis and characterization of immune-
related pathways within the tumor microenvironment (TME), as well as at the systemic level. 
The overall goal of this thesis is, thus, to obtain greater insight into the complexity and 
heterogeneity of the TME in human melanoma, as well as to investigate immune modulation 
beyond the TME, which ultimately influences the immune system throughout the whole body. 
To achieve this, we established two main objectives: to precisely characterize local and 
systemic immune modulation (i) in untreated melanoma patients and (ii) in patients 
undergoing peptide vaccination or checkpoint blockade therapy with anti-cytotoxic T-
lymphocyte-asisctaed protein-4 (CTLA-4) antibody. In the first and main part of this thesis, 
we analyzed lymphatic vessels in relation to anti-tumor immune responses in tissues from 
vaccinated patients using a combination of immunohistochemistry (IHC) techniques, whole 
slide scanning/analysis, and an automatic quantification system. Strikingly, we found that 
increased lymphatic vessel density was associated with high expression of immune 
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suppressive molecules, low functionality of tumor-infiltrating CD8+ T cells and decreased 
cytokine production by tumor-antigen specific CD8+ T cells in the blood. These data revealed 
a previously unappreciated local and systemic role of lymphangiogenesis in modulating T cell 
responses in human cancer and support the use of therapies that target lymphatic vessels 
combined with existing and future T cell based therapies. In the second objective, we 
describe a metastatic melanoma patient who developed pulmonary sarcoid-like 
granulomatosis following repetitive vaccination with peptides and CpG. We demonstrated 
that the onset of this pulmonary autoimmune adverse event was related to the development 
of a strong and long-lasting tumor-specific CD8+ T cell response. This constitutes the first 
demonstration that a new generation tumor vaccine can induce the development of 
autoimmune adverse events. In the third objective, we assessed the use of Fourier 
Transform Infrared (FTIR) imaging to identify melanoma cells and lymphocyte 
subpopulations in lymph node (LN) metastasis tissues, thanks to a fruitful collaboration with 
researchers in Brussels. We demonstrated that the different cell types in metastatic LNs 
have different infrared spectral features allowing automated identification of these cells. This 
technic is therefore capable of distinguishing known and novel biological features in human 
tissues and has, therefore, significant potential as a tool for histopathological diagnosis and 
biomarker assessment. Finally, in the fourth objective, we investigated the role of colony-
stimulating factor-1 (CSF-1) in modulating the anti-tumor response in ipilimumab-treated 
patients using IHC and in vitro co-cultures, revealing that melanoma cells produce CSF-1 via 
CTL-derived cytokines when attacked by cytotoxic T lymphocytes (CTLs), resulting in the 
recruitment of immunosuppressive monocytes. These findings support the combined use of 
CSF-1R blockade with T cell based immunotherapy for melanoma patients. Taken together, 
our results reveal the existence of novel mechanisms of immune modulation and thus 
promote the optimization of combination immunotherapies against melanoma. 
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RÉSUMÉ 
Le mélanome cutané est un des cancers humains les plus invasifs et métastatiques et est 
responsable de 75% de la mortalité liée aux cancers de la peau. Les thérapies comme la 
chirurgie et la chimiothérapie ont échoué à contrôler le mélanome métastatique, par ailleurs 
les rechutes sous ces traitements ont été montrées fréquentes. Il est donc essentiel de 
développer et d’optimiser de nouvelles stratégies thérapeutiques pour améliorer les 
réponses thérapeutiques de ces patients. Durant les dernières décennies, les 
immunologistes spécialisés dans les tumeurs ont démontré qu’un patient atteint du 
mélanome pouvait développer spontanément une réponse immune adaptative à sa tumeur 
et que l’accumulation de cellules T spécifiques tumorales au sein même de la tumeur était un 
des plus puissants facteurs pronostiques. Les immunothérapies qui ont pour but 
d’augmenter les fonctions naturelles de ces cellules T spécifiques tumorales ont donc 
émergé comme des approches thérapeutiques très attractives pour éliminer les cellules du 
mélanome. Alors que les derniers essais cliniques ont démontré un progrès important dans 
le traitement des formes avancées du mélanome, le contrôle de la maladie à long-terme est 
seulement atteint chez une minorité des patients. La suppression immune locale et 
systémique apparaitrait comme une des raisons expliquant la persistance d’un mauvais 
pronostic clinique chez ces patients. Ces considérations soulignent la nécessité de mieux 
analyser et caractériser les voies immunitaires non seulement au niveau local dans le 
microenvironement tumoral mais aussi au niveau systémique dans le sang des patients. Le 
but de cette thèse est d’obtenir une plus grande connaissance de la complexité et de 
l’hétérogénéité du microenvironement tumoral dans les mélanomes mais aussi d’investiguer 
la modulation immunitaire au delà du microenvironement tumoral au niveau systémique. Afin 
d’atteindre  ce but, nous avons établi deux objectifs principaux : caractériser précisément la 
modulation locale et systémique du système immunitaire (i) chez les patients atteints du 
mélanome qui n’ont pas reçu de traitement et (ii) chez les patients qui ont été traités soit par 
des vaccins soit par des thérapies qui bloquent les points de contrôles. Dans la première et 
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majeure partie de cette thèse, nous avons analysé les vaisseaux lymphatiques en relation 
avec la réponse immunitaire anti-tumorale dans les tissus des patients vaccinés grâce à des 
techniques d’immunohistochimie et de quantification informatisé et automatique des 
marquages. Nous avons trouvé qu’une densité élevée de vaisseaux lymphatiques dans la 
tumeur était associée à une plus grande expression de molécules immunosuppressives ainsi 
qu’à une diminution de la fonctionnalité des cellules T spécifiques tumoral dans la tumeur et 
dans le sang des patients. Ces résultats révèlent un rôle jusqu’à là inconnu des vaisseaux 
lymphatiques dans la modulation directe du système immunitaire au niveau local et 
systémique dans les cancers de l’homme. Cette recherche apporte finalement des preuves 
du potentiel de combiner des thérapies visant le système lymphatique avec des autres 
immunothérapies déjà utilisées en clinique. Dans le second objectif, nous rapportons le cas 
d’un patient atteint d’un mélanome avec de multiples métastases qui a développé à la suite 
de plusieurs vaccinations répétées et consécutives avec des peptides et du CpG, un 
évènement indésirable sous la forme d’une granulomatose pulmonaire sarcoid-like. Nous 
avons démontré que l’apparition de cet évènement était intimement liée au développement 
d’une réponse immunitaire durable et spécifique contre les antigènes de la tumeur. Par là-
même, nous prouvons pour la première fois que la nouvelle génération de vaccins est aussi 
capable d’induire des effets indésirables auto-immuns. Pour le troisième objectif, nous avons 
voulu savoir si l’utilisation de la spectroscopie infrarouge à transformée de Fourier (IRTF) 
était capable d’identifier les cellules du mélanome ainsi que les différents sous-types 
cellulaires dans les ganglions métastatiques. Grâce à nos collaborateurs de Bruxelles, nous 
avons pu établir que les diverses composantes cellulaires des ganglions atteints par des 
métastases du mélanome présentaient des spectres infrarouges différents et qu’elles 
pouvaient être identifiées d’une façon automatique. Cette nouvelle technique permettrait 
donc de distinguer des caractéristiques biologiques connues ou nouvelles dans les tissus 
humains qui auraient des retombées pratiques importantes dans le diagnostic 
histopathologique et dans l’évaluation des biomarqueurs. Finalement dans le dernier objectif, 
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nous avons investigué le rôle du facteur de stimulation des colonies (CSF-1) dans la 
modulation de la réponse immunitaire anti-tumorale chez les patients qui ont été traités par 
l’Ipilimumab. Nos expériences in vivo au niveau des tissus tumoraux et nos co-cultures in 
vitro nous ont permis de démontrer que les cytokines secrétées par les cellules T spécifiques 
anti-tumorales induisaient la sécrétion de CSF-1 dans les cellules du mélanome ce qui 
résultait en un recrutement de monocytes immunosuppresseurs. Dans son ensemble, cette 
thèse révèle donc l’existence de nouveaux mécanismes de modulation de la réponse 
immunitaire anti-tumorale et propose de nouvelles optimisations de combinaison 
d’immunothérapies contre le mélanome. 
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INTRODUCTION 
 
1 Immune response 
The immune system may protect the host from potential tissue damage as seen during 
infection and cancer. The immune system is made up of two major arms, the innate and 
adaptive immune systems. The innate immune system is universal among animals and 
includes ancient forms of host defense against infection, while the adaptive immune system 
is more specialized and can be found only in vertebrates. 
1.1 Innate immune response 
Innate immunity provides the initial line of defense against microbes. Innate immune 
responses are induced by recognition of molecular structures common to related groups of 
microbes, and may not distinguish minor differences between invading pathogens. The 
innate immune system comprises several cell types, principally neutrophils, professional 
antigen-presenting cells (APCs) (i.e. macrophages, monocytes, dendritic cells (DC) and B 
cells) and natural killer (NK) cells. These cells express non-clonally distributed receptors 
called pattern recognition receptors (PRRs) that recognize pathogen-associated molecular 
patterns (PAMPs) found in microbes, or danger-associated molecular patterns (DAMPs) that 
are found in self-tissues (1). The binding of these molecules to their receptors on innate 
immune cells induces signal transduction, secretion of cytokines and chemokines, and 
maturation of DCs that promote the recruitment and activation of cells of the adaptive 
immune system. 
1.2 Adaptive immune response 
In contrast to innate immunity, more highly evolved defense mechanisms are stimulated by 
exposure to infectious agents and increase in magnitude and defensive capacity with each 
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successive exposure to a particular microbe. Since this form of immunity develops as a 
response to infection or inflammation and adapts during the course of the response, it is 
called adaptive immunity. The adaptive immune system is composed of two parts, called 
humoral immunity and cell-mediated immunity. The humoral response is mediated by B cells 
and is directed against extracellular pathogens such as bacteria, while the cellular response 
is directed against intracellular pathogens such as viruses. B and T cells express specific B 
cell receptors (BCR) and T cell-receptors (TCR) capable of recognizing a very large variety 
of potential pathogens. However, the repertoire of antigens recognized by any single BCR or 
TCR is very limited. 
Peptide antigens are presented on major histocompatibility complex (MHC) class I or II 
molecules on the cell surface. Cytosolic antigens are presented on MHC class I (present in 
almost any normal cell) and are recognized by TCRs of CD8+ T cells, while antigens in the 
endosomal compartment are presented on MHC class II (usually by APCs) and are 
recognized by TCRs of CD4+ T cells. CD4 and CD8 are two mutually exclusive co-receptors 
expressed by T cells. CD8 T cells have strong cytotoxic functions and are specialized to kill 
infected cells. CD4 T cells, also called T helper cells, support CD8 T cells in targeting and 
eliminating foreign antigens by producing cytokines such as the survival factor IL-2. CD4 T 
cells differentiate to specialized populations with dedicated functions, by polarizing into Th1, 
Th2, Th17, Th9, TFH and Treg cells. The presentation of a cognate antigenic peptide on MHC 
molecules by APCs and subsequent ligation of the TCR on naïve T lymphocytes in the lymph 
node (LN) is the first step in the induction of an adaptive immune response and is called 
priming (2). The successful development of the cellular immune response depends on this 
interaction. Once a T cell is activated, it proliferates, differentiates into effector cells and 
migrates to the inflamed tissues to eliminate cells displaying cognate antigen on the cell 
surface. After the T cell response reaches a peak the majority of the effector cells die, 
generally following the elimination of infected cells. Importantly, a minority of activated T cells 
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survive and become memory cells which are able to reactivate more quickly and strongly 
upon antigenic re-encounter. 
 
2 Anti-tumor immune response 
Cancer is the leading cause of death in developed countries (3). As described by Hanahan 
and Weinberg, cancer cells progressively acquire “hallmarks”, which allow them to survive, 
proliferate and eventually lead to clinically-detectable disease (4). Cancer cells are able to 
acquire these hallmarks in large part due to their genomic instability, and Darwinian selection 
of the most aggressive cells. Besides the properties that enable cancer cells to proliferate 
endlessly and resist cell death, cancer cells promote inflammatory mechanisms in the tumor 
microenvironment (TME) (5). Tumor-promoting inflammation is a powerful asset for the tumor 
as it facilitates access to necessary growth factors, as well as active prevention of tumor 
destruction by immune cells (6, 7). 
In the last decade, particular attention has been given to understanding the complex 
interactions between a developing tumor and the host immune system. It is known that the 
immune system operates as a significant barrier to tumor formation and progression in 
humans. Several studies have illustrated that a functional cancer immunosurveillance 
process actually exists. Firstly, immunosuppressed transplant recipients display higher 
incidence of nonviral cancer compared to an age-matched immunocompetent control 
population. A 4-fold increase in the incidence of in situ melanoma can be found in patients 
that have undergone transplants (8). Furthermore, in patients that have received organ 
transplants, melanoma constituted 5.2% of post-transplant skin cancers compared with an 
incidence of 2.7% in the general population (9). 
Secondly, cancer patients can also develop spontaneous adaptive and innate immune 
responses against cancer. Indeed, CD8+ and CD4+ T cell responses to tumor antigen have 
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been detected in the blood circulation as well as at tumor sites in patients (10, 11). It has also 
been found that tumor specific T cells can recognize tumor-derived epitopes and can kill 
tumor cells displaying these epitopes in vitro (12). The increased peripheral precursor 
frequency in cancer patients compared to healthy donors, as well as the proof of generation 
of memory cells at sites of antigen expression have been considered as hallmarks of 
immunization (13). Although these responses may not always be able to prevent the 
development of cancer they may, nevertheless, function to attenuate tumor growth. 
Finally, recent evidence points to the importance of the density of tumor-infiltrating 
lymphocytes (TILs) in relation to clinical outcome of cancer patients (14-16). The distribution 
of lymphocytes, as well as the quantification of the density and location of immune cells 
within the tumor (also termed immunoscore) has been shown to have a high prognostic 
impact (17-19). Specifically, high infiltration of memory Th1 and CD8+ T cells into the tumor 
microenvironment has been reported to correlate with favorable clinical impact in a large 
array of different types of tumors such as melanoma, head and neck, breast, ovarian, 
esophageal, prostate, lung, pancreatic, anal and urothelial cancer (20). The clinical impact of 
other T cell populations remains less clear. 
Taken together, these considerations highlight the important role that the immune system 
plays in protecting the host from tumor development and progression. 
2.1 Immune escape mechanisms and tumor microenvironment 
In spite of the development of an immune response to tumors and the accumulation of highly 
differentiated tumor-specific T cells at the tumor site, patients still frequently experience poor 
clinical evolution of their disease. This observation shed light on the existence of immune 
evasion mechanisms. 
Tumor escape mechanisms are numerous and diverse. Some changes occur directly at the 
level of the tumor cells (e.g. loss/down-regulation of antigen presentation, disruption of the 
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antigen processing machinery) while others involve modulation and disruption of the host 
immune system. 
Cancer cells may hamper the development of an anti-tumor immune response by negatively 
modulating T cell activation and proliferation and effector functions. These properties of T 
cells are necessary to protect the host from cancer or infections. Tumors develop several 
strategies to inhibit effector T cells. First, via expression of inhibitory surface receptors such 
as programmed-cell death ligand (PD-L1) and Fas ligand (FasL) (21). Second, via the 
production of certain cytokines such as transforming growth factor beta (TGF-β) (22) and, 
third, via the depletion of nutrients in the local environment such as arginine and tryptophan. 
The production of Indoleamine 2,3-dioxygenase (IDO), inducible nitric oxide synthase (iNOS) 
and arginase by cancer cells, as well as other cells such as macrophages and DCs, 
degrades tryptophan and arginine leading to functional T cell deficiency (23, 24). Other 
mechanisms by which tumors suppress T cells include inhibition of proinflammatory signals, 
attraction of immune suppressive cells such as T regulatory cells (Tregs) and myeloid-
derived suppressor cells (MDSC), and inhibition of DC maturation and CD4+ T helper cells 
(25). 
Over the past decades, it has been illustrated that tumor cells do not act in isolation, but are 
able to orchestrate fibroblasts, endothelial cells, pericytes, leukocytes, soluble factors and 
the extra-cellular matrix into a tumor-promoting microenvironment (TME). In this 
environment, malignant behavior is supported by the promotion of neoplastic transformation, 
tumor growth and invasion, protection from host immunity, development of therapeutic 
resistance, and establishment of niches for dormant metastases (26). There is increasing 
evidence that tumor evasion mechanisms (as described above) are, indeed, initiated and 
maintained by a constitutive interaction between tumors and the TME in mouse as well as in 
human cancers (27). 
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It has become clear that the TME is an inhospitable milieu for mounting an anti-tumor 
immune response. A thorough analysis of the immune suppressive mechanisms present in 
the TME is, thus, essential to better understand tumor/host interactions, upon which one can 
design novel immunotherapies that harness the full potential of the anti-tumor immune 
response. 
These principles apply to the majority of human cancers. However, we now know that cancer 
is an extremely heterogeneous disease in terms of, for example, the degree of genetic 
mutation of tumor cells or the extent of intratumoral infiltration by immune cells. Even within a 
single diagnostic group such as ‘colorectal cancer’ or ‘breast cancer’ there may be huge 
diversity. We have chosen to study human melanoma, a disease with frequent involvement 
of inflammatory mechanisms and immune cell infiltration. 
 
3 Melanoma 
Melanoma is a solid malignant tumor originating from the specialized pigmented cells known 
as melanocytes. Melanocytes are essential to protect the skin from the damaging effects of 
UV radiation by secreting the brown pigment, melanin. Melanoma arises most frequently 
from melanocytes in the skin, but melanoma may also develop from the eyes or mucosa. 
3.1 Epidemiology and risk factors 
Cutaneous melanoma is one of the most invasive and metastatic human cancers and causes 
75% of skin cancer mortality. Worldwide about 160,000 new cases of melanoma are 
diagnosed annually and melanoma incidence has risen 3-8% per year since the mid-1960s 
(28). At current rates, the lifetime risk for Caucasian men to develop invasive melanoma is 1 
in 39 and 1 in 58 in women. This contrasts dramatically with a lifetime risk of 1 in 1500 for 
people born in 1935 (29). Of all cancers, cutaneous melanoma ranks with the fifth incidence 
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among men and seventh among women and is the second leading cause of lost productive 
years (30). Therefore, this cancer has become an increasingly significant public heath 
problem. 
Geographical latitude, severe episodic sunburn in early life, and tanning bed exposure are 
important factors associated with melanoma (31). Other risk factors are a family history, 
immunosuppression, previous melanoma and the presence of multiple clinically atypical nevi. 
The locations on the body at which the disease most frequently occurs reflects its primary 
cause, UV exposure, as well as a relationship with the amount of skin pigmentation (32). 
3.2 Pathogenesis 
The pathogenesis of human melanocyte transformation remains to be fully understood. 
Ultraviolet solar radiation promotes malignant change in the skin via direct mutagenic effects 
on DNA. Specifically, the cellular constituents of the skin are stimulated to produce growth 
factors, cutaneous immune defenses are suppressed, and production of reactive oxygen 
species is promoted, leading to deoxyribonucleic acid (DNA) damage and suppression of 
apoptosis (28). Melanocytes progress through a series of steps toward malignant 
transformation by accumulating genetic abnormalities. Clark et al, proposed a model based 
on histopathological and clinical features that depict the proliferation of melanocytes in the 
process of forming nevi (e.g. benign nevi) and the subsequent development of dysplasia 
(e.g. dysplastic nevi), hyperplasia (e.g. radial-growth phase in the epidermis), invasion (e.g. 
vertical growth phase in the dermis) and metastasis (e.g. metastatic melanoma) (33). The 
frequency of the progression of nevi toward malignant lesions is still unknown and the 
majority of dysplastic nevi will not result in melanoma. Several models of the genetic basis of 
melanoma development and progression are based on Clark’s multi-step model. However, 
some studies have challenged this model by showing that melanoma may arise de novo from 
non-melanocytic nevi (34). 
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3.3 Diagnosis 
The most important factor for successful management of melanoma is early diagnosis. 
Melanoma is usually diagnosed by phenotypical pigmentation alterations. The mnemonic 
“ABCD” (Asymmetry, Border irregularity, Color variegation, Diameter >6 mm) created 20 
years ago have helped both clinicians and laypersons to recognize melanoma in its early 
clinical presentation (35). Nevertheless, any significant change in existing nevi or skin lesions 
should raise clinical suspicion because some melanomas do not display the classical 
features. Indeed, in some studies more than 50% of nodular melanoma were predominantly 
amelanotic (red or pink) (28). During the last decade, new computer-based technologies 
have improved diagnostic sensitivity and specificity (29). 
Pathologic examination remains the gold standard for diagnosis. The heterogeneous 
histological appearance of malignant melanoma has led to the frequent use of 
immunohistochemistry to achieve accurate and reliable diagnosis. The three antibodies 
S100, HMB45 and Melan-A are currently the most frequently used combination for 
melanocytic lesion diagnosis. S100 is the most sensitive marker of melanocytes but lacks 
specificity, whereas HMB45 (monoclonal antibody against group 100 protein) is a more 
specific marker that lacks sensitivity. Melan-A exhibits a sensitivity between that of S100 and 
HMB45 (36). Finally, the anatomopathological analyses of melanoma tissues allow to define 
the type of melanoma, the thickness, the ulceration and the mitotic rate. 
3.4  Melanoma classification 
Primary melanoma can present different growth patterns and incidence of these growth 
patterns varies according to sex, age and race. The four major growth subtypes (based on 
microscopic growth patterns) are superficial spreading melanoma (SSM), lentigo maligna 
melanoma (LMM), nodular melanoma (NM) and acral lentiginous melanoma (ALM) (37). This 
classification has been widely used both by clinicians and researchers, and the current World 
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Health Organization (WHO) classification of skin tumors is based on this system. Other 
systems of classification have also emerged in order to integrate clinicopathological features 
with somatic genetic alterations (34). Accounting for almost two thirds of all primary 
melanoma, SSM is the most common subtype and it is most frequent on sites with acute-
intermittent sun exposure whereas LMM is known to be related to chronic sun exposure. In 
contrast, ALM is mainly found on palm of hands and sole of feet and are therefore not linked 
to sun exposure. Although used clinically as descriptive tools, the different classifications 
have no prognostic value or therapeutic implications (34). 
3.5 Prognosis 
Evaluating the prognosis of the patient by an appropriate evaluation and staging of the 
cancer is essential for treatment planning, stratification and assessment of clinical trials. 
Primary tumor thickness (also known as the Breslow depth), ulceration, and a mitotic rate 
higher than 1/mm2 (assessed by the anatomopatholical analysis of the excised lesion) are 
factors associated with decreased survival rate and are the most widely used prognostic 
indicators for survival in malignant melanoma. However, these factors are still inaccurate for 
a significant number of patients. Up to 15% of patients with invasive thin tumors (< 1 mm) still 
develop metastatic disease (38). Similarly, a substantial proportion of patients with thick 
melanoma (≥ 4 mm) will have relatively long-term survival (58% for > 5 years) (39). 
Currently, clinical prognosis is based on the TNM classification, which describes the severity 
of the melanoma based on the size and extent of the tumor and whether or not it has spread 
to distant organs. TNM stages are ranking from stage I (localized melanoma) to stage IV 
(melanoma with distant metastasis) (40). It has been shown that patient survival is highly 
dependent on the stage of the disease. Yet, some disparities among stage are also 
observed, suggesting metastases may begin as a clinically silent event early in the 
development of a primary tumor. 
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As with other cancers, death is due to the development of distant metastases. Specifically, 
cutaneous melanoma is distinguished by its propensity for early metastatic spread via 
lymphatic vessels to regional lymph nodes, even at the early stages of tumor invasion. 
Lymph-node metastases, as detected by analysis of the sentinel lymph node (SLN) (first 
node draining the primary tumor), is one of the major determinants for the staging and clinical 
management of melanoma (41), although disease will recur in 22% of lymph-node-negative 
patients (42). 
Altogether, these results point out that there is an urgent need to identify more refined and 
dynamic prognostic indicators. The TME at the time of diagnosis, or of surgery, is a hallmark 
of how the patient and the tumor have interacted. Furthermore, different elements of the TME 
may impact the clinical evolution of cancer differently. Therefore, the analysis and 
characterization of the various components of the TME within the tumor could be one of the 
most promising and powerful prognostic markers (43). In this line, several studies have 
shown that the immunoscore and the immune contexture have a strong clinical impact and 
can predict response to immunotherapies (44). 
3.6 Treatments 
Complete surgical excision with wide margins represents the therapy of choice for primary 
melanomas. Additionally, radical lymphadenectomy can be undertaken when the SLN(s) is 
(are) positive or when one or more lymph node(s) is (are) clinically positive (palpable nodal 
enlargement or abnormal features on ultrasound imaging). For progressing disease, other 
treatments include chemotherapy (Dacarbazine), IL-2 or IFN-α therapies. However, these 
usually fail to control the disease and relapses occur frequently due to microscopic residual 
lesions. Therefore, targeted therapies and immunotherapies have emerged as promising 
anti-cancer strategies. 
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3.6.1 Targeted therapies 
Targeted therapies specifically target molecular alterations in melanoma. About half of 
cutaneous melanomas harbor a mutation of BRAF, primarily V600E, leading to activation of 
the MAPK pathway. Small molecule inhibitors of the MAPK pathway (e.g. BRAF or MEK 
inhibitors) have demonstrated remarkable clinical activity with responses in approximately 
half of the patients in phase II and III clinical trials leading to increased overall survival (45, 
46). Unfortunately, due to several modes of treatment resistance, the majority of responding 
patients will experience disease progression within an average time of six months (47, 48). 
However, combination regimens of BRAF-MEK inhibitors have been shown to overcome 
these resistance mechanisms at least partially, and thus significantly improve the 
progression free-survival time (49-51). 
3.6.2 Immune checkpoint blockade therapies 
Monoclonal antibodies that block immune-inhibitory pathways (e.g. anti-cytotoxic T-
lymphocyte–associated antigen 4 (CTLA-4) and anti-programmed death 1 (PD-1) receptor) 
or their ligands (e.g. PD-L1) aim to enhance T cell responses against tumor cells and can 
induce durable objective clinical responses. The significant proportion of patients with 
advanced unresectable melanoma who respond to such treatments attests to the potency of 
anti-melanoma immunity in tumor rejection (15% for anti-CTLA-4 therapy and 35-40% for 
anti-PD-L1 therapy) (52-54). Moreover, combination treatment with anti-CTLA-4 and anti-PD-
1 antibodies results in even increased rates of objective clinical responses (around 60%) (55, 
56) and represents, along with sequential therapies, the future of melanoma therapy (57). 
However, because of their capacity to overcome immune tolerance their toxicities are usually 
high, resulting in frequent autoimmune adverse events (58, 59). 
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Anti-CTLA-4 therapy 
CTLA-4 is a molecule expressed on the surface of CD4 and CD8 T cells as well as 
CD25+FoxP3+ regulatory T cells. CTLA-4 competes with CD28 to bind to its ligands B7-1 
(CD80) and B7-2 (CD86) on APCs. Therefore, CTLA-4 acts as an inhibitory molecule that 
limits activation of T cells and prevents them from prolonged activity (60). 
Two anti-CTLA-4 monoclonal antibodies, generated by different companies, have been 
tested in clinical trials in metastatic melanoma patients: Tremelimumab (Pfizer) and 
Ipilimumab/Yervoy (Bristol Myers Squibb), but only the latter was successful in phase III 
studies (61). Two important phase III studies have tested the clinical efficacy of Ipilimumab in 
advanced metastatic melanoma patients. In the first clinical trial, previously treated 
metastatic melanoma patients received either Ipilimumab, gp100 vaccine or the combination 
of both, in a randomized, double-blind manner (52). Treatment with Ipilimumab led to an 
improvement of median overall survival rates (10.0 and 10.1 months) compared with the 
gp100 vaccine-only treated group (6.4 months). In the second trial, metastatic melanoma 
patients that had not previously been treated received either dacarbazine or Ipilimumab in 
combination with dacarbazine in a double-blind manner (62). As in the first trial, Ipilimumab 
increased overall survival rates from 9.1 to 11.2 months. In the two trials, adverse events 
(mainly skin and gastro-intestinal auto-immune reactions) were noted in nearly all the 
patients. Based on these two exciting reports Ipilimumab was approved by the European 
Union (2010) and the Food and Drug Administration (FDA) (March 2011). 
Unfortunately, the clinical benefit following immune checkpoint blockade of CTLA-4 is limited 
to a fraction (about 15%) of treated patients, and the mechanisms of action are still poorly 
understood. Moreover, no reliable biomarkers of clinical efficacy are available to date. The 
identification of biomarkers that are associated with clinical responses to Ipilimumab may 
help to identify patients likely to benefit from the treatment. 
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Although other immunotherapies such as blockade of the PD-1/PD-L1 pathway or adoptive T 
cell therapy are in part very successful (63), they are not further described here as this thesis 
does not deal with patients who received these therapies. 
3.6.3 Anti-tumor vaccination 
Various vaccine formulations are currently used, with different forms of antigen (e.g. proteins, 
peptides, tumor lysates) and different delivery systems (e.g. dendritic cells, other antigen 
presenting cells, nanoparticles, recombinant viruses). Furthermore, adjuvants are essential 
components of vaccines. Indeed, they increase the immunogenicity of antigens by triggering 
the activation and maturation of dendritic cells (64). Peptide cancer vaccines have the 
potential benefits of being highly specific, stable and relatively easy to produce (65, 66). 
Furthermore, their low toxicity profiles suggest that they may be attractive options for cancer 
patients. 
Many studies of vaccine monotherapy conducted in patients with advanced cancers have 
yielded evidence of melanoma-specific immunization, but have failed to produce significant 
clinical response rates (about 5%) (67). Nevertheless, vaccines capable of inducing 
melanoma-specific immune activation still hold promise for eliminating or stabilizing 
microscopic or “minimal residual” disease (68). Despite the fact that significant technical and 
scientific progress has been achieved in the fields of vaccinology, much remains to be 
accomplished both in terms of efficacy and applicability (69). As for the combination of 
immune checkpoint blockade, co-treatment with tumor cell vaccines and other 
immunotherapies has been shown to improve clinical prognosis (70). Further 
characterization and assessment of primary tumors as well as metastatic tissues of these 
patients will not only extend our knowledge on the TME but also potentially identify novel 
cancer immunotherapeutic targets, which will improve the design of new combination 
therapies. 
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3.6.4 The LUD 00-018 study 
Research groups at the Ludwig Institute of Cancer Research, the CHUV and UNIL have 
conducted a cancer vaccine study. Between 2003 and 2011, a phase I clinical trial (LUD 00-
018 study, ClinicalTrials.gov Identifier NCT00112229) was completed to evaluate whether 
melanoma-specific immune responses could be induced through vaccination with melanoma 
antigenic peptide and adjuvants in patients diagnosed with stage III or IV melanoma. 29 
melanoma patients were included and vaccinated with Melan-A analog (ELA) or native (EAA) 
peptide ± Tyrosinase (YMD) peptide, CpG-B-7909 and Montanide ISA-51 adjuvants in order 
to stimulate tumor antigenic specific CD8+ T lymphocytes. 
At the beginning of the study, the patients were asked for their previous medical history 
(including other treatments received before this clinical trial), their age, the type and 
localization of their primary tumor. Their immune cell phenotypes were also determined at 
baseline. Patient survival and tumor response were assessed as readout for disease 
evolution. Furthermore, each patient was tested for the development of a specific immune 
response induced by the vaccination of the study: Melan-A-specific T cells and their 
functionality were measured by tetramer staining, enzyme-linked immunospot (ELISPOT) 
assay and intracellular cytokine staining for IFN-γ, IL-2, CD107a and TNF-α evaluation. 
Finally, the adverse events and the toxicity were also reported and were a part of the safety 
criteria. 
Results from this trial clearly demonstrated the immunogenic potency of vaccines composed 
of Melan-A peptide, CpG-B-7909 and Montanide ISA-51 in the induction of strong antigen-
specific CD8+ T lymphocyte responses, thereby supporting the continued development of 
this vaccine strategy (66). However, careful study of the characteristics of the tumor tissues 
and immune responses of these patients is required for a more complete understanding, 
which may support the improvement of future cancer vaccines. Indications of immune 
escape mechanisms or immune modulation in the local TME may explain the limited clinical 
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responses seen in vaccinated patients. As emphasized below, lymphatic vessels represent 
one potential key player. 
 
4 Lymphatic vessels 
4.1 Structure 
The lymphatic system is a systemic network of vessels and lymph nodes (LNs). In many 
ways, the lymphatic system complements the functions of the blood vascular system by 
regulating tissue fluid balance, facilitating interstitial protein transport, as well as serving 
immunological functions (71, 72). Lymphatic vessels have a distinct structure compared to 
blood vessels (Figure 1). Lymphatic capillaries have a thin endothelial wall and a wide lumen, 
which make them structurally optimal for the absorption or uptake of fluids, proteins and 
cells. Lymphatic endothelial cells (LECs) do not form adherent or tight junctions and their 
basement membrane is incomplete or nonexistent. Furthermore, the lymphatic vascular 
network, unlike the blood vascular system, lacks a central pump such that the transport of 
lymph depends solely on skeletal muscle contraction and respiratory movement.  
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Figure 1 Structure of the lymphatic vessels compared with blood vessels (Adapted from Karpanen et al, 2008).  
This particular system provides an environment for cells that is optimal for their survival since 
the shear stress is negligible. Lymphatic capillaries are connected to extracellular matrix 
fibers through anchoring filaments. When tissue pressure increases, the contraction of these 
anchoring fibers opens the capillaries to enable lymph fluid and immune cells to enter the 
lymphatic vascular system (73). Lymph first enters the peripheral capillaries before draining 
to precollecting lymphatic vessels, which merge into larger lymphatic vessels surrounded by 
a basement membrane and valves that prevent retrograde lymph flow. Lymph passes 
through several sequential LN and finally reaches the thoracic duct, from where it returns to 
the venous circulation (74). 
LNs are small organs of the lymphatic system that are widely distributed through the body 
and along the course of lymphatic vessels. Lymph nodes are key players in the development 
of an adaptive immune response and have several important functions such as recruiting 
naïve lymphocytes from the blood, collecting antigen and DCs from peripheral tissues and to 
provide the environment for antigen-specific tolerance or productive primary and secondary 
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effector responses. Lymph nodes are structured in two different compartments, the cortex 
and the medulla, that can be distinguished histologically (Figure 2). 
The cortex can be further subdivided into the paracortex (the T cell zone) and the more 
superficial B cell zone, composed of primary follicles containing germinal centers after 
antigen stimulation. The T cell zone contains specialized blood vessels knows as high 
endothelial venules (HEV) from which lymphocytes enter LNs. Interaction between antigen-
specific T cells and APCs takes place in this region. The paracortex is arranged in 
paracortical cords that are bordered by cortical sinuses (endothelial lined lymphatic spaces) 
(Figure 2). The follicles in the B cells zones are rounded areas mainly composed of B cells 
but also of follicular dendritic cells (FDC), T cells, macrophages and reticular cells. The 
medulla is a labyrinth of lymph-draining sinuses that are separated by medullary cords, which 
contain many plasma cells and some macrophages and memory T cells. A dense network of 
reticular fibers maintains this compartmentalized structure and ensures an efficient crosstalk 
between T cells and APCs (75). FDC produce CXCL13 which attracts and retains B cells in 
the B cell zone whereas CCL19 and CCL21 produced by fibroblastic reticular cells (FRC) aim 
to attract T cells and APCs in the T cell zone (76). 
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Figure 2 Structure of a lymph node. a) Schematic diagram showing the major structural components of a lymph 
node. The lymph fluid drains into the lymph nodes from afferent lymph vessels. From here the lymph is drained 
towards the subcapsular sinus, trabecular sinuses and medullary sinuses. b) Schematic representation of a 
paracotrical cord. The T cell area is represented in light blue, B-cell follicle in pink and lymph-filled sinuses in 
green. The cord is composed of reticular fibres and fibroblastic reticular cells (FRCs). A high endothelial venule 
(HEV) is found in the center of each cord and is surrounded by concentric layers of FRCs. (Adapted from Von 
Adrian et al, 2003) 
The lymph fluid drains into the LN from afferent lymphatic vessels. From there, it goes into 
the subcapsular sinus (the hollow space below the fibrous capsule that surrounds the LN), 
then to the trabecular sinuses into the LN parenchyma, then on to the medullary network of 
sinuses and finally exits the LN via the efferent lymphatic vessel. Lymph channels inside the 
LN are surrounded by FRC, macrophages and DCs, which can remove microorganisms or 
debris from the lymph as well as process antigen for presentation to B and T cells (Figure 2). 
4.2 Formation 
The formation of de novo lymphatic vessels (termed lymphangiogenesis) is a dynamic 
process during embryogenesis and is largely absent under physiological postnatal 
conditions. Indeed, in the adult, lymphangiogenesis only takes place during certain 
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pathological conditions such as inflammation, tissue repair and tumor growth (74). 
Lymphangiogenesis involves several molecular mechanisms. During embryogenesis, or 
under physiological conditions, lymphatic vessel endothelial hyaluronan receptor 1 (Lyve-1) 
is the first indicator of lymphatic endothelial competence (77). Prospero homebox protein 1 
(Prox-1) expression begins thereafter in a polarized manner. Prox-1 is the master regulator 
of lymphatic endothelial fate and differentiation. Endothelial cells expressing this gene start 
budding and migrating in the surrounding extracellular matrix from the vein under the 
influence of vascular endothelial growth factor-C (VEGF-C) and begin to form lymph sacs 
(78). Then, the differentiated LECs start to express podoplanin, which activates platelet 
aggregation and leads to the separation of the lymphatic system from the blood vascular 
system (79). Finally, further centrifugal growth of the lymphatic vessel network ensues, 
driven by VEGF-C and vascular endothelial growth factor receptor-3 (VEGFR-3), and results 
in the differentiation to lymphatic capillaries and collecting lymphatic vessels. 
4.3 Lymphangiogenic factors 
The first and most studied prolymphangiogenic factors are VEGF-C, vascular endothelial 
growth factor-D (VEGF-D) and their associated tyrosine kinase receptor, namely VEGFR-3. 
VEGF-C and VEGF-D are initially produced as prepropeptides and need to be processed in 
order to be fully mature. As they mature they increase their affinity for VEGFR-3 (80). The 
binding of these two proteins to their receptor induces the dimerization of VEGFR-3 
expressed on the lymphatic endothelium leading to proliferation, migration and survival of 
LECs (81). More recent data have suggested that VEGF-C/VEGF-D can also bind to 
vascular endothelial factor receptor-2 (VEGFR-2) presented on blood endothelial cells, and 
thus are also implicated in angiogenesis (82). Furthermore, VEGFR-2 is also expressed on 
LEC and has been implicated in lymphangiogenesis (83). These recent discoveries 
demonstrate the complexity and the similarities in the regulation of lymphangiogenesis and 
angiogenesis. 
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Genetic mouse models have demonstrated that VEGF-C (but not VEGF-D) is required for 
lymphatic development during embryogenesis and is postulated to intervene in the 
maintenance of lymphatic endothelial differentiation in adults (84). Further 
prolymphangiogeneic factors have recently been identified including angiopoietin, platelet-
derived growth factor (PDGF), hepatocyte growth factor (HGF), fibroblast growth factor 
(FGF) and insulin-like growth factor (IGF). Negative regulators of lymphangiogenesis such as 
TGF-β have also been described (74). 
4.4 Lymphatic markers and quantification 
Selection of optimal markers of the lymphatic endothelium is clearly a critical step in the 
assessment of lymphatic vessel density (LVD), since false data arising from low specificity 
staining must be avoided. Although recent data demonstrated a large spectrum of candidate 
lymphatic markers for which antibodies are available (VEGFR-3, Lyve-1, Prox-1, 
podoplanin), their specificity may remain imprecise (85). 
As mentioned earlier, VEGFR-3 is a tyrosine kinase that is predominantly expressed by 
LECs in adult tissues. However, VEGFR-3 expression was also been found in fenestrated 
capillaries of several organs and in endothelial cells of proliferating neovasculature in some 
cancers (86). Therefore, this marker is not reliable for discriminating between lymphatic and 
blood vascular endothelium. 
LYVE-1 is an integral membrane glycoprotein that functions as a receptor for hyaluronan, a 
ubiquitous extracellular matrix glycosaminoglycan involved in cell migration and 
differentiation. LYVE-1 is expressed in cardinal vein endothelium during embryogenesis but 
its expression then persists into adulthood in most afferent vessels and lymphatic sinuses, 
but is absent from thoracic duct. LYVE-1 is also abundant in discontinuous endothelia 
including human liver and spleen sinusoids but is absent from the haemovasculature, thus 
demonstrating that LYVE-1 is indeed a reliable marker for distinguishing lymphatic vessels 
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from blood vessels. Nevertheless, it can sometimes be downregulated in some tissues and 
can be absent in tumor-associated lymphatics (85). Furthermore, staining carried out on 
human LNs have shown poor specificity and positivity in some tumor-associated 
macrophages (87) (ref Swartz et al). Therefore, LYVE-1 should be use in combination with 
other lymphatic markers as podoplanin or Prox-1. 
Another marker of the lymphatic endothelium is Prox-1, which is the master regulator of 
lymphatic vasculature development during embryogenesis. Prox-1 has also been found in 
other cell types in the lens, heart, liver, pancreas and nervous system (88). A recent study by 
Park et al has shown that Prox-1 is the only exclusive marker currently available for LECs 
within human LNs, capable of marking lymphatic sinuses and vessels in every zone of the 
LN (89). In contrast to Prox-1, expression of LYVE-1 was restricted to the paracortical and 
medullary sinuses in most LNs and was not expressed by Prox-1+ LECs in the subcapsular 
and trabecular sinuses. These results highlighted that even LECs can have distinctive 
expression of markers and that different populations of LECs exist, at least in human LNs. 
Prox-1 has a nuclear localization and thus it is not an ideal marker for quantifying lymphatic 
vessels microscopically, but is a useful marker for multiplexed immunostainings. 
Podoplanin is a surface glycoprotein that is expressed in several cell types other than 
lymphatic vessels such as osteoblastic cells, lung alveolar type I cells and kidney podocytes 
(90). Compared to LYVE-1 and Prox-1, podoplanin (D2-40 is a monoclonal antibody that 
specifically recognizes human podoplanin) is considered as one of the most reliable 
lymphatic markers (85). However, podoplanin has been shown to be present only in small 
lymphatic vessels and not in larger ones that have smooth-muscle cells (88). 
A number of different methods have been developed to quantify lymphatic vessels in cancer 
tissues. These methods have already been reviewed and described (85, 90). Briefly, three 
important methods are frequently used while assessing lymphatic vessel numbers in human 
tissue slides. Firstly, the Weidner technique, the most widely used technique to count 
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lymphatic vessels, involves quantifying the lymph vessels at “hot spots”, defined as areas of 
increased vessel density. Histological slides of the tumors are first examined at low power 
(x10) to identify hot spots and then at higher magnification (20x or 40x) to quantify the 
number of vessels in these hot spots. The second one is the Chalkley method (Figure 3), 
which is based on the use of a Chalkley eyepiece graticule with 25 randomly distributed 
points. This method is also based on hot spot selection but then the graticule is positioned 
until the largest possible number of points is located over the stained LECs. The score 
obtained is an indicator of the relative area occupied by lymphatic vessels, as the score does 
not count the number of vessels but rather the number of points of the graticule overlaying 
the vascular structures. This method is considered to be more objective and reproducible 
and should be used to assess lymphatic vessels. Finally, computerized counting systems 
have the best performance in terms of accuracy and reproducibility. However, their 
widespread applications are hampered by the need for costly specialized equipment to 
perform analyses and the automatic software may count non-specific staining on 
nonendothelial structures as lymphatic vasculature structures. 
 
Figure 3 Representation of a Chalkley graticule on D2-40/Ki67 double stain of a melanoma metastatic lymph 
node. The points marked with red circles are considered positive (adapted from Pastushenko et al, 2015) 
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4.5 Lymphatic vessels in cancer 
4.5.1 Tumor lymphangiogenesis 
The expanding tumor mass can exploit the unique structural architecture and the 
microenvironment of the lymphatic vasculature. In most human cancers, the lymphatic 
vasculature serves as the primary route for the metastatic dissemination of tumor cells, which 
initially enter regional draining LNs prior to the establishment of metastases in distant organs. 
In fact, regional LN metastasis is often the most important prognostic factor for patients with 
malignancies and represents a major criterion for treatment choices. However, despite the 
importance associated with the presence of LN metastases in cancer progression the 
mechanisms of lymphatic metastasis formation remain poorly understood. Since the recent 
discovery of lymphatic vessel markers, new findings have been made regarding the 
particular role of the lymphatic system in tumor growth and progression. 
Similar to tumor-associated angiogenesis, tumors also acquire the ability to form new 
lymphatic vessels. Our understanding of tumor-induced lymphangiogenesis and its clinical 
impact on tumor progression and metastasis has primarily relied on mouse models of cancer. 
In 2001, Skobe et al, using a mouse model of breast cancer, were the first to prove that 
overexpression of VEGF-C in tumor cells significantly increased lymphatic vessel growth 
within and around the tumor leading to increased metastatic spread to LNs and distant 
organs (91). Further studies followed and confirmed these results (92, 93). Moreover, 
blockade of VEGFR-3 in mouse reduced tumor lymphangiogenesis and LN metastasis (94). 
However, proliferation and activation of lymphatic vasculature is not only restricted to the 
primary tumor microenvironment as some studies detected LN lymphangiogenesis within 
SLNs (95, 96). Interestingly, B cells have been shown to be a major source of 
lymphangiogenic factors and promote lymphangiogenesis in tumor draining LNs by secreting 
VEGF-C (97). Importantly, draining LN lymphangiogenesis can even start prior to tumor 
metastasis, indicating the creation of a premetastatic niche by the primary tumor (97, 98). In 
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addition, lymphangiogenic growth factors also act to enlarge and dilate lymphatic vessel size 
and lymphatic flow rate, facilitating the dissemination of tumor cells. Taken together, these 
murine tumor experimental systems have established that tumors can actively induce the 
growth of lymphatic vessels (mediated by prolymphangiogenic factors) and promote 
metastasis to LNs and possibly beyond to distal organs (94). 
On the other hand, our knowledge of the role of lymphatic vessels in tumor metastasis and 
their impact on prognosis in human cancer came from retrospective IHC analysis of tumor 
tissue samples and correlation with clinical outcome. Expression of VEGF-C occurs in a 
variety of human tumors such as breast, colon, gastric, head and neck, lung, squamous cell 
carcinoma and melanoma (93). In melanoma, statistically significant positive correlations or 
at least trends have been observed between VEGF-C expression, LVD, LN metastasis and 
prognosis (99-102). However, in some other studies this correlation between elevated VEGF-
C and either increased LVD, LN metastasis or survival was not observed (103-106), 
suggesting that the situation may be more complex and could vary depending on the cohort 
of patients studied. In line with this, increased intra and peritumoral lymphangiogenesis in the 
primary tumor as well as in the tumor-draining LNs have also been implicated in increasing 
LN metastasis, distant metastasis and poor prognosis in melanoma as well as in other types 
of cancer (e.g breast cancer, colon cancer, gastric cancer…) (107-111). Here again, 
exceptions exist and some studies did not identify lymphangiogenesis as an independent 
prognostic factor (105, 112). Patient cohorts studied, lymphatic markers selected and 
methods of quantification used are potential factors explaining this discrepancy. Furthermore, 
a higher density of lymphatic vessels in or around the tumor may be necessary but not 
sufficient for metastasis, as tumor cells may not have acquired the properties required for 
metastasis, such as invasiveness (103). 
The chemokines CC chemokine ligand 19 (CCL19) and CC chemokine ligand 21 (CCL21) 
and their associate receptor CC chemokine receptor 7 (CCR7) are also involved in tumor 
  
37 
 
dissemination via the lymphatic system. The CCR7/CCL21/CCL19 axis regulates several 
mechanisms involved in normal physiology and immunity. CCR7 is regarded as a LN homing 
receptor for lymphocytes and antigen-presenting cells and the CCR7/CCL21/CCL19 axis is 
also implicated in the organization of the thymic architecture, lymphoid neogenesis and the 
balance between immunity and peripheral tolerance (113). CCL19 and CCL21 are both 
expressed by LECs and FRCs. CCR7 expression within tumors correlates with metastasis to 
LNs in human malignancies (e.g. melanoma, colorectal cancer, gastric cancer…) (114-116) 
and mouse models have demonstrated the chemotactic migration of CCR7-positive tumor 
cells towards CCL21-producing LECs (117). Moreover, in vivo inhibition of LN metastases 
has been achieved using a soluble inhibitor of CCL21 (118). 
Overall, these considerations highlight the fact that lymphangiogenic growth factors and 
chemokines can systematically induce alterations in tissue stroma not only within the primary 
tumor but also in the draining LNs, secondary lymphoid organs and other distant metastatic 
sites, which may promote tumor cell dissemination. 
4.5.2 Immunoregulatory functions of tumor lymphangiogenesis 
Traditionally, lymphatic vessels were considered to be passive channels allowing tumor cells 
entrance and transport (119). However, new evidence is emerging suggesting that the 
lymphatic vasculature plays a more active role in tumor metastases through its action on the 
recruitment of cancer cells (120), the maintenance of cancer stem cell-like properties (121), 
and the antitumor immune response (74, 122). This immune modulation seems to be driven 
notably by VEGF-C as it may directly influence the maturation, phenotype, activity and 
recruitment of immune cell subsets (123-126). 
In line with this, Melody Swartz’s laboratory have proposed a novel hypothesis regarding the 
mechanism of lymphatic metastases, linking lymphangiogenic factors, tumor-associated 
lymphangiogenesis, and the induction of immune tolerance. Specifically, using a mouse 
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melanoma model, she has suggested that cells of the lymphatic vasculature may play an 
active role in mediating tumor tolerance. First, her group demonstrated the importance of the 
crosstalk between VEGF-C and CCL21 in promoting lymphatic invasion. Tumor-secreted 
VEGF-C induces the expression of CCL21 in LECs, which attract CCR7-expressing tumor 
cells to the lymphatic vessels. In addition to sensing the gradient established by LECs, tumor 
cells may also set up autologous gradients via the secretion of CCL21 in the extracellular 
matrix (127). Furthermore, VEGF-C itself can promote proteolytic activity and motility of 
tumor cells, and, therefore, enhance tumor aggressiveness (128). Secondly, the up-
regulation of CCL21 in the tumor stroma recruits lymphoid tissue inducer (LTi) cells, naïve T 
cells, Treg cells, and MDSCs. LTi cells direct the reorganization of local stroma into lymphoid 
tissue–like structures that support Treg cells and MDSCs and promote naïve T cell education 
leading to immune tolerance of the tumor (129).  
Furthermore, under physiological conditions, LN associated-LECs play an important 
immunoregulatory role in preventing autoimmunity by scavenging antigens and cross-
presenting them to T cells, which can lead to T cell anergy and deletion. In a cancer setting, 
the idea proposed is that lymphangiogenic tumors may hijack these mechanisms and cross-
present tumor antigens, leading to CD8+ T cell deletion and immune tolerance (130, 131). 
Preliminary results in mice have shown that anti-lymphangiogenic therapy (such as anti-
VEGFR3 antibody) can reverse the CCL21-induced lymphoid-like stroma and render an anti-
tumor vaccine (OVA+CpG) more effective when used in combination (data not published). 
These interesting results suggest that lymphatic vessels may have a role on the outcome 
and efficiency of immunotherapy. 
Taken together, these studies indicate that tumor-associated lymphatics and their respective 
draining LNs may promote tumor immune tolerance in murine models of melanoma and 
contribute to the generation of a TME that is permissive to malignant progression and 
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metastases. However, it remains unknown whether similar mechanisms of lymphatic-
mediated immune regulation exist in human melanoma. 
 
5 Summary of the introduction 
Cancer will become the first cause of mortality ahead of cardiovascular disease in the next 
few decades. The heterogeneity, unpredictable progression and resistance to treatment of 
this disease make it a health concern of paramount importance. Therefore, novel therapeutic 
strategies have to be explored and developed to improve curative responses in cancer. 
Given that patients can develop a spontaneous adaptive immune response to their cancer 
and that the quality and density of specific immune components within the TME can predict 
disease progression, immunotherapies that aim to induce an immune response are 
considered highly attractive approaches. Melanoma, in particular, has attracted the attention 
of tumor immunologists as its aggressiveness, immunogenic properties and the scarcity of 
potent therapeutic options have made it a promising model for developing immunotherapy. 
Indeed, multiple clinical trials have shown spectacular responses in melanoma patients to 
these therapies. However, complete regressions are infrequent and resistance to these 
therapies has been extensively described. Data from the literature strongly suggest that the 
TME modulates local and systemic immune responses to tumor and thereafter to therapies. 
In particular, lymphatic vessels have been shown to be active regulators of anti-tumor 
immune responses in tumor and draining LNs of mouse models of melanoma. Addressing 
this question in human melanoma by dissecting the link between lymphatics, immune cells 
and immune suppressive pathways both within the TME as well as systemically may reveal 
new knowledge of disease mechanisms and potentially identify targets for novel therapies.
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OBJECTIVES 
Various strategies (IHC, genetics,…) have been employed in an attempt to characterize and 
dissect tissue samples of cancer patients to improve diagnosis, prognostic evaluation and 
the design of combinatorial therapeutic approaches. Several recent publications pointed out 
the limited success of these different methods in assessing the complexity, heterogeneity 
and spatial relationships of the different cell types present in tumor tissue (18, 132). 
Immunohistochemical techniques that characterize the morphology, spatial relationships and 
phenotype of tissue-infiltrating cells are probably the methods with the greatest potential for 
insight into the wealth of information contained within the tissue. However, until recently, IHC 
data has not been used to it’s full potential due to a lack of tools for systematic quantification 
and automated analysis. Indeed, a large part of the IHC staining analysis has typically been 
done by visual assessment on specifically selected fields and has been shown to be 
subjective with a very high level of inter-observer variability (133). The emergence of 
computer-based image analysis systems has overcome these limitations and offers the 
advantage of analyzing quality, high-resolution digital images via dedicated software to 
obtain precise and quantitative data from an entire tissue or from specific regions within the 
tumor. The results obtained with these methods are accurate, reproducible and can be 
shared and reviewed by external evaluators (e.g. pathologists) (134-136). 
Overall, these facts underscore the need for a better understanding of the composition and 
spatial relationships between tumor cells and their microenvironment. The ultimate goal of 
this thesis was, thus, to obtain greater insight into the complexity and heterogeneity of the 
TME in human melanoma with the help of multiple recently developed IHC techniques. To 
achieve this, we established two main objectives: to precisely characterize the local and 
systemic immune modulation (i) in untreated melanoma patients and (ii) in patients 
undergoing vaccination or checkpoint blockade therapies. 
  
42 
 
Four studies have emerged from these two aims: 
(1) The analysis of lymphatic vessels in relation to anti-tumor immune response in peptide-
vaccinated patients through a combination of IHC techniques, whole slide scanning/analysis, 
and an automatic quantification system 
(2) The description of an auto-immune adverse event in a peptide-vaccinated patient by IHC 
and ex-vivo peripheral blood mononuclear cells (PBMC) analysis 
(3) The development of a new diagnostic tool for melanoma metastasis in LNs of peptide-
vaccinated patients using Fourier Transform Infrared (FTIR) imaging 
(4) The role of colony-stimulating factor-1 (CSF-1) in modulating the anti-tumor response in 
Ipilimumab-treated patients using IHC and in vitro co-culture assay 
The data generated as part of this thesis are not routinely assessed but are nevertheless key 
aspects in deciphering mechanisms responsible for immune responses. Thus, they may 
improve future clinical biomarker implementation and patient management. 
 
1 Analysis of lymphatic vessels in relation to anti-tumor immune response 
This project originated from recent studies from the group of Melody Swartz, evaluating the 
role of the lymphatic system in anti-tumor immunity. They demonstrated that lymphatic 
vessels are directly involved in sculpting the TME and in shaping the anti-tumor immune 
response in mouse primary melanoma and melanoma-draining LNs (129, 130). Based on 
this, we set out to better understand the cellular and molecular interactions between 
lymphatics and immune cells in melanoma patients. Specifically, the goal of this study was to 
investigate correlations between lymphatic vessels, immune cells and immune suppressive 
molecules within human melanoma-associated tissues. We hypothesized that higher density 
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of lymphatic vessels will be associated with higher expression of immune suppressive factors 
and an altered anti-tumor T cell response.  
To test our hypotheses, we selected a cohort of vaccinated melanoma patients for whom 
formalin-fixed paraffin-embedded (FFPE) tissues were available (primary melanoma, 
metastatic LNs and non-metastatic LNs). We phenotypically characterized the lymphatic 
vessels, immune cell populations and immune suppressive molecules within these tissues by 
IHC and multiplex staining. We then developed a software-assisted image analysis protocol 
to precisely quantify staining within entire tissue sections. Finally, we compared our IHC 
results to clinico-pathological and prognosis factors for the cohort of patients. 
Results from this objective are described in manuscript 1 on page 45 of this thesis. 
 
2 An autoimmune adverse event following multiple cycles of vaccination 
Recently, significant progress has been made in developing therapeutic cancer vaccines. 
Specifically, the use of potent adjuvants such as the TLR ligand, CpG, in ‘new generation’ 
vaccines has been shown to give rise to strong activation of cancer-specific T cells without 
inducing serious autoimmune adverse events in cancer patients. During one such vaccine 
clinical trial performed by our institute, a stage IV metastatic melanoma patient receiving 
repetitive vaccination with peptides and CpG developed a pulmonary sarcoid-like 
granulomatosis.  
We hypothesized that the development of a strong and long lasting specific immune 
response to the vaccine may have led to the development of an autoimmune pulmonary AE. 
To explore this hypothesis, we analyzed ex vivo PBMC collected at different time points 
before and after vaccination by flow cytometry. We also evaluated the capacity of the tumor 
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antigen-specific CD8+ T cells to produce IFN-γ by ELISPOT assay. Finally, we collected the 
clinical data and the radiological images done during the course of his disease. 
Results from this objective are described in manuscript 2 on page 107 of this thesis. 
 
3 Development of a new diagnostic tool for identification of lymph node 
melanoma metastases 
Early diagnosis of melanoma is essential to reduce mortality and select appropriate 
treatments. Currently, diagnosis of melanoma is mainly based on visual inspection of skin or 
LN sections with optical microscopy. Melanoma usually exhibits a wide spectrum of 
histological appearances and some pigmented lesions can mimic melanoma histologically. A 
high degree of inter-observer discrepancy has also been highlighted for micrometastasis 
detection in LNs. These various factors introduce the possibility for significant errors in the 
diagnosis of melanoma and stress the need to have a powerful and objective method to help 
in the diagnosis of this malignancy. We assessed the potential of a new technique based on 
infrared (IR) spectroscopy to identify melanoma cells and characterize lymphocytes in 
metastatic lymph nodes and in non-metastatic LNs of melanoma patients. 
Results from this objective and my specific contributions are described in manuscript 3 on 
page 114 of this thesis. 
 
4 The role of CSF-1 in modulating the anti-tumor immune response 
CSF-1 and its receptor, CSF-1R, are known to regulate the migration, differentiation and 
survival of macrophages and their precursors (137). Furthermore, tumor-associated 
macrophages (TAMs) represent key orchestrators of various tumor-promoting processes and 
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have been identified as an independent poor prognosis factor in several cancer types (138). 
Recent studies have shown that treatment with anti-CSF-1R antibody decreased pro-tumoral 
CSF-1R+CD163+TAMs in patients with various tumor types and altered T cell tumor 
microenvironment composition (139). 
For this project, we postulated that CSF-1 is secreted by melanoma cells and investigated 
whether this occurs in response to specific attack by cytotoxic T lymphocytes (CTLs). To test 
this hypothesis, we first performed CSF-1 quantification in the plasma of Ipilimumab-treated 
patients before and after therapy. Next, CSF-1 protein expression was measured in the 
supernatant of untreated melanoma cells, cytokine-treated melanoma cells or melanoma 
cells that were co-cultured with melanoma-specific CTLs. To determine whether direct CTL-
melanoma cell contact was necessary to induce CSF-1 induction, melanoma cells were 
treated with tumor necrosis factor-alpha (TNF-α) and interferon gamma (IFN-γ), two 
cytokines that are secreted by activated CTLs. We also compared levels of CSF-1 mRNA in 
untreated melanoma cell lines and melanoma cell lines cultured in the presence of 
melanoma-specific CTLs using a differential gene expression microarray and NanoString 
technology. Finally, we selected FFPE primary melanoma and cutaneous melanoma 
metastasis samples from the same patients and assessed CSF-1, CSF-1R and CD163 in 
situ expression in regions of high and low CD8+ T cell infiltration. 
Results from this objective are described and my specific contributions in manuscript 4 on 
page 160 of this thesis. 
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RESULTS 
Pursuing objectives 1-4 lead to four manuscripts presented here.  
The four manuscripts are entitled: 
1) Local and distant immune modulation associated with lymphangiogenesis in 
melanoma patients 
2) Pulmonary sarcoid-like granulomatosis after multiple vaccinations of a long-term 
surviving metastatic melanoma patient 
3) Identification of melanoma cells and lymphocyte subpopulation in lymph node 
metastases by FTIR imaging histopathology 
4) Adaptive immune resistance via CSF-1 produced by melanoma cells 
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1 Local and systemic immune modulation associated with 
lymphangiogenesis   in melanoma patients 
In this study, we investigated correlations between lymphatic vessels, immune cells and 
immune suppressive molecules within human melanoma-associated tissues. We established 
that increased lymphatic vessel density was associated with high expression of immune 
suppressive molecules, low functionality of tumor-infiltrating CD8+ T cells and decreased 
cytokine production by tumor-antigen specific CD8+ T cells in the blood. These data revealed 
local and systemic roles of tumor-associated lymphatics in modulating T cell responses in 
human cancer. None of the results presented here are published and should therefore be 
considered as preliminary and confidential. 
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Abstract 
Tumor induced lymphangiogenesis may precede metastasis, and is associated with poor 
patient survival. Furthermore, tumor-associated lymph vessels are known to impair host 
immune responses in mouse models, but this concept remains unexplored in humans. We 
hypothesized that the density of lymphatic vessels may impact on the quality of anti-tumor T 
cell responses in melanoma patients. Therefore, we characterized the tumor 
microenvironment (TME) in primary melanomas, metastatic lymph nodes (LNs) and non-
metastatic LNs by immunohistochemistry (IHC) and quantitative image analysis. Lymphatic 
vessels (Prox-1, podoplanin), immune cells (CD8, CD4, FoxP3, CD19) and lymphangiogenic 
and immunosuppressive molecules (VEGF-C, IDO, INOS, Arg-1) were assessed in specific 
anatomical regions. Significant positive correlations between lymphatic vessels and VEGF-C, 
iNOS and IDO were observed in primary tumors and in LN metastases. Consistent with 
studies in mouse, lymphatic vessels were associated with locally enhanced infiltration of 
CD8+ T cells. Importantly, we show for the first time that low functionality of local CD8+ T 
cells, and decreased cytokine production by tumor-antigen specific CD8+ T cells in circulating 
blood were associated with increased lymph vessel density. Interestingly, lymphatic vessel-
associated immune modulation was also evident in non-metastatic LNs adjacent to 
metastatic ones, emphasizing loco-regional effects and underscoring systemic immune 
suppression. Together, these data reveal a previously unrecognized local and systemic role 
of lymphangiogenesis in modulating T cell responses in human cancer. 
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Introduction 
In the last decade, particular attention has been given to understanding the complex 
interactions between a developing tumor and the host immune system. It is known that the 
immune system can operate as a significant barrier to tumor formation and progression in 
humans (1). Tumor cells can express immunogenic antigens through mutation, and adaptive 
immune responses can be mounted in tumor-bearing hosts (2, 3). Furthermore, strong 
memory Th1/cytotoxic T cell responses correlate with favourable clinical outcomes in a large 
array of human malignancies, including melanoma (4-6).  
In spite of the development of an immune response to tumors and the accumulation of highly 
differentiated tumor-specific T cells at the tumor site in cancer patients, immune responses 
are rarely capable of complete tumor eradication (2, 7). Tumors develop multiple strategies 
to inhibit effector T cells, including triggering of surface inhibitory molecules, attraction of 
immune suppressive cells (e.g. T regulatory cells (Tregs) and myeloid-derived suppressor 
cells (MDSCs)) and production of enzymes that deplete essential nutrients for T cell 
activation and proliferation such as indoleamine 2,3-dioxygenase (IDO), inducible nitric oxide 
synthase (iNOS) and arginase (8, 9). It is now recognized that these tumor immune escape 
mechanisms are initiated and maintained by specific interactions between tumor cells and 
their TME.  
Lymphatic vessels have been shown to play important roles in malignant diseases. In human 
melanoma, expression of the lymphangiogenic vascular endothelial growth factor-C (VEGF-
C) in the tumor promotes lymphangiogenesis, LN metastases and poor prognosis (10-14). 
The formation of a lymphatic network within the tumour and the tumour-draining LNs 
facilitates the migration of invasive tumor cells. More recent mouse studies demonstrate 
additional roles of lymphatics and their associated chemokines in promoting tumor 
progression and metastasis to the tumor-draining LNs (15-17). Indeed, lymphatic endothelial 
cells (LECs) can suppress immunity and promote tolerance in multiple ways such as (a) 
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inhibiting the maturation of dendritic cells (DC), (b) producing molecules such as IDO, iNOS 
and transforming growth factor beta (TGF-β) and (c) impairing T cell activation through direct 
presentation of exogenous antigens and expression of inhibitory molecules (e.g. 
programmed cell death ligand 1 (PD-L1)) (18). Taken together, these findings support the 
emerging hypothesis that tumor-induced lymphangiogenesis may regulate host immunity 
and, thus, constitute a new target for cancer immunotherapy. However, to date the effects of 
tumor-associated lymphangiogenesis on host anti-tumor immunity in humans remain to be 
established.  
The aim of this study was to determine whether tumor-associated lymphatic vessels are 
associated with modifications of the immune profile in selected anatomical compartments of 
melanoma patients. We characterized the TME of primary melanoma, metastatic LNs and 
non-metastatic LNs of melanoma patients by IHC and quantitative image analysis. We 
developed a novel method enabling quantitative assessment of unusually large tissue fields. 
To characterize lymphatic vessels, we used the markers Prox-1 and podoplanin, in 
combination with VEGF-C. Furthermore, we characterized the immunosuppressive 
molecules Arg-1, iNOS, and IDO, and various lymphocyte populations (CD8, CD4, FoxP3 
and CD19). Finally, the results from tissue analyses were compared to numbers and 
functionality of tumor antigen specific CD8 T cells from peripheral blood. 
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Material and Methods 
 
1. Patients 
29 metastatic melanoma patients that had been included in phase I prospective vaccination 
trial (LUD 00-018 study, ClinicalTrials.gov Identifier NCT00112229) at the Ludwig Cancer 
Research Center (LICR, CHUV hospital, Lausanne, Switzerland) between 2003 and 2011 
were the main subjects of our study and were therefore reviewed for formalin-fixed paraffin-
embedded (FFPE) tissue specimen’s availability (Table S1). These patients were recruited 
and vaccinated as described in (19, 20). Briefly, 29 HLA-A2+ patients with histologically 
proven metastatic melanoma of the skin expressing Melan-A/MART-1 were included upon 
informed consent, and received 4 vaccinations subcutaneously in monthly intervals 
composed of Melan-A analog (ELA) or native (EAA) peptide ± Tyrosinase (YMD) peptide, 
CpG-7909 and Montanide ISA-51 adjuvants. The patients were evaluated for immune 
response (CD8+ T cell response), treatment toxicity, tumor response and survival (Table S2). 
On the 29 patients included in the study, 25 were selected for analysis and 4 were excluded 
(one patient had uveal melanoma and three patients did not have any FFPE tissues 
available). 14 primary melanoma samples from 14 patients, 33 metastatic LNs from 14 
patients (25 metastatic LNs were taken before the vaccination and 10 metastatic LNs were 
taken after the end of the vaccination trial) and 23 non-metastatic LNs from 20 patients (17 
non-metastatic LNs were taken before the vaccination and 6 non-metastatic LNs were taken 
after the end of the vaccination trial) were obtained and were analysed for their immune cell 
types, lymphatic vessel and immunosuppressive molecule densities (Table S3, S4 and Fig. 
S1A-J). 14 non-metastatic LNs from 12 patients were from negative LN dissection and 9 non-
metastatic LNs from 8 patients were from positive LN dissection.  
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2. Immunohistochemistry (IHC) 
Chromogenic IHC staining 
4-µm tick tissue sections were first deparaffinised in xylene and rehydrated by sequential 
incubation in EtOH/water solutions. Tissues were then treated with 3% H2O2 in distilled water 
for 5 minutes to quench endogenous peroxidase activity. Heat-induced antigen retrieval was 
performed in Tris-EDTA buffer (pH 9) for 1’30’’ in a steamer. Subsequently, sections were 
incubated at room temperature with primary antibodies to CD8 (clone C8/144b, Dako, 1:30, 
32 min), CD4 (clone 4B12, Novocastra, 1:10, 90 minutes), CD19 (clone BT51E, Novocastra, 
1:50, 32 min), FoxP3 (clone 236a/E7, Abcam, 1:50, 60 min), Podoplanin (clone D2-40, 
Covance, 1/400, 60 min), Prox-1 (R&D, 1:100, 32 min), VEGF-C (Invitrogen, 1:20, 40 min), 
IDO (from Brussels, 1:500, 40 min), iNOS (Thermoscientific, 1:75, 40 min), Arg-1 
(Mybiosource, 1:300, 40 min), Melan-A (clone A103, Dako, 1:50, 32 min), melanosome 
(clone HMB45, Dako, 1:50, 32 min) and S100 (Novocastra, 1:800, 40 min) followed by a 
secondary anti-mouse (K4001, Dako), anti-rabbit (DK4003, Dako) or anti-goat antibody 
(Histofine RTU-Biosciences) RTU/HRP ENVISION for 30 minutes. 3-amino-9 ethylcarbazole 
(AEC) was used as a red chromogen (K3464, Dako) for CD4, S100, Melan-A and 
melanosome and Diaminobenzidine (DAB, K3468, Dako) as a brown chromogen (K3468, 
Dako) for the rest of the antibodies. After rinsing with water, sections were counterstained 
with Hematoxylin Gill II (Merck 1.05175) and coverslipped with xylol. CD8, CD4, CD19, 
FoxP3, Podoplanin, Prox-1, Melan-A, S100 and Melanosome were done on Ventana 
BenchMark machine using Cell Conditioning 1 (CC1, 950-124, Ventana) as a buffer for heat-
induced antigen retrieval with varied time for the different antibodies, other reagent and time 
was done as described above. iNOS, VEGF-C, Arg-1 and IDO were done manually with the 
above-mentioned protocol. Positive controls included tonsil, lung, liver and colon. 
Immunostaining with appropriate isotype control antibodies were used as negative controls.  
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Conventional immunofluorescence staining  
As for chromogenic IHC staining, 4-µm tick tissue sections were first deparaffinised in xylene 
and rehydrated by sequential incubation in EtOH/water solutions. Antigen retrieval was 
performed using a 15 minutes incubation in boiling Tris-EDTA buffer (pH 9), following 30 
minutes incubation in blocking solution (TBS+0.01% Triton X-100+2%BSA+2%total serum 
from host secondary antibody). Sections were incubated overnight at 4°C with primary 
antibodies to CD8 (clone C8/144b, Dako, 1:30), Podoplanin (clone D2-40, Covance, 1/200), 
Prox-1 (R&D, 1:100), iNOS (Thermoscientific, 1:75), Arg-1 (Mybiosource, 1:300), IDO (from 
Brussels, 1:500), CCL21 (Atlas antibodies, 1:200) and PD-L1 (Cell Signaling,1:200). Alexa 
Fluor 488-labeled donkey anti-mouse IgG (Invitrogen, 1:400), 568-labeled donkey anti-goat 
IgG (Invitrogen, 1:600) and 647-labeled donkey anti-rabbit IgG (Invitrogen, 1:800) antibodies 
were used as secondary antibodies and incubated for 1 hour at room temperature. After 
stringent washes, sections were counterstained with DAPI (Vector Laboratories, Burlingame, 
CA) for 5 minutes and coverslipped with mounting medium (Vectashield mounting media). 
Positive controls were done on tonsils, LNs and skin tissues. Negative slides used TBS 
instead of primary antibody, with other conditions constant. Images were obtained with 
confocal microscope ZEISS LSM 700 UPRIGHT. 
Tyramide Signal Amplification (TSA) system 
Multiplex stainings were done on the same slides described in part 1 using the automated 
Discovery ULTRA Staining Module (Ventana, Roche). Staining was done in consecutive 
rounds and each round consisted of: antigen retrieval, blocking, primary antibody, secondary 
antibody and TSA amplification as described before (21). Following primary antibodies were 
used: CD8 (clone SP16, Fischer Scientific AG, 1:1000), Granzyme B (Clone Grb-7, 
Monosan, 1:100) and PD-1 (Clone MRQ-22, BioSB, 1:1200). Polyclonal goat anti-mouse 
Immunoglobulins/HRP (P044701, DAKO) and polyclonal goat anti-rabbit 
Immunoglobulins/HRP (P044801, DAKO) were used as secondary HRP-labelled antibodies. 
This was followed by consecutive incubations with TSA reagents: TSA Cyanine 3 
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(NEL744B001KT, Perkin Elmer (PE)), TSA Cyanine 5 (NEL745B001KT, PE), TSA Cyanine 
3.5 (NEL763B001KT, PE), TSA Fluorescein (NEL741B001KT, PE), TSA Cyanine 5.5 
(NEL766B001KT, PE). Sections were counterstained with DAPI (422801, Lucerna Chem 
AG) and coverslipped with mounting medium (S3023, DAko fluorescence mounting media). 
3. Staining quantification 
Imagescope Aperio software 
Whole slide digital images were obtained for each specimen stained with Chromogenic IHC 
staining using NanoZoomer 2-HT digital slide scanner (Hamamatsu). The resulting high-
resolution digital images were analysed using the ImagescopeTM software, version 12.1 
(Aperio Technologies, Vista, CA, USA) using the positive pixel cell algorithm 9.1 as 
previously described and validated (22). Briefly, this algorithm detects pixels that match input 
parameters set for the algorithm and generates four output values based on the pixel’s color 
range: haematoxylin or negative signal (blue in mark-up image), weak positive (yellow in 
mark-up image), positive (orange in mark-up image) and strong positive (brown in mark-up 
image) (Fig. S2A). Using these parameters, the strong non-specific (brown) as well as the 
weak positive (yellow) signals were considered as debris background staining, whereas the 
positive value (orange) was considered as specific. Folds, debris, holes were also removed 
manually to be exclude from the staining quantification analysis. Quantification of the staining 
in the tissue selected was reported as a relative abundance ratio, which was based on the 
number of positive pixels (orange) divided by the total number of pixels (blue + yellow + 
orange + brown). The relative abundance ratio was reported in % and represented the 
percentage of density per tissue area for the quantified staining. Results obtained were 
controlled to match with visual inspection. 
The positive pixel cell algorithm has been applied in the total tissue of the non-metastatic 
LNs whereas metastatic LNs and primary tumors have first been divided into relevant 
histological regions. For metastatic LNs, we selected 6 different zones. 1) tumor cells, 2) 
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stroma, 3) residual LN, 4) reactive connective tissue, 5) capsule, 6) total tissue. For the 
primary melanoma tumor, we selected 4 different regions: 1) Invasive Margin (IM), 2) Center 
of the tumor (CT), 3) Peritumoral region and 4) Normal skin. Finally, a trained pathologist 
confirmed the quality of all the zone and analyses.  
Vectra multispectral analysis system (Perkin Elmer) 
Fluorescence slides stained with TSA system were scanned in a batch format by using the 
Vectra multispectral imaging system (Perkin-Elmer). Tissue finder algorithm was first applied 
to scan the entire tissue in low power field and then 15 20x multispectral images were 
randomly acquired from the collected areas. Images were processed by using inForm tissue 
finder software (PerkinElmer). For unmixing of the images and analysis, the spectral libraries 
of DAPI as well as of all the fluorochroms were generated. The percentages of Granzyme B 
and PD-1 that colocalized with CD8 within the tumor areas were calculated through a 
thresholded colocalization analysis (Fig. S2B). Thresholds used to determine the cutoff for all 
three antibodies stains were set visually. 
4. Statistical analysis 
The non-parametric Mann–Whitney U test was used to assess statistical significance of 
differences between two data sets. Correlation coefficients were computed using 
Spearman's non-parametric test. To compare categorical data, One-Way ANOVA Kruskal-
Wallis unparametric test was applied with post-hoc test Dunn correction. A p value of less 
than 0.05 was considered to indicate significance. Analyses were performed with GraphPad 
Prism, version 6.0b.  
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Results 
Method for quantitative IHC assessment in specific tissue zones of tumors from 
melanoma patients 
Frequently, IHC staining is quantified by visual assessment (HSCORE). This method can be 
subjective and can lead to variability depending on the observer, especially when evaluating 
the expression of novel markers. Recently, the emergence of automated IHC measurement 
using computer-based analysis systems began to overcome these limitations. To date our 
knowledge of lymphatic vessel density and the distribution and infiltration of immune cells in 
melanoma samples comes from visual and/or computer-based quantification of specific 
regions (i.e. hot spots) or from small core biopsies containing representative areas of tumor 
or stroma tissue. For our analyses, we used a ‘whole-slide’ imaging software (Aperio 
Technologies, Vista, CA, USA) to quantify staining upon distinctly defined tissue zones.  
For our IHC quantification strategy, we selected four zones in each of the 14 primary 
melanomas selected (Fig. 1A): 1) Invasive Margin (IM), 2) Center of the tumor (CT), 3) 
Peritumoral region and 4) Normal skin. Tumor cells were identified based on Melan-A, 
Melanosome (HMB45) and S100 positive staining or morphological criteria (large atypical 
and pleomorphic cells with abundant eosinophilic cytoplasm, visible nucleoli and mitosis) 
when these markers were negative. The invasive margin (IM) was defined as a tumor region 
of 400-µm width between the tumor and the reticular dermis. The remaining tumor was 
defined as center of the tumor (CT). The peritumoral region was defined as a region of 400-
µm width in the dermis surrounding the invasive margin. Finally, normal skin was determined 
as a region of 200-µm width separated by at least 1mm from tumor cells. Normal skin was 
identifiable on 9 primary tumor samples (64%).  
For the analysis of lymph node metastases, we pre-selected 33 metastatic LNs from 14 
melanoma patients. 10 metastatic LNs were excluded from the analysis because of the 
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presence of large regions of tumor necrosis (2/10), presence of excessive melanin pigments 
rendering analysis impossible (5/10), tumor metastasis less than 1mm2 (1/10) or tumor 
metastasis size more than 98% of the entire LN (2/10). In the 23 remaining metastatic LNs, 
we defined six different zones corresponding to the different micro-anatomical regions (Fig. 
1B): 1) tumor cells, 2) stroma, 3) residual LN, 4) reactive connective tissue, 5) capsule, 6) 
total tissue. The tumor cell zones were determined as previously described for primary 
tumors. Stroma was defined as connective tissue surrounding the tumor cells (present in 14 
(61%) metastatic LNs). Regions of the LN that did not match the tumor or stroma criteria 
were considered as “residual LN” (these zones were similar to non-metastatic LN regions) in 
19 metastatic LNs (83%). A dense and inflammatory irregular connective tissue was present 
around the LN and was described as reactive connective tissue (present in 13 (56%) 
metastatic LNs). Finally, the capsule was composed of thin dense irregular connective tissue 
surrounding the LN and was present in 16 (69%) metastatic LNs. 
Importantly, we also studied non-metastatic LNs that had been obtained through lymph node 
dissection surgery. We analyzed the total area without defining specific zones in these 23 
non-metastatic LNs. 
Enhancement of lymphatic vessels in melanoma tissues 
LECs are commonly described as being positive for Prox-1 (in the nucleus) and podoplanin 
and/or Lyve-1 (on the membrane). But depending on the tissue types investigated and the 
heterogeneity of tumor-associated lymphatic endothelium, their specificity can be variable 
(23). To optimize the characterization of tumor-associated lymphatics, we first stained 
primary melanoma tumors, metastatic LNs and non-metastatic LNs for Prox-1 and 
podoplanin by IHC. Interestingly, we found expression of Prox-1 and podoplanin in the 
analysed tissues (Fig. 2A – F).  Melanoma cells in primary tumor and in metastatic LNs 
expressed Prox-1 in the cytoplasm (Fig. 2B, 2D) in combination with other melanoma cell 
markers such as Melan-A (Fig. S3A). As expected, lymphatic vessels in the primary tumor 
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(Fig. 2A) and in the tumor region of metastatic LNs (Fig. 2C) expressed podoplanin and 
nuclear Prox-1. In the stromal region of metastatic and in non-metastatic LNs Prox-1 better 
identified LECs since, in some tissue sections, other cells also expressed podoplanin such 
as follicular dendritic cells (FDCs) in germinal centres (Fig 2C, 2E). However, alpha-sma 
staining did not colocalize with podoplanin in the three different tissues tested (Fig. S3B). 
Given these results we decided to optimize our lymphatic vessel quantification strategy using 
podoplanin in the primary tumor and in the tumor region of the LNs and Prox-1 in the stroma 
of metastatic and non-metastatic LNs as LEC-specific. Immunofluorescence imaging 
confirmed the co-expression of podoplanin and nuclear Prox-1 as being the best combination 
to identify lymphatic vessels in all tissues analysed (Fig. S3C).  
Demonstration of lymphangiogenesis in primary tumors 
Lymphatic vessels are found in prominent hot spots both within and around primary 
cutaneous malignant melanoma (24). Moreover, melanoma lesions have been shown to 
have higher intratumoral lymphatic vessels density (LVD) compared to benign melanocytic 
lesions, likely due pro-lymphangiogeneic factors such as VEGF-C secreted by tumor cells 
(25). Indeed, in our study, lymphatic vessel staining quantification of the primary tumor (IM, 
CT and peritumoral areas) and the adjacent normal skin revealed increased Prox-1 and 
podoplanin-expressing lymphatics in the IM and peritumoral areas compared to the adjacent 
normal skin (Fig. 3A, 3B). A positive correlation was observed between podoplanin and Prox-
1 in the IM (Spearman correlation, rho = 0.57, p = 0.08) and in the peritumoral area (rho = 
0.5, p = 0.12), validating the fact that lymphangiogenesis occurs primarily in these zones 
(Fig. 3C). VEGF-C is a growth factor produced by tumor cells and tumor-associated 
macrophages (TAM) that promotes lymphangiogenesis. To assess potential pro-
lymphangiogenic roles of VEGF-C, we compared VEGF-C expression in the different regions 
of the primary tumor and correlated VEGF-C with the two lymphatic markers. In comparison 
with podoplanin and Prox-1, we did not observe a statistically significant difference in VEGF-
  
62 
 
C expression throughout the tumor regions and the adjacent normal skin (Fig. 3D). However, 
VEGF-C correlated positively with Prox-1 in the peritumoral area (rho = 0.63, p = 0.04) (Fig. 
2E) whereas only a trend was seen for podoplanin in the peritumoral area (rho = 0.5, p = 
0.09) (Fig. 2F).  
Association of lymphatic vessels with immune suppressive molecules and immune 
cells in primary tumors 
Next, we assessed associations between lymphatic vessels and immune suppressive 
molecules. Interestingly, there was a highly significant positive correlation between 
lymphatics and iNOS expression in IM of the primary tumor (rho = 0.74, p = 0.004) but not in 
the CT (rho = 0.32, p = 0.29) or in the peritumoral region (rho = -0.11, p = 0.72) (Fig. 4A). 
iNOS was mainly produced by melanoma cells and lymphatic vessels did not display 
cytoplasmic expression of iNOS (Fig. 4D). In contrast, lymphatics correlated positively with 
IDO expression in the CT of the primary tumor (rho = 0.58, p = 0.04) (Fig. 4B) but neither 
iNOS nor IDO were expressed by lymphatic vessels (Fig. 4E). Finally, there were no 
statistically significant correlations among lymphatic vessels and Arg-1 expression in the 
three different regions (Fig. 4C, 4F).  
A major aim of our study was to evaluate and quantify the density of infiltrating lymphocytes 
in primary tumors using CD8, CD4, CD19 and FoxP3 markers and to investigate potential 
associations with lymphatic vessels. While correlating these markers with podoplanin, we 
found highly significant associations between lymphatic vessels and CD8+ cells in the three 
different regions of the primary tumor (CT: rho = 0.69, p = 0.01; IM: rho = 0.66, p = 0.01 and 
Peritumoral: rho = 0.78, p = 0.003) (Fig. 5A, 5E). Interestingly, we saw that these 
associations held true not only between different patients but also in different regions of a 
particular patient’s tumor, implicating that regions with a greater density of lymphatics have 
higher CD8+ infiltration compared to regions with lower density of lymphatics. Analysis of 
CD4+ and CD19+ cells in relation to lymphatics showed positive trends for CD4 only in the IM 
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(IM: rho = 0.3, p = 0.07) (Fig. 5B) and for CD19 in the three regions of the tumor samples 
(CT: rho = 0.37, p = 0.12; IM: rho = 0.51, p = 0.16 and Peritumoral: rho = 0.26, p = 0.13) (Fig. 
5C). No significant correlations were seen for FoxP3+ infiltrating cells (CT: rho = 0.31, p = 
0.35; IM: rho = 0.3, p = 0.34 and Peritumoral: rho = 0.19, p = 0.54) (Fig. 5D). In order to 
better assess the phenotype of CD8+ infiltrating cells, we performed multiplex staining for 
CD8, PD-1, and Granzyme B on 10 primary melanoma samples. Importantly, CD8+ cells in 
the tumor were found to be mostly Granzyme B- than Granzyme B+ (Mann-Whitney, p = 
0.0003) (Fig. 5F) and mostly PD-1- than PD-1+ (p = 0.004) (Fig 5G). No statistically significant 
association was observed between lymphatic vessels in the tumor and infiltration of 
CD8+GranzymeB- (rho = 0.31, p = 0.42), CD8+GranzymeB+ (rho = 0.32, p = 0.49), CD8+PD-1- 
(rho = 0.05, p = 0.91) or CD8+PD-1+ (rho = 0.26, p = 0.49) (Fig. 5H).  
Correlations between anti-tumoral T cell responses and vaccination 
Patients in this cohort had been included in a cancer vaccine trial in which they received 
monthly subcutaneous (s.c) injections of Melan-A/MART-126-35 peptide and CpG-B 7909, 
emulsified in incomplete Freund’s adjuvant (IFA). The phenotype and the functionality of 
specific CD8 T cells in the blood of these patients had been assessed previously (20, 26). 
Briefly, peripheral blood mononuclear cells (PBMC) were collected at different time points 
during the course of vaccination and direct ex vivo tetramer analysis of Melan-A-specific 
CD8+ T cells and Enzyme-Linked ImmunoSpot (ELISPOT) analysis of total PMBC for IFN-γ 
production after 24 hours incubation with Melan-A were performed. The peak value of Melan-
A-specific CD8+ T cells and IFN-γ producing Melan-A specific CD8+ T cells reached during 
the study was used to assess the response to vaccination. Since we observed that lymphatic 
vessel density correlated with both higher iNOS expression and higher T cell infiltration in the 
tumor, we evaluated lymphatic vessel density in the primary tumor together with the T cell 
response to vaccination. No correlation was found between lymphatics in the primary tumor 
and peak frequencies of Melan-A specific CD8+ T cells in the blood reached during the study 
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(Fig. 6A). Remarkably, more lymphatic vessels in the IM were associated with less IFN-γ 
production by Melan-A specific CD8+ T cells present in the blood of patients during the 
vaccination study (IM: rho = -0.8, p = 0.01). In contrast, lymphatics present in the CT and the 
peritumoral area did not correlate negatively with frequency of IFN-γ-producing Melan-A 
specific CD8+ T cells in the blood (CT: rho = -0.4, p = 0.19; Peritumoral: rho = 0.02, p = 0.93) 
(Fig. 6B). The same association between lymphatics and IFN-γ-producing Melan-A specific 
CD8+ T cells was also observed for iNOS (Fig. 6C, 6D), suggesting that iNOS expressing 
cells attracted by lymphatic vessels in IM impair the functionality of Melan-A specific CD8+ T 
cells responding to the vaccine. Moreover, we also found a positive correlation between 
Melan-A expression in the IM and the frequency and functionality of Melan-A specific CD8 T 
cells in the blood of vaccinated patients (Fig. 6E, 6F). 
Associations between lymphatic vessels, infiltrating immune cells and immune 
suppressive molecules in metastatic LNs  
Regional LN metastases are important for prognosis and treatment decisions. LNs are the 
primary sites of adaptive immune responses. Since we found that the density and the 
phenotype of lymphatic vessels in the IM of primary tumors correlated with the quality of the 
anti-tumoral T cell response, we hypothesized that similar associations may be seen in 
metastatic LNs of these patients. Indeed, in metastatic LNs we found that greater lymphatic 
vessel density in the tumor region correlated positively with higher CD8+ cell infiltration in the 
tumor areas of metastatic LNs (rho = 0.6, p = 0.002) (Fig. 7A, 7E). Here again, no correlation 
was detected between lymphatic vessels and CD4+ cell infiltration in the tumor (rho = 0.27, p 
= 0.22) (Fig. 7B). Strikingly, as opposed to primary tumors, positive associations between 
lymphatic vessel density were found for CD19+ (rho = 0.68, p = 0.0007) (Fig. 7C) and FoxP3+ 
(rho = 0.44, p = 0.03) (Fig. 7D) infiltrating cells, as observed in the tumor region of metastatic 
LNs, suggesting potentially immune suppressive roles of lymphatic vessels. IHC 
quantification of Granzyme B and PD-1 expression in tumor-infiltrating CD8+ cells in primary 
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tumor highlighted greater infiltration of CD8+GranzymeB- (p < 0.0001) (Fig. 7F, left panel) 
and CD8+PD-1- (p = 0.0003) (Fig. 7F, right panel) in the tumor region. However, we did not 
find a positive correlation between tumor-associated lymphatic vessels and infiltration of 
CD8+GranzymeB- (rho = -0.66, p = 0.88), CD8+GranzymeB+ (rho = 0.07, p = 0.88), CD8+PD-
1- (rho = 0.02, p = 0.98) and CD8+PD-1+ (rho = 0.26, p = 0.49) (Fig. 7G). Similar to the IM of 
primary tumors, iNOS expression in the tumor region of metastatic LNs was found to 
correlate with tumor-associated lymphatic vessels (rho = 0.47, p = 0.02) (Fig. 7H). 
Interestingly, compared to primary tumors, some tumor-associated lymphatic vessels 
demonstrated direct expression of iNOS in the cytoplasm (Fig. 7J), thus suggesting direct 
and active modulation of TME by tumor-associated lymphatics. Even if positive associations 
were observed between lymphatic vessels and IDO+ expressing cells (rho = 0.49, p = 0.02) 
(Fig. 7I), direct expression of IDO in LECs was not observed (Fig. 7K). Arg-1 was not 
associated with lymphatic vessels density and was not expressed by LECs (data not shown). 
Finally, these different positive associations between lymphatic vessels, immune cells and 
immune suppressive molecules did not hold true in stroma regions of metastatic LNs (data 
not shown).  
Mouse melanoma tumors have been reported to pre-condition future sites of metastasis in 
the lymph node by enhancing lymphangiogenesis, inducing an immunotolerant 
microenvironment and thus impairing the development of anti-tumor immunity (27, 28). This 
mechanism has been shown to be driven by secretion of VEGF-C and CCL21 by tumors (16, 
17). To address the potential role of VEGF-C in modulating host antitumor immunity in 
human melanoma, we looked at associations between VEGF-C and tumor infiltrating 
immune cells and immune suppressive molecules in metastatic LNs. We observed a strong 
positive correlation between VEGF-C expression in the tumor region of metastatic LNs with 
iNOS (rho = 0.47, p = 0.0002) (Fig. 8A, 8E) and IDO (rho = 0.69, p = 0.021) (Fig. 8B, 8E) in 
the same region. Furthermore, a positive trend was also seen with CD8 (rho = 0.29, p = 0.17) 
(Fig. 8C, 8E) and FoxP3 (rho = 0.34, p = 0.11) (Fig. 8D, 8E) but not with CD4 (rho = -0.14, p 
  
66 
 
= 0.51) or CD19 (rho = 0.17, p = 0.44) (data not shown). We found similar trends in the 
stroma regions of metastatic LNs, although the results were not statistically significant due to 
the limited number of samples containing a region of stroma (data not shown). 
Recent studies have suggested that larger size melanoma metastases in lymph nodes 
correlate with shorter progression-free survival (29). We therefore postulated that the degree 
of tumor-infiltration may have an impact on tumor-associated lymphatic vessels by inducing 
them to promote a more immune suppressive TME. Tumor size was calculated by taking the 
mean of the total number of positive and negative pixels (= total tumor density) in Melan-A, 
HMB45 and S100 stained slides divided by the total number of pixels of the entire LN (= LN 
size). Metastatic LNs were ordered by tumor size and divided into two groups. (Fig. 9A, left 
panel). Metastatic LN tumor sizes below the median were considered as “low tumor-
infiltrated LNs” and those above the median as “high tumor-infiltrated LNs” (Fig. 9A, right 
panel). Remarkably, lymphatic vessels present in the tumor regions of high-tumor infiltrated 
LNs were associated with higher infiltration of CD8+ cells (rho = 0.79, p = 0.0008) (Fig. 9B), 
CD19+ cells (rho = 0.64, p = 0.04) (Fig. 9D) and FoxP3+ (rho = 0.71, p = 0.02) (Fig. 9E) but 
not CD4+ cells (rho = 0.06, p = 0.86) (Fig. 9C) compared to lymphatics present in the tumor 
of low-tumor infiltrated LNs. Furthermore, these lymphatic vessels were also associated with 
higher iNOS+ cells (rho = 0.66, p = 0.04) (Fig. 9F) and (rho = 0.87, p = 0.001) VEGF-C+ cells 
(Fig. 9H) as well as higher iNOS expression in their cytoplasm compared to those of low-
tumor infiltrated LNs (Fig. 9G). 
Lymphatic vessels, immune cells and immune suppressive molecules in non-
metastatic LNs 
In parallel, we also analyzed 23 non-metastatic LNs from the same patients. A positive trend 
was observed between lymphatic vessels and CD8+ (rho = 0.31, p = 0.15) (Fig. 10A) cell 
infiltration. No correlation was found with CD4+ (rho = -0.002, p = 0.98) (Fig. 10B), CD19+ 
(rho = -0.14, p = 0.54) (Fig. 10C) or FoxP3+ (rho = 0.34, p = 0.19) (Fig. 10D) infiltrating cells. 
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In line with what we saw for the primary tumor and metastatic LNs, we saw more 
CD8+Granzyme B- cells than CD8+Granzyme B+ in the total area of non-metastatic LNs (p < 
0.0001) (Fig. 10E). However, no statistically significant difference was observed between the 
number of CD8+PD-1- and CD8+PD-1+ cells in the total area of non-metastatic LNs (p = 0.37) 
(Fig. 10F). Interestingly, we found a positive trend between lymphatic vessels and CD8+PD-
1- (rho = 0.47, p = 0.12) and CD8+PD-1+ (rho = 0.45, p = 0.14) but not with CD8+GranzymeB- 
(rho = 0.26, p = 0.39) or CD8+GranzymeB+ (rho = 0.07, p = 0.88) (Fig. 10G). As in primary 
tumor and metastatic LNs, lymphatic vessels were strongly positively associated with iNOS 
(rho = 0.67, p = 0.0004) (Fig. 10H) but in contrast they were not associated with IDO (rho = 
0.12, p = 0.61) (data not shown) or VEGF-C (rho = 0.23, p = 0.32) (data not shown). 
Consistent with all melanoma tissues analyzed in this study, no correlation was observed 
between lymphatic vessels and Arg-1 expression (rho = 0.24, p = 0.25) (data not shown). As 
seen in metastatic LNs, some lymphatic vessels in non-metastatic LNs were also seen to 
express iNOS in their cytoplasm. Finally, also similar to metastatic LNs, VEGF-C correlated 
positively with iNOS (rho = 0.63, p = 0.002) and IDO (rho = 0.47, p = 0.02) (data not shown). 
Several studies have examined immune parameters in regional lymph nodes of melanoma 
patients, and have shown that LNs close to the primary melanoma or nodal metastases were 
less immunologically reactive than were more remote nodes as assessed by indices 
including the area occupied by the density of paracortical dendritic cells (DC) and T cells, 
capacity of T cells to inhibit or enhance melanoma cell growth in vitro, and the frequency of 
high endothelial venules (HEV) (30). These data suggest that the proximity of tumor-draining 
LNs to tumor cells can have an impact on anti-tumor immunity. As such, we analyzed non-
metastatic LNs with regard to the positivity of the total LN dissection from which they were 
derived. Of 23 non-metastatic LNs, 14 were from LN dissections where at least one LN was 
found to be positive for melanoma metastasis (“positive LN dissection” or “LN diss. +”). The 
remaining nine non-metastatic LNs were from LN dissections where no melanoma 
metastasis was found in any of the LNs removed (“negative LN dissection” or “LN diss. -”). 
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Interestingly, non-metastatic LNs from positive LN dissections had higher CD8+ and CD4+ (p 
= 0.04) cells compared to LNs from negative LN dissections (Fig. 11A, right and left panel). 
Statistical significance was not reached for FoxP3+ cells (p = 0.06, data not shown) and no 
difference was observed for CD19+ cells (p = 0.91, data not shown). A greater number of 
podoplanin+ (p = 0.005) and Prox-1+ (p = 0.02) lymphatic vessels were seen in LNs from 
positive LN dissections compared to negative LN dissections (Fig. 11B, right and left panel). 
In line with this, the non-metastatic LNs from positive LN dissections showed more iNOS (p = 
0.03) and Arg-1 (p = 0.02) but not more IDO (p = 0.12) or VEGF-C (p = 0.17) expression 
than LNs from negative LN dissections (Fig 11C). However, we did not find differences 
between the two groups for Granzyme B and PD-1 expression in CD8+ cells (Fig. 11D). 
Finally, lymphatic vessels in non-metastatic LNs from positive LN dissections showed a 
positive trend with CD8+ (rho = 0.4, p = 0.15) (Fig. 11E) cells but were negatively correlated 
with CD4+ (rho = -0.55, p = 0.04) (Fig. 11F) cells compared to LNs from negative LN 
dissection. No difference was observed for CD19+ (rho = -0.13, p = 0.66) and FoxP3+ cells 
(rho = 0.16, p = 0.57) (data not shown). iNOS (rho = 0.52, p = 0.04) expression correlated 
with lymphatic vessels within LNs from positive LN dissections compared to those from 
negative LN dissections (Fig. 11G). However, there was no correlation with Arg-1 (rho = -
0.12, p = 0.65), IDO (rho = -0.14, p = 0.62) or VEGF-C (rho = 0.32, p = 0.27) in LNs from 
positive LN dissections (data not shown). Importantly, higher iNOS expression in LEC was 
found in LNs from positive LN dissections as compared to those from negative LN 
dissections (Fig. 11H, upper and lower panel) 
Discussion 
Although researchers have long appreciated the clinical relevance of lymphangiogenesis in 
the TME (31) and the involvement of the lymphatic system in malignant spread, the 
underlying mechanisms remain poorly understood. Mouse melanoma models have recently 
demonstrated immune-modulatory effects of lymphangiogenesis in primary tumors and 
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draining LNs (16, 17, 32), thus proposing a link between lymphangiogenesis and poor clinical 
outcome of cancer patients (13, 24, 33). However, corresponding human data was still 
missing. In the present study, we assessed for the first time human lymphatic vessels as an 
active modulator of anti-tumor immunity and identified new associations between lymphatic 
vessels, immune cells and immune suppressive molecules in human melanoma tissues 
(Table 1). These findings improve our understanding of lymphangiogenesis as a tumor 
metastasis promoter, by linking it to the sculpting of host immunity, considered critical to 
tumor progression. 
The methodology of lymphangiogenesis quantification is predominantly based on the 
assumption that functional increases in lymphatic vessels during tumor growth occur in “hot 
spots” (i.e. areas of particularly high density of lymphatic vessels) (23). In recent decades, 
the majority of studies that investigated links between lymphangiogenesis and clinical 
outcome in human melanoma tissues have used staining quantification methods based on 
visual inspection and selection of hot spots (e.g. Weidner and Chalkley method) (25, 34, 35). 
Despite the recent emergence of computer-assisted image analysis that reduces the 
variability and subjectivity in quantifying lymphatic vessels, studies were still based on either 
selected hot spot regions or randomly selected fields (10, 36). In line with this, Balsat et al 
recently questioned the relevance of counting lymphatic vessels in hot spots by comparing 
intra- and peritumoral lymphatic vessel density using the hot spot technique with that 
determined by a computerized method on early cervical cancer tissues (37). While 
comparing the two groups they found that inter-observer variability obtained after 
quantifications within hot spot regions reached 33.8% and 23.6% of intra- and peritumoral 
LVD respectively. The same was even true for intra-observer variability, whereas this 
variability did not exceed 5% with the whole slide analysis using the computer–assisted 
technique. Furthermore, few studies have investigated and compared LVD in different 
involved and non-involved melanoma tissues (38). 
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We analysed specific regions as well as entire tissue sections of different melanoma-
associated tissues with dedicated analysis software. Our quantification of lymphatic 
vasculature and further markers covers unusually large tissue areas in a reproducible 
manner. However, this zone-defined method is time consuming and not well suited to 
analysis of large numbers of cases. In our study, we used the pixel count algorithm 
(ImageScopeTM, Aperio) to quantify lymphatic vessels, immune cells and immune 
suppressive molecules. This algorithm presents several advantages as well as 
disadvantages. Pixel based analysis has been shown to be more precise than cell-counting 
algorithms, especially in the setting of dense cell concentrations such as in LNs (data not 
published). Pixel based analysis has been validated as an accurate strategy by which to 
assess the relative density of positively stained cells in tissue sections (22). However, pixel 
counts may not be precise in the setting of high heterogeneity in the cell size, and did not 
represent the numbers of distinct lymphatic vessel structures or cells per tissue area. 
Moreover, such algorithms are imprecise in capturing the area and circumference of vessel 
lumens, and in the evaluation of potentially important structural and morphological features of 
lymphatic vessels and other cells (39). 
As recommended recently, we used podoplanin in combination with the nuclear marker Prox-
1 to specifically quantify lymphatic vessels (23). However, recent studies pointed out that 
podoplanin can also be expressed by melanoma cells, cancer-associated fibroblasts (CAFs) 
(40), fibroblastic reticular cells (FRCs) (41) and FDCs (42) in lymphoid organs. We did not 
find podoplanin staining in melanoma cells when considering either primary melanoma or 
metastatic LNs. These data agree with Jokinen et al who showed absence of podoplanin 
expression in cutaneous melanoma devoid of spindle cell morphologic features (43). Co-
staining of alpha-sma and podoplanin did not reveal any colocalization between the two 
markers in any of the tissues analysed, suggesting that podoplanin expression does not 
correlate with alpha-sma positive CAFs and FRCs. Podoplanin expression in CAFs in human 
primary melanoma was described in only one IHC study, however in absence of co-staining 
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with alpha-sma, CD10, CD34, desmin, or similar markers (40). In addition, a recent 
comprehensive study by Kitano et al showed that stromal CAFs express podoplanin in only 
some but not all types of cancers (44). Melanoma was not considered in this study. The 
heterogeneity of CAFs and the lack of specific markers to identify them could explain these 
discrepancies and underscore the need for further studies on podoplanin expression in 
human melanoma tissue samples. Nevertheless, we observed podoplanin staining in the 
germinal centers of non-metastatic LNs suggesting positive FDCs, but we did not confirm this 
finding with antibodies specific for FDCs.  
Surprisingly, we found Prox-1 staining in the cytoplasm of melanoma cells. Prox-1 is a 
forkhead-box-transcription factor widely known to have an IHC nuclear expression pattern, 
notably in LECs but also in tumor cells, as previously described in colon cancer (45). 
However, recent evidence suggests that cytoplasmic Prox-1 IHC staining is not a false-
positive expression, though this needs to be validated through more in-depth techniques like 
in situ hybridization (46). One possible explanation is that Prox-1 is enriched and activated in 
the cytoplasm before being translocated to the nucleus to become functionally active (47). Of 
note, other studies have also investigated the expression of Prox-1 and validated its 
cytoplasmic expression by reverse transcription polymeras chain reaction (RT-PCR), PCR or 
western blot (48, 49). Nevertheless, further investigation is required to understand the 
potential role of cytoplasmic expression of Prox-1 in tumor pathogenesis and cancer 
invasion. 
It has been reported that LVD is higher in and around primary melanomas compared to 
melanocytic nevi and normal dermis (25, 50, 51), thus supporting the data described here. 
The comparison of melanoma with normal skin suggests that lymphangiogenesis into the 
tumour must have occurred, even if we did not assess proliferation of LEC as now 
recommended by an international consensus on lymphangiogenesis quantification (23). In 
contrast, we did not find statistically significant differences between intra- (neither CT nor IM) 
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or peri-tumoral lymphatic vessel density as described by others (34, 52). However, other 
studies have also not found significant differences, or even contradictory results (36, 53). The 
major difference between our findings and those of Straume et al and Toader et al is that we 
have determined the relative density of lymphatic vessels within and around the entire 
melanoma and not by hot spot selection. Moreover, our quantification method relies on the 
analysis of two distinct regions within the primary melanoma, namely the IM and CT, which 
are not generally distinguished in other studies.  
Many reports have now established the role of VEGF-C in promoting lymphangiogenesis and 
lymph node metastases in mouse models of cancer as well as in human tumors (31). 
Nonetheless, a direct relationship between high immunohistochemical VEGF-C expression 
and high LVD has not always been found in cutaneous melanoma (34). This observation 
suggests the existence of additional mechanisms of action of VEGF-C on lymphatic vessels 
and tumor metastasis, such as promoting dilation of collecting lymph vessels and increasing 
lymph fluid drainage (54). Likely due to the limited number of patients analyzed in this study, 
we only found a positive trend between VEGF-C expression and lymphatic vessels in the 
peritumoral region of primary melanoma. It may well be that VEGF-C expression by cells 
other than tumor cells has a stronger impact on intratumoral lymphangiogenesis. In support 
of this interpretation, Boon et al found higher percentages and intensities of VEGF-C staining 
in TAMs compared to tumor cells, in their study on 113 primary melanomas (55). 
Furthermore, Gallego et al showed that VEGF-C expression by peritumoral dermal 
fibroblasts in primary melanoma was associated with the presence of metastases in regional 
lymph nodes, whereas this association was not seen with VEGF-C expression by tumor cells 
(56).  
Taken together, our results suggest that VEGF-C promotes tumor lymphangiogeneis in 
primary tumors, particularly in and around the invasive margin. In line with this, several 
studies have concluded that the extent of invasive margin and peritumoral 
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lymphangiogenesis was the most important prognostic factor for melanoma metastases (57, 
58).  
The role of VEGF-C and lymphangiogenesis, which enables and enhances communication 
between tumors and draining lymph nodes, in modulating anti-tumor immune responses has 
not yet been explored in human cancer. Here, we report for the first time a positive 
association between lymphatic vessels and CD8+ T cell infiltration in primary cutaneous 
melanoma. In contrast to CD8+ T cells, only a positive trend was seen for CD4+ T cells and 
CD19+ B cells. Interestingly, these associations were found in the three different zones 
delimited in the primary tissue sections, suggesting that lymphatic vessels may promote 
accumulation of CD8+ T cells not only around but also within the tumor mass.  
Although controversy has prevailed on the presence and functionality of intratumoral 
lymphatic vessels (with regard to fluid drainage or transport of tumor cells) in mouse models 
of human fibrosarcoma, melanoma and prostate cancer (57, 59), intratumoral lymphatics 
have been observed in human melanoma and were found more frequently in patients with 
LN metastases (24). In this regard, Ondondo et al have recently shown that naïve T cells can 
accumulate within tumors through lymphatic vessels in a fibrosarcoma mouse model, 
suggesting that tumor-associated lymphatics not only drain lymph to the tumor-draining LNs 
but can also deliver lymph directly to the tumor, thus potentially attracting immune cells (60). 
Furthermore, Shields et al reported that CCL21-secreting mouse melanoma tumors induced 
the formation of lymphoid-like reticular stroma networks and enhanced the recruitment of T 
cells, specifically regulatory T cells, within the tumor mass, therefore creating an immune 
suppressive microenvironment (17). In contrast, we did not find significant associations 
between lymphatic vessels and FoxP3+ cells. Nevertheless, CD8 T cells in the TME were 
found to be preferentially Granzyme B negative and PD-1 negative. These findings are 
compatible with the notion that CD8 T cells were not highly differentiated (Granzyme low) or 
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activated (PD-1 low). However, this interpretation is not definitive and alternative 
explanations are possible. 
Further ex-vivo analysis will be needed to better characterize the phenotype and the 
functionality of the immune cells present in primary tumor with high LVD compared to those 
with low LVD. This knowledge will be important to assess the contribution of these cells to 
the antitumor immune response and their involvement in shaping the progression of the 
tumor. Finally, in-depth analysis of the expression of chemokine and homing receptors on 
immune cells and lymphatic vessels, as well as mechanistic studies, will be required in order 
to understand which cells are attracted by lymphatic vessels, potentially explaining the 
differences seen in correlations of lymphatic vessels and immune cells in this study. 
Nevertheless, our data suggest that LECs not only express trafficking molecules that affect 
migration of immune cells, but also play several other roles in modulating immune 
responses. 
Although the presence of HEVs have been described in primary melanoma and have been 
linked to a good clinical outcome (61, 62), conflicting results exist in regard to the presence 
of tertiary lymphoid structures (TLSs) in primary melanoma, in spite of the fact that the latter 
frequently contain HEVs (63, 64). While we found a positive association between lymphatics 
and CD19+ B cells in the primary tumor, we did not detect B cell clusters in the tumor 
samples examined here. However, this increased infiltration of B cells in association with 
lymphatic vessels in primary melanoma underlines the probable involvement of lymphatics in 
shaping the humoral immune response. There is still a paucity of information on the 
interactions between lymphatics and B cells and this needs to be further delineated to better 
understand the role of humoral immunity in cancer.  
It has been shown recently that LECs not only express trafficking molecules that affect the 
migration of immune cells, but also possess the appropriate machinery to modulate T cell 
function. Indeed, studies have reported that LECs could directly induce T cell tolerance as 
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well as suppress DC-mediated T cell activation by secreting a variety of immune suppressive 
factors such as TGF-β, IDO and iNOS (18).  In one study, Kornek et al reported that mouse 
in vitro-expanded LECs mediated direct suppression of T cell proliferation and that IFN-γ 
derived from activated T cells was essential for this suppressive mechanism (65). A 
subsequent report from Nörder et al demonstrated that human in vitro IFN-γ-activated LECs 
produce IDO that suppresses T cell activation (66). However, these findings stemmed from in 
vitro studies of normal mouse and human LN derived-LECs. To date, these possible 
mechanisms of direct modulation of T cell function by LECs have not been shown in the 
cancer setting. Here, we observed significant associations between lymphatic vessels and 
iNOS expression at the invasive front and IDO expression in the CT. However, we observed 
neither iNOS nor IDO expression in tumor-associated lymphatics. It is of note that lymphatic 
vessels and iNOS expression in the IM of primary tumors was associated with an impaired 
functionality of Melan-A specific T cells in the blood following vaccination, suggesting that 
LECs are indeed active immune regulators and suppress T cell function in human melanoma 
patients. The reason that these findings were only found in the IM and not in the other zones 
defined in the primary tumor is still obscure and will require further investigation. 
Nevertheless, it is reasonable to assume that immune suppressive capacity is preferentially 
found in aggressive parts of tumors such as in the IM. Our study was only focused on 
possible associations between lymphatics and immune suppressive factors, therefore further 
mechanistic studies will be needed to address the role of LECs on the modulation of the anti-
tumor immune response. 
It is now well-established that tumor cells generate and secrete factors that can suppress 
immune responses in tumor-draining LNs (30, 67, 68). Since we found the same 
associations between lymphatic vessels, immune cells and immune suppressive molecules 
in metastatic LNs as in primary tumors from the same patients, our study identifies tumor-
draining LNs as a tissue for immunosuppression and suggests that the mechanisms 
operating there may be similar to those in primary tumors (69). These changes are 
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consistent with earlier reports that the tumor-promoting roles of lymphatics also occur in 
tumor-draining LNs in mouse models of melanoma (16). Furthermore, these positive 
associations between lymphatics, immune cells and immune suppressive factors such as 
iNOS and IDO held true in metastatic LNs with bigger tumor size. Interestingly, iNOS 
expression was found in the cytoplasm of tumor-associated lymphatics in these LNs, a 
finding that was not evident in the primary tumor. These data indicate that the degree of 
tumor-infiltration impacts on tumor-associated lymphatic vessels by inducing them to 
promote a more tolerogenic TME. We are currently continuing our analyses to determine 
whether lymphatic vessel phenotypes and functions differ between high and low tumor-
infiltrated LNs.  
In contrast to primary tumors, we found a significant correlation between lymphatic vessels 
and FoxP3+ lymphocytes. The question of whether regulatory T cells play an important role in 
melanoma progression and metastasis formation is still unanswered, and conflicting data 
have been reported with regard to clinical impact (6). Notably, although still recognized as 
the most specific marker for regulatory T cells, Foxp3 can also be expressed by activated 
human T lymphocytes (70). It is, therefore, difficult to draw conclusions on the phenotype of 
Foxp3+ lymphocytes in immunohistochemical studies. Further, more detailed studies on the 
relationship between Foxp3+ regulatory T cells and lymphatic vessels are warranted. 
Evidence from mouse models suggests that secretion of VEGF-C by tumor cells or other 
cells (e.g. B cells) induces LN lymphangiogenesis, fosters tumor metastases and suppresses 
anti-tumor immunity (16, 27, 28, 71). Although these mechanisms have been appreciated, 
the importance of the communication between the tumor and the draining LNs in suppressing 
anti-tumor immune responses (3), as well as the roles of tumor VEGF-C and 
lymphangiogenesis in modulating tumor immunity remained largely unexplored. Here, we 
provided the first evidence that VEGF-C is associated with iNOS and IDO expression in the 
tumor of metastatic LNs of melanoma patients, thus suggesting the induction of a tolerogenic 
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TME. Interestingly, VEGF-C correlated positively with CD8+ T cells and FoxP3+ lymphocytes. 
As recent data have shown that elements of the immune, inflammatory and angiogenic tumor 
microenvironment can have a strong impact on the prognostic value of CD8+ T cells (69), 
analysis of the overall inflammatory components of the TME and phenotype and functionality 
of immune cells will undoubtedly reveal information on the global immune contexture induced 
by VEGF-C in tumor-draining LNs of melanoma patients.  
Many studies have identified alterations in both local and regional immune functions of 
metastatic tumor-draining LNs that may contribute to expansion and metastasis formation 
(30). However, only limited data exists on the differences between LNs from node positive 
patients and node negative patients with regard to their immune function. Zuckerman et al 
examined differences in immune cell signatures between tumor-free LNs of node negative 
breast cancer patients and tumor-invaded sentinel lymph nodes (SLNs), tumor-free SLNs or 
tumor-free non-sentinel lymph nodes (NSLNs) of node positive breast cancer patients (38). 
This study provided the first report that immune-related gene expression (e.g. antigen 
presentation, cell cycle…) was down-regulated in node positive patients compared to those 
in node negative patients not only locally, but also systemically in circulating immune cells of 
these patients.  
In line with this, we investigated the immunological differences between non-metastatic LNs 
from patients with positive versus negative LN dissection surgery samples. We notably 
demonstrated that non-metastatic LNs from positive LN dissections were characterized by 
higher relative density of T lymphocytes, lymphatic vessels and immune suppressive 
molecules such as iNOS and Arg-1, as compared to those from negative LN dissections. 
However, we did not find a significant difference with regard to Granzyme B and PD-1 
expression on CD8+ T cells. Strikingly, lymphatic vessels correlated positively with iNOS but 
negatively with CD4+ T cells in non-metastatic LNs from positive LN dissections, as 
compared to those from negative LN dissections. These results suggest that lymphatic 
  
78 
 
vessels may induce immune dysfunction and alteration in non-metastatic LNs of positive LN 
dissection patients, thus implying that immune modulator functions of lymphatic vessels 
could be systemic and occur beyond the TME, prior to metastasis formation. Further detailed 
evaluation of immune functions in relation to lymphatics in non-metastatic LNs of both 
positive and negative LN dissection patients might provide important clues regarding the 
events leading to the development of melanoma LN metastasis.   
Mouse melanoma models have demonstrated the tumor-promoting role of lymphatics in the 
tumor and draining LNs. Here we describe novel associations between lymphatic vessels, 
immune cells and immune suppressive molecules within different tissues of melanoma 
patients. Lymphatic vessels were positively associated with iNOS and IDO as well as with 
locally enhanced CD8+ T cell infiltration within primary melanoma tissues and in metastatic 
LNs. Interestingly, non-metastatic LNs showed similar associations, albeit less pronounced. 
Nonetheless, these associations were predominantly seen in non-metastatic LNs from 
positive LN dissection patients. It is of note that tumor-associated lymphatic vessels were 
associated with systemically altered CD8 T cell responses. Taken together, these results 
strongly suggest that lymphatic endothelium is an active modulator of antitumor immune 
responses locally within different human melanoma tissues and systematically throughout 
large parts of the immune system. Due to the relatively small size of our patient cohort, these 
results should be validated in a larger independent cohort. Furthermore, since these findings 
are based on correlations found between different IHC markers, it would be particularly 
interesting to further investigate the underlying mechanisms with in-depth studies on both the 
function and phenotype of immune cell subsets by ex-vivo functional analysis as well as 
gene expression profiling and further systems biology analyses. A major aim in the 
development of cancer immunotherapies is to overcome suppression of anti-tumor T cell 
responses. Our study provides evidence that lymphatic endothelium is implicated in this 
suppression in melanoma patients, thus providing a rationale to launch clinical trials 
associating treatments that target lymphatic vessels, combined with established and future 
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immunotherapies (such as anti-PD-1 or anti-CTLA-4 antibodies, adoptive T cell therapy or 
vaccination), thereby improving treatment efficacy for cancer patients. 
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Figure legends 
Figure 1. Histological zones defined in primary melanoma and metastatic LNs. A) 
Representation of the different histological zones in one primary melanoma stained with 
Melan-A: center of the tumor (green), Invasive margin (red), peritumoral region (pink) and 
normal skin (light blue). B) Representation of the different histological zones in one 
metastatic LN stained with Melan-A: tumoral zone (green), stromal zone (red), residual LN 
(light blue), reactive connective tissue (dark blue), capsular and subcapsular zone (yellow) 
and total zone (pink). 
Figure 2. Podoplanin as a specific lymphatic vessel marker in tumor areas of primary 
tumors and metastatic LNs, and Prox-1 as a specific lymphatic vessel marker in 
stromal areas of LNs. Representative images of (A) podoplanin and (B) Prox-1 staining in 
the (i) IM, (ii) CT and (iii) peritumoral area. (C) Podoplanin and (D) Prox-1 staining in the (i) 
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tumor and (ii) stroma region of metastatic LNs. (E) Podoplanin and (F) Prox-1 staining (i) in 
non-metastatic LN. Scale bar, 100 µm.  
Figure 3. Lymphangiogenesis primarily occurs in the invasive margin (IM) and 
peritumoral area of primary tumors and correlates with VEGF-C expression in 
peritumoral areas. The density and the individual data points of (A) Prox-1 and (B) 
podoplanin expression in the different histological zones of primary melanoma tissues. Error 
bars indicate mean ± SEM (one-way ANOVA Kruskal-Wallis unparametric test with post-hoc 
test Dunn correction). C) Spearman correlation of Prox-1 positive lymphatic vessels in the 
CT, IM and peritumoral area of primary tumors in relation to podoplanin positive lymphatic 
vessels in the same areas. D) The density and the individual data points of VEGF-C 
expression in the different histological zones of primary melanoma tissues (one-way ANOVA 
Kruskal-Wallis unparametric test with post-hoc test Dunn correction). Spearman correlation 
of (E) Prox-1 and (F) podoplanin positive lymphatic vessels in the CT, IM and peritumoral 
area of primary tumors in relation to VEGF-C density in the same areas. Statistically 
significant differences are highlighted in bold, when p values were < 0.05. (CT): center of 
tumor; (IM): invasive margin; (Peri.): peritumoral area and (N. skin): normal skin. 
Figure 4. Lymphatic vessels in the IM of primary tumors correlate with iNOS 
expression but not IDO or Arg-1. Spearman correlations of podoplanin positive lymphatic 
vessels in the CT, IM and peritumoral area of primary tumors in relation with (A) iNOS, (B) 
IDO and (C) Arg-1 density in the same areas. Immunofluorescence staining showing Prox-1 
and podoplanin positive lymphatic vessels with (D) iNOS, (E) IDO and (F) Arg-1 staining in 
the IM of primary tumor tissues. Scale bar, 50 µm. Statistically significant differences are 
highlighted in bold, when p values were < 0.05. (CT): center of tumor; (IM): invasive margin; 
(Peri.): peritumoral area; (podo): podoplanin.  
Figure 5. Tumor-associated lymphatic vessels correlate with increased tumor-
infiltrating CD8+ cells. Spearman correlation of podoplanin positive lymphatic vessels in the 
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CT, IM and peritumoral area of primary tumors in relation to (A) CD8, (B) CD4, (C) CD19 and 
(D) FoxP3 density in the same areas. E) Immunofluorescence staining of Prox-1 and 
podoplanin positive lymphatic vessels with CD8 in a primary tumor with low lymphatic vessel 
density (left panel) and one with high lymphatic vessel density (right panel). Scale bar, 50 
µm. Quantitative IHC analysis of tumor-infiltrating (F) CD8+GranzymeB- and 
CD8+GranzymeB+ cells/mm2 and (G) CD8+PD-1- and CD8+PD-1+ cells/mm2 in 10 primary 
melanomas. Error bars indicate mean ± SEM (nonparametric unpaired Mann-Whitney t test). 
H) Spearman correlation of podoplanin positive lymphatic vessels in the primary tumor in 
relation to CD8+GranzymeB-, CD8+GranzymeB+; CD8+PD-1- and CD8+PD-1+ tumor-
infiltrating cells/mm2. Statistically significant differences are highlighted in bold, when p 
values were < 0.05. (CT): center of tumor; (IM): invasive margin; (Peri.): peritumoral area and 
(Prim. Tum.): primary tumor 
Figure 6. Patients with increased lymphatic vessel density and iNOS expression in the 
IM of the primary tumor show impaired anti-tumoral T cell responses to vaccination. 
Spearman correlations of podoplanin, iNOS and Melan-A density in the CT, IM and 
peritumoral area of primary tumor tissues in relation to percentages of circulating (A, C and 
E) Melan-A specific CD8+ T cells and (B, D and F) IFN-γ producing circulating Melan-A 
specific CD8+ T cells respectively, reached during the vaccination. The data show peak 
values, i.e. the maximum value reached during the vaccination study for each patient. 
Percentages of Melan-A specific CD8+ T cells were determined by direct ex-vivo tetramer 
staining, and percentages of IFN-γ producing Melan-A specific CD8+ T cells were determined 
by direct ex-vivo ELISPOT analysis, following overnight incubation with Melan-A peptide. 
Statistically significant differences are highlighted in bold, when p values were < 0.05. (CT): 
center of tumor; (IM): invasive margin and (Peri.): peritumoral area  
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Figure 7. Tumor-associated lymphatics in metastatic LNs are associated with 
infiltration of CD8+, CD19+ and FoxP3+ cells, and with expression of iNOS. Spearman 
correlations of podoplanin positive lymphatic vessels in the tumor region of metastatic LNs in 
relation to (A) CD8, (B) CD4, (C) CD19 and (D) FoxP3 density in the same area. E) 
Immunofluorescence staining of Prox-1 and podoplanin positive lymphatic vessels with CD8 
in the tumor region of a metastatic LN with low lymphatic vessel density (left panel) and one 
with high lymphatic vessel density (right panel). F) Quantitative IHC analysis of tumor-
infiltrating CD8+GranzymeB- and CD8+GranzymeB+ cells/mm2 (left panel) and CD8+PD-1- and 
CD8+PD-1+ cells/mm2 (right panel) in 12 metastatic LNs. Errors bars indicate mean ± SEM 
(nonparametric unpaired Mann-Whitney t test). G) Spearman correlation of podoplanin 
positive lymphatic vessels in the tumor region of metastatic LN in relation to 
CD8+GranzymeB-, CD8+GranzymeB+; CD8+PD-1- and CD8+PD-1+ tumor-infiltrating cells per 
mm2. Spearman correlation of podoplanin positive lymphatic vessels in the tumor region of 
metastatic LNs in relation to (H) iNOS and (I) IDO density in the same areas. 
Immunofluorescence staining showing Prox-1 and podoplanin positive lymphatic vessels with 
(J) iNOS and (K) IDO in the tumor region of a metastatic LN. Scale bar, 50 µm. Statistically 
significant differences are highlighted in bold, when p values were < 0.05. (Podo): 
podoplanin.  
Figure 8. Tumor expression of VEGF-C is associated with IDO and iNOS expression in 
metastatic LNs. Spearman correlations of VEGF-C density in the tumor region of metastatic 
LNs in relation to (A) iNOS, (B) IDO, (C) CD8 and (D) FoxP3 density in the same area. E) 
Representative images of VEGF-C, iNOS, IDO and FoxP3 in tumor region of metastatic LNs 
with high VEGF-C density (upper panel) and low VEGF-C density (lower panel). Scale bar, 
100 µm. Statistically significant differences are highlighted in bold, when p values were < 
0.05. 
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Figure 9. Tumor-associated lymphatics in high-tumor infiltrated LNs are associated 
with higher infiltration of CD8+, CD19+, FoxP3+ and VEGF-C+ cells and with higher 
expression of iNOS. A) (Left panel): The different metastatic LNs in relation to the 
percentage of the tumor size in the entire LN. (Right panel) Representative image of tumor 
and stroma histological zones in a low and a high tumor-infiltrated LNs. Spearman correlation 
of podoplanin positive lymphatic vessels in the tumor of low tumor-infiltrated LNs and high-
tumor infiltrated LNs in relation with (B) CD8, (C) CD4, (D) CD19, (E) FoxP3 (F) iNOS and 
(H) VEGF-C density in the same area. G) Immunofluorescence staining showing Prox-1 and 
podoplanin positive lymphatic vessels with iNOS in a low tumor-infiltrated LN and a high-
tumor infiltrated LN. Scale bar, 50 µm. Statistically significant differences are highlighted in 
bold, when p values were < 0.05. (Low Tum LNs): low tumor-infiltrated LNs; (High Tum LNs): 
high tumor-infiltrated LNs. 
Figure 10. Tumor-associated lymphatics in non-metastatic LNs are not associated with 
infiltration of CD8+ T cells or IDO but express iNOS. Spearman correlation of podoplanin 
positive lymphatic vessels in the total area of non-metastatic LNs in relation to (A) CD8, (B) 
CD4, (C) CD19 and (D) FoxP3 density in the same areas. Quantitative IHC analysis of (E) 
CD8+GranzymeB- and CD8+GranzymeB+ cells/mm2 and CD8+PD-1- and (F) CD8+PD-1+ 
cells/mm2 in 12 non metastatic LNs. Error bars indicate mean ± SEM (nonparametric 
unpaired Mann-Whitney t test). G) Spearman correlation of podoplanin positive lymphatic 
vessels in non-metastatic LNs in relation to CD8+GranzymeB-; CD8+PD-1- and CD8+PD-1+ 
tumor-infiltrating cells per mm2. H) Spearman correlation of podoplanin positive lymphatic 
vessels in the total area of non-metastatic LNs in relation to iNOS. Statistically significant 
differences are highlighted in bold, when p values were < 0.05.  
Figure 11. Non-metastatic LNs from positive LN dissections have higher infiltrating 
immune cells, lymphatic vessels, iNOS and Arg-1 than non-metastatic LNs from 
negative LN dissections. The density of (A) (left panel) CD8, (A) (right panel) CD4, (B) (left 
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panel) podoplanin, (B) (right panel) Prox-1, (C) (left panel) iNOS, (C) (middle left panel) IDO, 
(C) (middle right panel) Arg-1 and (C) (right panel) VEGF-C in non-metastatic LNs from 
negative LN dissection and in non-metastatic LNs from positive LN dissection. Error bars 
indicate mean ± SEM (nonparametric unpaired Mann-Whitney t test). D) Quantitative IHC 
analysis of CD8+GranzymeB-, CD8+GranzymeB+, CD8+PD-1- and CD8+PD-1+ cells mm2 in 5 
non-metastatic LNs from negative LN dissection and 7 non-metastatic LNs from positive LN 
dissection, respectively. Error bars indicate mean ± SEM (one-way ANOVA Kruskal-Wallis 
unparametric test with post-hoc test Dunn correction). Spearman correlation of podoplanin 
positive lymphatic vessels in non-metastatic LNs from negative and positive LN dissection in 
relation to (E) CD8, (F) CD4 and (G) iNOS density. H) Immunofluorescence staining showing 
Prox-1 and podoplanin positive lymphatic vessels with iNOS in a non-metastatic LN from a 
negative LN dissection patient (upper panel) and in a non-metastatic LN from a positive LN 
dissection patient (lower panel). Scale bar, 50 µm. Statistically significant differences are 
highlighted in bold, when p values were < 0.05. (LN diss. -): non-metastatic LNs from 
negative LN dissection, and (LN diss. +): non-metastatic LNs from positive LN dissection. 
Supplementary Figure 1. Representative images of immunohistochemical staining of 
formalin-fixed paraffin embedded non-metastatic LNs tissue sections for each 
antibody. Representative images of staining for (A) CD8, (B) CD4, (C) CD19, (D) FoxP3, (E) 
podoplanin (F) Prox-1 (G) VEGF-C (H)  iNOS (I) IDO and (J) Arg-1. 
Supplementary Figure 2. Image analysis with the pixel-count algorithm (ImageScope, 
Aperio) and with thresholded colocalization algorithm (Inform, Perkin-Elmer). 
Representative images of various densities of CD4+ T lymphocytes in metastatic LN 
demonstrating that the image-analysis output from ImageScope matches visual evaluation. 
A) (Upper panel) Example of a metastatic LN stained with anti-CD4 antibody. (Lower panel) 
Pseudo-colored image of upper panel illustrating the four output values of the pixel-count 
algorithm: haematoxylin or negative signal (blue), weak positive (yellow), positive (orange) 
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and strong non-specific (brown) and the respective relative units obtained. B) (Left panel) 
Fluorescence multiplex IHC of primary tumor stained with anti-CD8 (magenta), anti-PD-1 
(red) and anti-Granzyme B (green). (Right panel) Score segmentation image of left panel 
illustrating use of the InForm analysis software.  
Supplementary Figure 3. Prox-1 is expressed in the cytoplasm of melanoma cells and 
alpha-sma positive cells do not express podoplanin. A) Immunofluorescence staining 
showing Prox-1 with Melan-A in primary tumor. B) Immunofluorescence staining showing 
Prox-1 and podoplanin positive lymphatic vessels with alpha-sma in primary tumor (left 
panel), metastatic LN (middle panel) and non-metastatic LN (right panel). C) 
Immunofluorescence staining showing Prox-1 and podoplanin positive lymphatic vessels. 
Scale bar, 50 µm. 
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Figure 5 
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Figure 6 
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Figure 8 
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Figure 10 
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Supplementary Table 1 
Stage III (n = 21) Stage IV (n = 8)
Median 60.1 37.9
Range 27.7 – 75.1 24.5 – 71.8
Male 13 (62%) 5 (63%)
Female 8 (38%) 3 (38%)
SSM 9 (43%) 5 (63%)
NM 6 (29%) 2 (25%)
ALM 1 (5%) 0 (0%)
Ocular 1 (5%) 0 (0%)
Unknown 4 (19%) 1 (13%)
N0 1 (5%) 3 (38%)
N1 3 (14%) 1 (13%)
N2 and N3 17 (81%) 4 (50%)
ED 4 (19%) 5 (63%)
NED 17 (81%) 3 (38%)
0 5 (24%) 2 (25%)
1 5 (24%) 3 (38%)
 ≥ 2 10 (48%) 2 (25%)
Unknown 1 (5%) 1 (13%)
In-transit metastases 9 (43%) 4 (50%)
Distant LN and distant skin - 6 (75%)
Lung - 3 (38%)
Visceral and other - 3 (38%)
 Radiotherapy 3 (14%) 2 (25%)
 Chemotherapy 4 (19%) 1 (13%)
 IFN and/or TNF 5 (24%) 2 (25%)
 Vaccination with Melan-A peptide 5 (24%) 4 (50%)
Metastatic LN 8 (38%) 4 (50%)
In-transit or satellite metastases 8 (38%) 1 (13%)
Distant metastases 6 (29%) 5 (63%)
Survival and Follow-up
Relapse during study 14 (67%) 4 (50%)
Progression during study 3 (14%) 3 (37%)
Mortality 11 (52%) 6 (75%)
Disease free survival (months)
Mean ± std.dev 28.01 ± 39.5 30.7 ± 41.9
Overall survival (months)
Mean ± std.dev 51.7 ± 44.2 51.5 ± 47.2
(ALM) acral lentiginous melanoma; (ED) evidence of disease; (NED) no evidence of disease
(SSM) superfical spreading melanoma; (NM) nodular melanoma; 
Suplemtary Table 1. Patients characteristics
Age
Sex
Primary melanoma type
Evidence of disease
During the study
At the start of the study
N Stage (2009 staging system)
Number of metastatic LN
Sites of distant metastases
Previous therapy
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Supplementary Table 2 
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Supplementary Table 3 
Primary Tumor Non-met LN Met LN Non-met LN Met LN
26.Apr.00 1 - - - -
16.Dec.02 -  1(1) 3(3) - -
30.Jan.04 - - - (3) 1(1)
19.Apr.05 - - -  1(1)  1(1)
12.Jul.06 - - - (4) 1(3)
19.Jul.01 1 - - - -
19.Sep.01 - 1(28) - - -
10.Jul.98 1 - - - -
8.Aug.01 - 1(5) - - -
1.Aug.93 1 - - - -
23.Jun.99 - (7) - - -
5.Feb.03 - 1(8) 1(2) - -
18.Feb.04 - - -  1(1) -
29.Sep.99 / - - - -
15.Dec.99 - (8) - - -
30.Mar.04 - - - 1(3)  2(2)
14.Jan.98 1 - - - -
7.Jun.00 - 1(13)  1(1) - -
27.Jun.03 - (9) - - -
20.Aug.03 - (1) - - -
11.Mar.02 1 - - - -
15.Nov.06 - - - 1(13) -
29.Sep.99 / - - - -
6.Feb.02 - 1(12) 1(7) - -
11.Dec.03 - - - - /
7.Jun.05 - - - -  1(1)
15.Mar.04 1 - - - -
2.Jun.04 - 1(25) - - -
7.Mar.05 / - - - -
1.Jun.05 - 1(29)  1(1) - -
21.Mar.05 1 - - - -
15.Jun.05 - 1(20) - - -
7.Oct.05 1 - - - -
11.Jan.06 - 1(17) - - -
18.Apr.96 1 - - - -
3.Feb.00 - -  1(1) - -
1.Mar.00 - 1(8) 4(8) - -
20.Dec.01 - - 3(3) - -
20.Jul.98 1 - - - -
21.Nov.01 - 1(40) 3(14) - -
19.Nov.08 - - - 1(3) -
1.Jan.94 / - - - -
5.Nov.03 - 1(6) - - -
25.Nov.04 1 - - - -
12.May.06 - - - 1(7) 1(1)
3.Mar.04 1 - - - -
26.May.04 - 1(17) - - -
9.Mar.05 - 1(7) - - -
25.Jan.05 1 - - - -
3.Mar.05 - 1(36) / - -
20.Dec.04 1 - - - -
16.Mar.05 - (8) / - -
8.Jun.05 - - - 1(20)  1(1)
22.May.96 1 - - - -
10.Jun.96 - -  2(2) - -
26.Jun.96 - (14) - - -
13.Oct.03 / - - - -
7.Dec.04 - 1(12)  1(1) - -
2.Sep.92 1 - - - -
6.Apr.06 - -  2(2) - -
24.Apr.07 - - - -  2(2)
21.Nov.95 1 - - - -
2.Aug.06 - 1(2) - - -
8.Jan.07 1 - - - -
27.Apr.07 - 1(7) - - -
LAU 1264 22.Apr.05 1 - - - -
14.Aug.07 - - - / /
/ tissues not found
− no tissue
LAU 1144
LAU 1189
(LN) lymph nodes; (non met LN) non-metastatic lymph nodes; (met LN) metastatic lymph nodes
LAU 1017
LAU 1013
LAU 975
LAU 936
LAU 1129
LAU 1034
LAU 648
LAU 706
LAU 1015
The numbers represent the samples collected from pathology department and analysed in this study
(n) number of total individual LN collected per surgery
LAU  818
LAU 321
LAU 444
LAU 392
LAU 1090
LAU 205
LAU 627
LAU 618
LAU 371
LAU 701
LAU 672
LAU 972
LAU 1022
Supplemtary Table 3. Patient tissues selected from the LUD 00-018 study 
Patient Surgery
Pathological samples
Pre-vaccination Post-vaccination
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2 Pulmonary sarcoid-like granulomatosis after multiple vaccinations of a 
long-term surviving metastatic melanoma patient 
In this study, we report the case of a long-term surviving metastatic melanoma patient (stage 
IV) who exhibited pulmonary sarcoid-like granulomatosis following the development of a 
strong T-cell response to repetitive cycles of vaccination with peptides and CpG. This paper 
is the first report describing an autoimmune pulmonary adverse event related to a cancer 
vaccine. It was published in the December 2014 edition of  Cancer Immunology Research. 
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3 Identification of melanoma cells and lymphocyte subpopulations in lymph 
node metastases by FTIR imaging histopathology 
In this study, we created and used an FTIR imaging tool to automatically identify the main 
cell types and structures composing metastatic LNs and non-metastatic LNs. We established 
that cell types present in the LNs (e.g., melanoma cells and lymphocytes subpopulations) 
have different infrared spectral features and can be recognized by FITR imaging. In addition, 
we showed that a Parital Least Squares Discriminant Analaysis (PLS-DA) model was 
capable of predicting whether lymphocytes originated from invaded or non-invaded LNs. This 
project was predominantly carried out by Dr. Noémie Wald (Eric Goormaghtigh Group, 
Université Libre de Bruxelles, Bruxells, Belgique). I contributed to this work by gathering the 
FFPE samples of metastatic LNs and non-metastatic LNs, choosing the staining and 
identifying the different regions in the metastatic LNs. The manuscript has been submitted to 
BBA-Molecular Basis of Disease and is currently under review.  
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Abstract 
While early stages of melanoma are usually cured by surgery, metastatic melanomas are 
difficult to treat because the widely available options have low response rates. Careful and 
precise diagnosis and staging are essential to determine patient’s risk and to select 
appropriate treatments. Fortunately, the recent progress in immunotherapy is very 
encouraging. In this context, it is important to characterize the intratumoral infiltration of 
immune cells in each patient, which is however not done routinely due to the lack of 
standardized methods. In this study, we used Fourier Transform Infrared (FTIR) imaging 
combined with multivariate statistical analyses to investigate non-metastatic and metastatic 
lymph nodes from melanoma patients. Our results show that the different cell types have 
different infrared spectral features allowing automated identification of these cell types. High 
recognition rates were obtained using a supervised Partial Least Square Discriminant 
Analysis (PLS-DA) model. Melanoma cells were recognized with 87.1% sensitivity and 
85.7% specificity, showing that FTIR spectroscopy has similar detection power as 
immunohistochemistry. Besides, FTIR imaging could also distinguish lymphocyte 
subpopulations (B and T cells). Finally, we investigated the changes in lymphocytes due to 
the presence of metastases. Interestingly, specific features of spectra of lymphocytes 
present in metastatic or tumor-free lymph nodes could be evidenced by PCA. A PLS-DA 
model was capable of predicting whether lymphocytes originated from invaded or non-
invaded lymph nodes. These data demonstrate that FITR imaging is capable to distinguish 
known and also novel biological features in human tissues, with potential practical relevance 
for histopathological diagnosis and biomarker assessment.  
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Introduction 
Melanoma is the most aggressive form of skin cancer. It is responsible for approximately 
80% of deaths caused by cutaneous malignancies [1,2]. While early stages of melanoma are 
usually cured by surgery, metastatic melanomas are difficult to treat because the widely 
available treatment options such as chemotherapy or radiotherapy do not show high 
response rates [3,4]. The prognosis of patients and treatment selection depend on disease 
stage, which is determined based on a series of parameters including primary tumor 
thickness, ulceration, mitotic rate, and metastases in lymph nodes and other organs [5,6]. 
Routinely, melanoma cells in tissues (for example in the sentinel lymph node) are detected 
by visual inspection under the microscope of the hematoxylin and eosin (H&E) stained 
sections of the resection by a trained pathologist. Detection of melanoma cells remains a 
challenge because they present a wide variety of histological features and patterns of 
spreading [7]. Moreover, the anatomopathological study of tissue sections is time consuming, 
and to some degree subjective with consequent inter-observer discrepancies [8]. For the 
identification of melanoma cells, some additional techniques are available. Confirmation of 
the presence of melanoma can be achieved by immunohistochemistry [9], Fluorescence In 
Situ Hybridization (FISH) or by Comparative Genomic Hybridization (CGH) [10–12].  
In this last decade, the importance of stromal and infiltrating cells in tumor progression has 
been highlighted in numerous studies [13,14]. In particular, the presence of immune cells at 
the tumor site has been shown to play an important role in patient’s outcome [13,15–17]. The 
presence of Tumor-Infiltrating Lymphocytes (TIL) in primary melanomas [18] and in 
metastatic lymph nodes [19] has been shown to positively correlate with survival. 
Furthermore, the presence of these TIL is also associated with successful outcome to 
immunotherapies such as with the CTLA-4 specific antibody ipilimumab [20]. Yet, it is also 
recognized that the immune system plays a dual role in cancer development and progression 
[17]. While some immune cells suppress tumor growth by killing or inhibiting tumor cell 
proliferation, other immune cell types can promote tumor progression. Thus, the final 
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outcome depends on the subpopulations of immune cells present at the tumor site [21]. 
Cytotoxic T cells (CD8+) and T helper-1 cells (CD4+) both play an active role in tumor 
reduction while the function of B cells is less clear [21]. Several studies showed that B cell 
infiltration in primary melanoma and metastases correlated with survival advantage [22,23] 
whereas another study showed, in mice, that B cell depletion improves the immune 
destruction of the tumor [24]. 
It is now clear that characterization of tumor immune cell infiltration is important. Although 
this can be assessed by immunohistochemistry, this is not currently done because of the lack 
of standardized methods. Moreover, the current techniques for histopathological 
characterization can only assess a small number of proteins (immunohistochemistry) or 
genomic abnormalities (FISH). On the contrary, Fourier Transform Infrared (FTIR) imaging 
brings global information on the biochemical content of the cells and tissues. The technique 
was shown to be a useful tool to obtain unique fingerprints of different cell types. FTIR 
spectroscopy is a vibrational technique based on the interaction of an infrared beam with the 
covalent bonds of biological molecules. FTIR is sensitive to all molecules (proteins, lipids, 
nucleic acid, carbohydrates…) and particularly to protein secondary structure [25,26]. 
Moreover the IR spectrum reflects the nature, chain length and unsaturation of lipids [27,28]. 
In the study of prokaryotic and eukaryotic cells, FTIR has been shown to provide information 
about cell strain [29], cell cycle [30,31] and various metabolic perturbations caused by 
candidate anticancer drugs [32]. 
When coupled with a microscope device, this technique provides spatially resolved 
information on the biochemical content of the different cell types and structures present in 
tissue sections. FTIR imaging was recently recognized as an emerging tool for 
histopathological studies [33–35]. Particularly in cancer research, the technique has proven 
its value in various cancer types [36–38]. Nevertheless, few papers report on the study of 
melanoma [38–41] or lymphocytes [42,43] by FTIR imaging. Two studies have shown the 
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possibility to differentiate benign nevi from malignant melanomas [38,41] while another study 
has demonstrated that FTIR imaging was sensitive enough to distinguish different subtypes 
of primary melanoma [44]. 
The present study demonstrates the potential of FTIR for the identification of main cell types 
present in melanoma metastases in lymph nodes. It focuses specifically on the identification 
of melanoma cells and the different subpopulations of lymphocytes that infiltrate the tumor. 
Multivariate statistical models were built to predict the identity of cell types in tissue sections 
of melanoma metastases. These models were established in training sets and then validated 
in tests sets of different patient sections. 
Materials and Methods 
1. Patient samples 
Thirty-four biopsies of melanoma metastases in lymph nodes from 14 patients were collected 
by the Ludwig Cancer Research Center at the University Hospital of Lausanne, Switzerland. 
All the biopsies were formalin-fixed and paraffin-embedded (FFPE). These 34 FFPE-
metastases were used for the first section of this article. Eight additional metastatic lymph 
nodes and eight non-metastatic lymph nodes from the same patients were used in the 
second section. Written informed consent was obtained based on the study protocol, 
approved by the ethical commission of the University of Lausanne. 
2. Tissue handling and immunohistochemistry 
Eight adjacent sections of 5 µm thickness were cut from each FFPE melanoma metastasis. 
One of them was deposited on a special microscope slide, transparent to infrared light (BaF2 
slides, ACM, Villiers St. Frederic, France) and was used for FTIR measurements. Tissue 
sections were first deparaffinized in xylene and rehydrated in an ethanol gradient. One 
section was stained with hematoxylin and eosin (H&E) and the six sections left were stained 
by immunohistochemistry. For this purpose, tissues were treated with 3% H2O2 in distilled 
water for five minutes or 0.5% H2O2 in methanol for 10 minutes to quench endogenous 
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peroxidase activity. Antigen retrieval was carried out by heating the sections in a Tris–EDTA 
buffer (pH 9) for 1’30'' in a steamer. Subsequently, the slides were incubated in Tris-HCL 
buffer (pH 7.6) for 15 minutes. Sections were incubated for 40 minutes at room temperature 
with the primary antibody for CD8 (clone C8/144B, Dakocytomation, Glostrup, Denmark), 
CD4 (clone 4B12, Novocastra, Newcastle Upon Tyne, UK), CD19 (clone BT51E, Novacastra, 
Newcastle Upon Tyne, UK), S100 (Novocastra, Newcastle Upon Tyne, UK), Melan-A (clone 
A103, Dako, Glostrup, Denmark) and melanosome (clone HMB45, Dakocytomation, 
Glostrup, Denmark) followed by a secondary anti-mouse antibody RTU/HRP ENVISION 
(K4001, Dakocytomation, Glostrup, Denmark) for 30 minutes. Diaminobenzidine (DAB) was 
used as a brown chromogen (K3468, Dakocytomation, Glostrup, Denmark) for CD8 and 
CD19 and 3-amino-9-ethylcarbazole (AEC) was used as a red chromogen (K3464, 
Dakocytomation, Glostrup, Denmark) for CD4, S100, Melan-A and melanosome. The slides 
were then counterstained with Hematoxylin (Merck 1.05175) for 5-8 seconds and mounted 
with xylol. Immunostaining with appropriate isotype control antibodies were used as negative 
controls. All stained sections were scanned with a NanoZoomer (Hamamatsu, Hamamatsu, 
Japan) and images were analyzed with NDPview program (Hamamatsu, Hamamatsu, 
Japan). The stained sections were analyzed with assistance of a trained pathologist. 
3. FTIR measurements 
The FTIR data were collected using a Hyperion 3000 FTIR imaging system (Bruker Optics, 
Ettlingen, Germany), equipped with a liquid nitrogen cooled 64x64 Mercury Cadmium 
Telluride (MCT) Focal Plane Array (FPA) detector, in transmission mode. The size of an 
image covers an area of 180x180 µm2 and was composed of 4096 pixels of 2.8x2.8 µm2 
each. It must be noted that true spatial resolution can be significantly lower than the pixel 
size, depending on the wavelength. It took about 5 minutes to record an infrared image 
composed of 4096 spectra at a spectral resolution of 8 cm-1 and where each spectrum is the 
average of 256 scans. Larger images could be obtained by associating several unit images 
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(4096 spectra) side by side. Pixels can also be binned 2x2 to record larger images but this 
lead to a spatial resolution decrease (e.g. 5.6 µm pixel size for 2x2 binning). 
4. Data analysis 
4.1 Preprocessing 
All spectra were preprocessed as follows. Water vapor contribution was subtracted as 
described previously [45,46] with 1956-1935 cm-1 as reference peak and CO2 peak was 
flattened between 2450 and 2250 cm-1. The spectra were baseline-corrected. Straight lines 
were interpolated between the spectra points at 3620, 2995, 2800, 2395, 2247, 1765, 1724, 
1480, 1355, 1144 and 950 cm-1 and subtracted from each spectrum. Spectra were 
normalized for equal area between 1725 and 1481 cm-1 (amide I and II bands). The signal to-
noise-ratio (S/N) was then systematically checked on every spectrum. It was required to be 
greater than 350 when noise was defined as the standard deviation in the 2000-1900 cm-1 
region of the spectrum and the signal was the maximum of the curve between 1750 and 
1480 cm-1 after subtracting a baseline passing through these two points.  
4.2 Difference spectra 
Difference spectra allow emphasizing the spectral variations between two distinct conditions. 
Difference spectrum was built by subtraction of the spectra of B cells from the spectra of the 
T cells.  
4.3 Statistical analyses  
Principal Component Analysis (PCA), as described previously [47], is an unsupervised 
multivariate method enabling variable reduction by building linear combinations of 
wavenumbers varying together, called Principal Component (PC). The first principal 
component explains most of the data variance. The second principal component, 
uncorrelated to the first one, accounts for most of the residual variance and so on. Usually 2 
to 6 PCs are sufficient to explain the major proportion of the original variance of the data set 
and reducing the description of each spectrum to 2 to 6 numbers representing the projection 
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(scores) of the spectra on the PCs. One advantage of the method is that it extracts the 
important information as a set of new orthogonal variables, the Principal Components (PCs) 
[48,49]. 
K-means clustering is an unsupervised analysis based on a nonhierarchical iterative 
algorithm. This analysis aims at partitioning n spectra into k clusters on basis of the spectral 
features. The process to organize spectra in clusters can be described as follows: each IR 
spectrum is defined by a point in a p-dimensional space (p being the number of data points 
of the spectra). In this space, k points are initially chosen randomly. They represent the origin 
of each cluster. The k parameter is chosen by the operator. The distances between these k 
points and all the spectra are then calculated. Each spectrum is then associated with a 
cluster to minimize its geometrical distance to the position of the origin of the cluster. Once 
every spectrum is assigned to a cluster, centroids of the clusters are calculated and the 
distances of the spectra to the centroids are again computed. The spectra are reorganized 
so that each spectrum is assigned to the cluster with the nearest centroid. The centroid 
positions are recalculated until none of the spectra needs to be reassigned to another 
cluster. The whole process is repeated several times with different starting points (k points). 
As a result of this analysis, spectra with similar features are in a same cluster and spectra 
within different clusters are as dissimilar as possible [50,51]. This analysis was applied here 
on spectra recorded on large area of tissue sections (c. a. 100 000 spectra). Images were 
colored so that each pixel was associated with a cluster and each cluster was associated 
with a color. To provide information about the similarities that exist among the different 
clusters, a dendrogram was built. This was performed in carrying a hierarchical clustering on 
the centroid of each cluster. 
The Multivariate Analysis of the Variance (MANOVA) indicates whether one group among 
others is significantly different. The MANOVA was performed in this study using the score on 
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the first 6 PCs obtained after a PCA on the series of spectra from B cells and T cells from the 
database.  
Partial Least Square Discriminant Analysis (PLS-DA) is a supervised discriminant method 
based on the PLS regression models [52]. This analysis requires a priori knowledge about 
the classes of spectra. PLS-DA was used to extract latent variables of the data set that 
enable the construction of a factor allowing to predict a class. 
From the confusion tables, sensitivity and specificity were calculated for each cell type class 
as follows. Sensitivity was calculated as Sv= TP/(TP+FN) and specificity as Sp=TN/TN+FP, 
where TP, FN, TN and FP correspond to True Positive, False Negative, True Negative and 
False Positive respectively [53]. 
Preprocessing (correction of the spectra for water vapor contribution, baseline subtraction 
and normalization), PCA, MANOVA, K-means clustering and PLS-DA were carried out by 
Kinetics, a custom made program, running under Matlab (Matlab, Mathworks Inc). 
Results 
1. Identification of the main cell types 
Thirty-four biopsies of melanoma metastases invading lymph nodes from 14 different 
patients were analyzed by infrared spectroscopy. The main goal of the work was to 
characterize the infrared spectra of the major cell types composing these melanoma 
metastases and to create an automatic tool for spectral histopathological recognition. The 
workflow of the experiments is schematically represented in Figure 1. For each FFPE biopsy, 
eight adjacent sections were cut (step 1) and each one was stained with either H&E or one of 
the six different immunohistochemistry stainings selected or left unstained (step 2). Six 
different antibodies targeting four different cell types were used: anti-HMB45/anti-S100/anti-
Melan-A to target melanoma cells, anti-CD4 to target helper T cells, anti-CD8 to target 
cytotoxic T cells and anti-CD19 to target B cells. One section remained unstained for infrared 
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measurements and was deposited on a material transparent to infrared light (Barium fluoride 
(BaF2) slide) (step 3).  
The H&E stained section and the immunostained sections were used as references to 
localize the main cell types on the unstained section with the help of a pathologist. On the 
basis of this visual inspection, six main cell types were identified: the melanoma cells, the 
erythrocytes, the lymphocytes (T and B cells), the endothelial cells composing small 
capillaries and finally the connective tissue. This last category included the capsule and the 
wall of the vascular tissues. A database composed of spectra from the main cell types was 
built. The process to collect spectra from one cell type is illustrated in Figure 1 (step 4). Up to 
500 FTIR measurements (4096 spectra each) were recorded in total. For each FTIR 
measurement, around one hundred spectra were selected. The composition of the spectral 
database is described in Table 1. This table lists, for each cell type category, the number of 
spectra, the number of biopsies and the number of patients from which spectra were 
acquired.  
First of all, one mean spectrum was computed from all the spectra of each category. These 
mean spectra are represented in Figure 2. Visual inspection of these spectra already shows 
that some differences can be observed in some parts of the IR spectrum. For example, the 
erythrocyte category shows differences in the lipid region (3000-2800 cm-1), the amide II 
band and the 1400-1000 cm-1 region.  
Another way of analyzing the differences between the spectra and, at the same time, to 
reduce considerably the number of variables is the Principal Component Analysis (PCA). In 
order to obtain a reasonable number of spectra that can be visualized on a PCA score plot, 
we first averaged the c. a. 100 spectra selected per measurement. In turn, 500 mean spectra 
were obtained and the PCA was computed. The score plot resulting from this analysis is 
shown in Figure 3a. It can be observed that the main cell types cluster together. This 
separation between erythrocytes (in green), the connective tissue (in red), the melanoma 
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cells (in orange) and the lymphocytes (in blue and purple) mainly occurs along PC1 and 
PC2. We also observed that endothelial cells and melanoma cells show similar spectra and 
are close in the score plot. Only partial separation occurs between T cells, B cells and B cells 
from the germinal centers in this plot. While p values, obtained after computation of a 
MANOVA on the projection of the spectra on the six first PCs, indicate that the mean spectra 
of lymphocyte subtypes are significantly distinct (p values <0.05, data not shown), only a 
trend to separation exists between these subpopulations of lymphocytes on a PCA score plot 
when individual spectra are considered. This separation can be better observed in the PCA 
including only spectra from lymphocytes (Figure 11). Accordingly, in a first step, all 
lymphocyte types were included in one category for the following analyses of this section. 
The part b of Figure 3 depicts the first three principal components that represent about 84 % 
of the variance. They can give some clue about biochemical differences between the cell 
types that will be discussed later. 
The results reported above obtained on representative mean spectra suggest that there is an 
intrinsic difference between the IR spectra of the main cell types found in melanoma invaded 
lymph nodes. Yet, they do not provide a robust tool to recognize individual spectra. In a 
second step, we used the Partial Least Square Discriminant Analysis (PLS-DA) to create a 
predictive model able to recognize these main cell types. Based on this supervised analysis, 
we built two successive models as represented in Figure 4. A first level model built on the 
1800-1000 cm-1 spectral region was used to differentiate the epithelial cells, the erythrocytes, 
the lymphocytes and the connective tissue. The first class named epithelial cells included 
melanoma cells as well as endothelial cells. These two cell types were grouped in one class 
because of their spectral similarities even if, according to histology, endothelial cells are quite 
distinct from epithelial cells. Finally, a second level model, built on the two combined spectral 
regions; 3000-2800 and 1800-1000 cm-1, was used to distinguish melanoma cells from 
endothelial cells. The spectral regions used for these two models were determined after 
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building 10 PLS-DA models on 100 cm-1 range between 3000-2800 cm-1 and 1800-1000 cm-1 
in order to determine which spectral region presented the best predictive power (data not 
shown). 
To assess and validate these models, we divided our spectral database into two parts: a 
training set and a test set. Different patients were included in the training set and in the test 
set for external validation. Two different distributions, randomly assigned between these two 
sets, were tested. These distributions are described in Table 2. For the two distributions, 
biopsies from 8 patients were used in the training set whereas biopsies from 6 patients were 
used for the validation of the models.  
Results of prediction for patients included in the test sets are shown in Table 3a and b. Table 
3a shows the percentages of the spectra predicted by the first level model as belonging to 
one of each class: epithelial cells, erythrocytes, lymphocytes and connective tissue. The 
second table (3b) presents the confusion matrix obtained when the second level model was 
applied to the first class (epithelial cells) determined above. This second level model 
identified melanoma cells versus endothelial cells from the “epithelial cell” class spectra 
identified with the first level model. Globally, percentages of correct recognition, shown on 
the diagonal of the tables, range from 81.8 to 100 % for the first model. Similarly percentages 
for correct recognition of the second model range from 91.7 to 97.3 % for the melanoma cells 
and endothelial cells. Sensitivities and specificities of the model to identify each cell type 
were computed and are shown in Table 3. 
As a supplementary control, we applied these two successive models to an infrared image of 
2.2x2.2 mm recorded from the metastasis of a patient who was not included in the training 
sets described in Table 2a. The result of this prediction is shown in Figure 5 e. Each pixel of 
the infrared image is predicted by the first level model and receives a color according to its 
membership. Then spectra predicted as belonging to the epithelial cells class were 
reanalyzed by the second level model. To assess the quality of the prediction the same area 
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of the tissue from the adjacent stained sections are shown (a, b, c and d). These stainings 
show the localization of the melanoma cells (HMB45+), the helper T cells (CD4+) and the B 
cells (CD19+) and the capillaries are visible on the H&E section. A good correspondence can 
be observed between these 5 images (a, b, c, d and e). Interestingly, quantitative information 
can be immediately obtained from the IR images. In this area of the tissue section, 38.7 % of 
the area is occupied by melanoma cells while 37.9 % is composed of lymphocytes. 22.5 % is 
represented by the endothelial cells and capillaries and only 0.8 % was composed of pure 
connective tissue according to the model. 
2. Identification of lymphocyte subpopulations 
This second section of the paper aimed to differentiate and identify subpopulations of 
lymphocytes using immunohistochemistry as references. After visual inspection of the scans 
of the sections stained for CD4+ T cells and CD8+ T cells corresponding respectively to 
helper and cytotoxic T cells, these two subtypes of T cells were merged in one same group 
for our analyses. In practice, they were too mixed in the tissues and could not be identified 
with sufficient certainty on the adjacent unstained section used for IR imaging. In order to 
analyze the differences between subpopulations of lymphocytes, we recorded larger IR 
images (mappings) on areas containing both T cells and B cells. K-means clustering were 
applied on these different mappings (from different patients) and high levels of similarities 
were observed between immunohistochemistry and the cluster analysis. One example is 
represented in Figure 6 with a K-means clustering composed of 6 groups. In the IR clustering 
image (Figure 6d), there is a good match between clusters and cell types. The yellow cluster 
(number 4) clearly corresponds to the melanoma cells. The B cells are represented by 
cluster number 2 while the T cells correspond to cluster number 1. The dendrogram (e) 
shows that the spectra of these two subtypes of lymphocytes are very similar. A similar 
analysis was obtained for five different biopsies and, after referring to the corresponding 
immunohistochemistry, spectra from the 2 clusters corresponding respectively to B cells and 
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to T cells were extracted. Difference spectra were obtained for each biopsy upon subtracting 
spectra corresponding to B cells from spectra corresponding to T cells. They are shown in 
Figure 7 for each biopsy. 
Similar bands can be observed in the difference spectra, e.g. from 1500 to 1000 cm-1 and 
1800-1700 cm-1 while the amide I region of the difference spectra is less reproducible (1700-
1600 cm-1). These difference spectra show a high level of resemblance among different 
patients, meaning that common spectral features can be found for B and T cells for different 
patients. As similar features appeared for all patients, we built a predictive model able to 
identify these two lymphocyte subpopulations in general. A model was trained with the 
individual spectra extracted from the previous cluster analysis on the 1800-1000 cm-1 
spectral region. Spectra from 4 biopsies were used to build the model which was then 
validated on the remaining biopsy. One example of this external validation is shown in Figure 
5f. The 3 PLS-DA models (2 successive levels) were applied on this infrared image: a first 
level model to identify epithelial cells, lymphocytes, erythrocytes and connective tissue, a 
second level model to identify melanoma cells and endothelial cells and another second level 
model that identify B and T cells (see also Figure 4). Importantly spectra from this patient 
were not included in any of the training sets of these three models. A good agreement was 
observed between the IR image and the two immunohistochemistry stainings corresponding 
to T cells (CD4+) and B cells (CD19+). Another example for a different patient is shown as 
supplemental data (Figure 12). 
3. Comparison of lymphocyte populations from metastatic and non-metastatic 
lymph nodes 
We have shown above that the IR spectrum of lymphocytes contains sufficient information to 
discriminate between B cells and T cells. It has been shown in a previous study that spectra 
of lymphocytes obtained from lymph nodes and tonsils could be easily separated into two 
classes called “activated” and “non-activated” [47]. The activation state was previously 
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determined on the basis of a microscopic examination by a pathologist. Furthermore, these 
“activated” and “non-activated” lymphocytes were distinguishable from the lymphocytes 
infiltrating breast tumor [47]. It was therefore of interest to question the impact of melanoma 
metastases on the lymphocytes of an invaded lymph node, even in regions not in direct 
contact with the melanoma cells. In the last part of the study, we compared eight metastatic 
lymph nodes and eight non-metastatic lymph nodes from the same patient (16 lymph nodes 
in total). Six FTIR measurements (of 4096 spectra each) of T cells were recorded for each 
biopsy. For each measurement, a subset of 300 individual spectra was randomly selected 
and for each subset a mean spectrum was computed. All together, we obtained 80 mean 
spectra (5 per lymph node) and these were submitted to a PCA. The score plot of the PCA 
shows that a difference indeed exists between the lymphocytes present in lymph nodes 
invaded by a metastasis when compared to those without any metastasis (Figure 8a). The 
clustering between these two groups of lymphocytes arises from PC3, which is illustrated in 
Figure 8b. 
In the PCA above, we analyzed mean IR spectra. However, if IR imaging is going to be 
applied on IR images of lymph nodes sections, it is also necessary to identify the spectra at 
the pixel level (i.e. individual spectra). We therefore performed PLS-DA to classify spectra of 
lymphocytes according to their localization in lymph nodes with or without metastases. One 
hundred individual spectra were randomly selected for each patient from their metastatic and 
non-metastatic lymph nodes. One lymph node (either metastatic or non-metastatic) was 
removed at a time from the training set, and the membership of the spectra from this lymph 
node was predicted. This was computed 16 times after removing the spectra of each lymph 
node at a time. The result of this prediction is represented in Figure 8, as a bar chart and 
corresponds to the percentage of spectra correctly predicted as belonging to the class 
(metastatic or non-metastatic lymph node). Overall, the spectra of 15 lymph nodes among 
the 16 were correctly predicted (93.75 % of the lymph nodes). One of the 15 correctly 
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predicted lymph nodes was just at the limit for correct assignment (50% of the prediction of 
the spectra) and one lymph node among the 16 was a false negative. 
Discussion 
Results presented in this paper show that spectra from different cell types (erythrocytes, 
melanoma cells, endothelial cells, lymphocytes and connective tissue) in lymph nodes 
invaded by melanoma metastases have different spectral features. In turn, these cell types 
can be identified on the basis of their infrared spectra. Unsupervised multivariate statistics 
such as PCA do not require any a priori knowledge on the data. Yet, PCA score plots 
suggest that the global chemical composition of these main cell types present significant 
differences which dominate the sources of variance found through the data sets. Observation 
of the shape of the PCs can bring some clue on the chemical origin of the differences found 
among cell types. The separation between the main cell types occurs when projecting the 
spectra on the plane made by the first two PCs (Figure 3). The shape of the first two PCs in 
the amide I and amide II range is sigmoidal. In the amide I range, a minimum near 1620 cm-1 
and a maximum near 1670 cm-1 are characteristic of a change in the secondary structure of 
the proteins [25,26]. A similar shift was observed in the amide II range, also suggesting a 
change in the secondary structure. This result means that proteins present in the different 
cell types may differ in their secondary structure content. This can be easily understood for 
the connective tissue composed of spectra from the capsule of the lymph node as well as 
from the wall of the different vascular tissues such as vessels and arteries. They all contain a 
large fraction of collagen fibers. Collagen is a very peculiar protein that forms triple helices 
which have an IR spectrum characterized by a maximum at 1638 cm-1 [26]. Differences 
between lymphocytes and the other cell types were mainly observed in the 1300-1000 cm-1 
spectral region and more precisely near 1230 and 1080 cm-1 corresponding to the stretching 
of the phosphate groups (asymmetric and symmetric respectively) (Figure 2). As described 
previously, these two bands are mainly due to a contribution of nucleic acids [54,55] and 
could underline a difference in the nucleic acid content/state of lymphocytes (relative to the 
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protein). Lymphocytes are small cells with a high nuclear-cytoplasmic (NC) ratio (size of the 
nucleus/size of the cytoplasm; 3:1) when compared to normal cells [56]. This could explain 
the difference between nucleic acid/protein ratio for lymphocytes when compared to 
endothelial cells or erythrocytes (cells without any nucleus). An increased NC ratio is also a 
characteristic observed in malignant cells and particularly in melanoma [57]. A high level of 
nucleic acid contribution was also observed here in the spectrum of melanoma cells. 
High recognition rates were obtained using a supervised PLS-DA model. Running 
successive models instead of a one-step model was found to improve very significantly the 
correct recognition rates when large mapping were analyzed in external validation. The 
erythrocytes were best recognized with 100 % of correct assignment. This is in agreement 
with observations by PCA that erythrocytes are chemically very different from all other cell 
types. This difference is likely related to the absence of nucleus and presence of large 
hemoglobin content. FTIR imaging did not achieve perfect separation between lymphocytes 
and epithelial cells. A similarity between these two classes was already observed in the 
score plot of the PCA. An explanation could be that both lymphocytes and melanoma cells 
present high nucleus/cytoplasm (NC) ratios. Yet, melanoma cells were recognized with 
87.1% sensitivity and 85.7% specificity. This is important because melanoma cells present a 
wide range of histological features. They can mimic epithelial, hematologic, mesenchymal 
and neural tumors [9]. As a result, they are difficult to recognize by visual inspection under a 
microscope, remaining one of the most challenging areas of pathology [7,10]. The sensitivity 
obtained here by FTIR spectroscopy is comparable to the one obtained with other methods 
used to identify melanoma cells in tissue sections. Immunohistochemistry is the primary tool 
to distinguish melanoma from other cell types, using antibodies specific for melanocytic 
specific antigens (e.g. Melan-A, S100 or HMB45). These antigens are also expressed in 
melanocytes, the normal counterpart of melanoma cells [9]. S100 is the marker with the 
highest sensitivity (97 to 100%) but shows a low specificity (75-87%) because this protein is 
also expressed by a variety of other cells. HMB45 is less sensitive (58-83% for metastatic 
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melanoma and 77-100% for primary melanoma) but is more specific. The sensitivity of 
Melan-A ranges from 75 to 92 % while the specificity ranges from 95 to 100% [9]. This 
means that sensitivity and specificity obtained by FTIR spectroscopy are similar to the one 
obtained by current immunohistochemistry methods. Furthermore, usually more than one 
staining is required as the expression of melanocytic antigens (e.g. HMB45, Melan-A) 
decreases drastically as a function of the progress of the disease and is frequently absent in 
metastases [9,58]. A study showed that their expression is absent in more than 20% of 
melanoma lesions [58]. Other more recent techniques to identify melanoma cells are 
Fluorescence In Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH). 
They are respectively based on the detection of chromosomal alterations and on changes in 
DNA copy numbers on the entire genome [10,12,59]. Sensitivity and specificity of FISH reach 
87% and 95%, respectively [11]. However, these two techniques are expensive and time-
consuming and CGH does not bring information on the spatial distribution in the tissue as the 
DNA needs to be isolated and purified [10]. For FISH, only 4 probes can be used at a time, 
meaning that only 4 genomic alterations can be studied simultaneously. Overall, FTIR 
imaging appears as a promising technique to study lymph node histological sections. 
Quite interestingly, FTIR imaging could make the difference between subpopulations of 
lymphocytes. The fact that B and T cells could be distinguished on the basis of unsupervised 
analysis (K-means) is very encouraging. It means that infrared spectroscopy is sensitive 
enough to highlight, in an unsupervised manner, subtle differences that exist between B cells 
and T cells. These lymphocytes have different functions but are similar concerning their 
hematopoietic origin and are expected to be relatively similar in their molecular composition. 
A good correspondence was observed between immunohistochemistry stainings of T and B 
cells and the FTIR images where a K-means cluster analysis was applied. Importantly, a 
supervised PLS-DA model built on spectra of some patients could be validated on spectra 
from other patients. These results are in agreement with results obtained in a previous study 
on human spleen sections [42]. Unsupervised analysis such as clustering was shown to be 
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capable of identifying B and T cells in frozen sections of human spleen using the 1800-950 
cm-1 spectral region. The difference between B and T cell spectra obtained in that study was 
quite consistent with the one obtained here, in particular in the region of the bands near 1240 
and 1080 cm-1 corresponding to the asymmetric and symmetric stretching of PO2- groups. 
Another study on lymph nodes invaded by breast cancer [43] reported that it was possible, 
based on unsupervised analysis, to detect differences between B and T cells. Nevertheless, 
these two studies did not use immunohistochemistry to confirm the B or T cell origins and did 
not create predictive supervised models to generalize it to several patients. 
At this point of the discussion, it is worth pointing out that tissues are complex structures and 
lymphocytes are often mixed with small capillaries or other immune cells such as 
macrophages or dendritic cells. Therefore spectra of lymphocytes could be affected by the 
surrounding tissue and could contain a mix contribution of different cell types. In Figure 10, 
different areas of five H&E stained sections containing mainly B cells and T cells are 
displayed. We can observe that lymphocytes are usually significantly mixed with other cell 
types and that it is particularly true for the T cell areas. A question can therefore be raised 
about the differences previously observed between T and B cells. This difference could arise 
either from T and B cells themselves or from a particular mix with stromal cell spectra. The 
possibility to distinguish T cells from B cells on the basis of their intrinsic molecular content 
only was established in previous studies where T and B cells were purified from blood 
samples [42,60]. This suggests that origin of the differences could be found in the subtle 
differences of the biochemical composition of these cells alone. Yet, we cannot rule out a 
contribution of the stroma. 
The last part of the paper investigated the changes undergone by the lymphocytes when 
metastases are present in the same lymph node. Interestingly, features of spectra of 
lymphocytes present in invaded or non-invaded lymph nodes were quite significantly 
different. An analysis of the principal component describing this change indicated that the 
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main differences occurred in the region of the spectra where the contribution of the nucleic 
acids is prominent. We also showed that supervised analysis such as PLS-DA was capable 
of predicting whether lymphocytes originated from invaded or non-invaded lymph nodes. 
These models were validated externally as the spectra of one lymph node were removed 
from the training set and the model was then validated on these spectra. Fifteen lymph 
nodes out of 16 were correctly predicted. We could not accurately decipher the reason for 
the difference but a hypothesis about the activation state of the lymphocytes can be 
proposed. So far, only few infrared studies about lymphocytes have been published.  
Two groups have worked on lymphocyte activation and two studies have shown that it was 
possible to observe differences induced by activation of B cells [61,62]. The first study 
showed that lymphocyte activation in vitro by different stimuli could be detected by FTIR after 
90 minutes only. The second study showed that B cells in the germinal centers of activated 
lymph nodes were spectroscopically different from the non-activated B cells in the mantle 
area of the follicles [61]. Moreover, a study carried out in our laboratory reported that 
lymphocytes from secondary lymphoid organ (tonsils and lymph nodes) present different IR 
spectra based on their activation state [47]. All together these publications indicate that the 
observed differences could be associated with activation. The results presented in this paper 
and the ones previously published [61,62] suggest a potential use of FTIR in the 
characterization of the activation state of lymphocytes. Nonetheless, further characterization 
of the activation and differentiation state of the lymphocytes in these tissue sections would be 
required for a more in-depth understanding (e.g. through the characterization and 
quantification of cytokine production). Clinically, this result also suggests that it could be 
possible to identify the presence of (micro-)metastases through the impact they have on 
lymphocytes. The success rate of such an approach remains to be established. 
Potential applications of the results reported in this study are at least twofold. First, FTIR 
imaging can facilitate the detection of (micro-)metastases of melanoma in lymph nodes, and 
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can therefore also contribute to disease staging [15,16,63]. The current limitation is the large 
size of the data when imaging large tissue sections. Yet, the technology is now just able to 
record and analyze images recorded on tissue sections in the cm2 size. Secondly, FITR 
imaging allows the identification and the quantification of lymphocyte subpopulations in the 
tumor microenvironment, providing important additional information to evaluate cancer 
patients. Besides such practical applications, FITR imaging can provide novel insights into 
the complex biology of tissues, promoting research in e.g. immunology, metabolism and 
further fields of bio-medical sciences. 
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Tables 
 
Table 1: Description of the spectral database. For each cell type, the table indicates the 
number of individual spectra, the number of biopsies and the number of patients collected for 
this study. 
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Table 2: Repartition of the patients in the training set and the test set for the two PLS-DA 
models built for the recognition of the five main cell types identified in melanoma metastases: 
melanoma cells, erythrocytes, connective tissue, endothelial cells and lymphocytes (a and b, 
respectively, for the first and second model). Patients are represented by their code and the 
number of biopsies used for each patient is written in brackets. The total number of patients, 
biopsies and spectra used for each set are indicated below each column. 
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Table 3: Validation of the cell type recognition models: a. for the 4 main histological classes 
(epithelial cells, erythrocytes, lymphocytes and connective tissue) and b. for the 2 subclasses 
of epithelial cells (melanoma cells and endothelial cells). The confusion matrix was obtained 
by averaging the two matrices obtained on the two different test sets (see Table 1) and show 
the mean ± standard deviation. 
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Figures 
 
 
Figure 1: Schematic representation of the experimental workflow. 1. Each formalin-fixed and 
paraffin-embedded (FFPE) melanoma metastasis was cut in eight adjacent sections of 5 µm 
thickness. 2. The first section was H&E stained and six of them were immunostained with 6 
antibodies (anti-HMB45, anti-S100, anti-Melan-A, anti-CD19, anti-CD4 and anti-CD8). The 
last one remained unstained and was used to record IR measurements. The stained sections 
were used as references to localize the areas of measurements. 4. For each infrared image 
(composed of 4096 spectra) one hundred spectra of a particular cell type were selected to 
build a spectral database. 
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Figure 2: Mean IR spectra of the main cell types constituting melanoma metastases in lymph 
nodes. Each mean spectrum is the average of at least 2500 spectra. 
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Figure 3: PCA analysis of the infrared spectra of various cell types. a. PCA score plot of the 
500 mean spectra averaged each from around 100 individual spectra. b. Representation of 
the first three PCs: PC1 in blue, PC2 in red and PC3 in green (1800-1000 cm-1 range). The 
variance explained by each PC is indicated (in %) on the axes. 
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Figure 4: Schematic representation of the strategy used for spectral histopathology 
recognition. Three different PLS-DA models were built. A first level model discriminated the 4 
main cell types: epithelial cells, erythrocytes, lymphocytes and connective tissue. A second 
level model distinguished the melanoma cells from the endothelial cells. Finally, a third model 
of second level identified subtypes of lymphocytes: T cells and B cells. 
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Figure 5: Application of two-level models for the identification of cell types. Visible images of 
a H&E stained section of a melanoma metastasis in a lymph node of 2.2x2.2 mm (a), 
HMB45+ immunostained adjacent section (b), CD4+ immunostained section (c), CD19+ 
immunostained section (d) and IR images of the corresponding area of the unstained section 
from which the spectra where predicted with different PLS-DA models. e. A first level model 
was applied to predict the membership of the spectra to one of the 4 main classes and a 
second level model was then applied on the spectra predicted to the epithelial class to 
identify them as belonging to melanoma cells (orange) or endothelial cells (pink). f. 
Application of the third PLS-DA model to identify T cells and B cells. Pixels were 2x2 binned. 
The patient was not included in the training set of any of the three models. 
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Figure 6: Identification of lymphocyte subtypes. a. Visible images of an H&E stained section 
of melanoma metastasis in lymph node. The field of view is 1.5x2.2 mm2 (a), adjacent 
CD19+ immunostained section (b), adjacent CD4+ immunostained section (c), and infrared 
image of the unstained section (d). A K-means clustering analysis was applied on the 
centroids. Each cluster is represented by a color, with the corresponding dendrogram (e). 
Pixels were binned 2x2. 
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Figure 7: Difference spectra obtained in subtracting spectra of the cluster corresponding to B 
cells from the spectra of the cluster corresponding to the T cells for 5 different biopsies (a to 
e). 
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Figure 8: a. PCA score plot of the mean spectra of lymphocytes recorded from 8 metastatic 
lymph nodes (in red) and 8 non-metastatic lymph nodes (in purple) of 8 patients. b. 
Representation of the third principal component responsible for the discrimination. 
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Figure 9: Validation of the PLS-DA model. Each bar of the chart corresponds to one of the 
16 models built to recognize spectra of lymphocytes as belonging to metastatic or non-
metastatic lymph nodes. The bar height corresponds to the percentage of spectra correctly 
predicted as belonging to one of the class. The PLS-DA models were trained on the 1800-
950 cm-1) spectral region. 
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Figure 10: Images of H&E stained sections on areas composed mainly of lymphocytes from 
5 different biopsies (corresponding to the 5 ones presented in Figure 7). The left column 
corresponds to B cells and the right column to T cells. The areas were identified based on 
the adjacent immunostained sections (CD19+ for B cells and CD4+/CD8+ for the T cells). The 
size of each image is around 180 µm x 180 µm corresponding to the size of one IR image. 
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SUPPLEMENTARY DATA 
 
 
 
 
 
 
 
Figure S1: Score plot of the PCA calculated from individual spectra of T cells, B cells and B 
cells from the germinal centers from the database of spectra as described in Table 1.  
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Figure S2: Identification of lymphocyte sub-types by infrared imaging. Visible image of an 
H&E stained section of a melanoma metastasis in lymph node. Image size is 1.5 x2.2 mm2 
(a), CD19+ immunostained section (b), CD4+ immunostained section (c), and IR image of the 
corresponding area of the unstained section from which the spectra where predicted with 
different PLS-DA models (d). A first level model was applied to predict the membership of the 
spectra to one of the 4 main classes, a second level model was then applied on the spectra 
predicted as “epithelial” to identify them as belonging to melanoma cells (orange) or 
endothelial cells (pink). Another second level model was applied to predict membership of 
lymphocytes to B or T cells. Pixels were binned 2x2. The patient was not included in the 
training set of any of the three models. 
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4 Adaptive immune resistance via CSF-1 produced by melanoma cells 
In this study, we investigated the role of CSF-1 in modulating the anti-tumor response in 
ipilimumab-treated patients using IHC and in vitro co-cultures, revealing that melanoma cells 
produce CSF-1 via CTL-derived cytokines when attacked by CTLs, resulting in the 
recruitment of immunosuppressive monocytes. This work was performed in close 
collaboration with Natalie Neubert (Daniel Speiser Group). I contributed by gathering the 
FFPE tissues from ipilimumab treated patients, setting up the staining quantification method 
and analysing the results leading to Figure 3. I also performed CSF-1 quantification in the 
blood of these patients leading to Figure 1 and 4. None of the results presented here are 
published and should therefore be considered as preliminary and confidential.  
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Abstract  
Colony stimulating factor-1 (CSF-1) is a key regulator of monocyte / macrophage migration 
and differentiation, and promotes their pro-tumorigenic functions. CSF-1-receptor (CSF-1R) 
blockade has shown promising results in the treatment of patients with tenosynovial giant cell 
tumors and in mouse models of cancer including melanoma. Here we investigated whether 
CSF-1 plays a role in patients with cutaneous melanoma. We first show that CSF-1 
concentrations were significantly increased in the serum of 14 metastatic melanoma patients 
compared to healthy controls. Subsequently, our in vitro study demonstrates that CSF-1 
remained undetectable in supernatant of melanoma cells, but reached high concentrations 
when co-cultured with melanoma-specific cytotoxic T lymphocytes (CTLs) or stimulated with 
tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ). Furthermore, 
immunohistochemical analysis of primary tumors and metastases revealed that CSF-1 and 
CSF-1R correlated with the frequencies of CD8+ T cells and CD163+ macrophages in the 
tumor microenvironment (TME). Finally, in peripheral blood mononuclear cells (PBMC) of 
these patients, CSF-1 concentrations correlated with CD8+ T cell differentiation and the 
frequency of myeloid-derived suppressor cells (MDSC). Thus, CTLs attacking melanoma 
cells secrete TNFα and IFNγ, which in turn induce CSF-1 production by melanoma cells, 
resulting in the recruitment of immunosuppressive monocytes. These findings support the 
combined use of CSF-1R blockade with T cell based immunotherapy for melanoma patients. 
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Introduction 
CSF-1 and its cognate receptor, CSF-1R, are known to regulate the migration, proliferation, 
differentiation and survival of monocytes, macrophages and their precursors (1). Triggering 
of CSF-1R also drives the recruitment of tumor-associated macrophages (TAMs) and 
promotes the differentiation of TAMs toward an immunosuppressive and pro-tumorigenic 
phenotype (2,3). TAMs represent key orchestrators of various tumor-promoting processes 
and have been identified as an independent poor prognosis factor in several cancer types 
(4). Indeed, clinical studies have shown that treatment with anti-CSF-1R antibody decreased 
CSF-1R+CD163+ TAMs and induces a shift toward higher CD8+/CD4+ T cell ratios in the TME 
of various tumor types (5). Furthermore, overexpression of CSF-1 has been correlated with 
poor prognosis in cancer of the reproductive system such as ovarian, uterine, breast and 
prostate cancers (6). Thus, there is ample evidence that in most types of solid tumors, TAMs 
are involved in tumor progression through their recruitment by CSF-1. 
TAMs can suppress anti-tumor T cells in the TME (7). Recently, two reports using mouse 
melanoma models have observed that blockade of CSF-1R using the CSF-1R kinase 
inhibitor PLX3397 in combination with adoptive T cell therapy improves treatment efficacy as 
compared to single treatments (8,9). Both studies found a strong decrease in F4/80+ TAMs 
as well as an increase of IFNγ secretion by tumor infiltrating CD8+ T cells after combination 
therapy. Importantly, the anti-tumor effect of PLX3397 was dependent on CD8+ T cells. 
Taken together these results suggest that CSF-1R blockade in combination with T cell 
therapy is a promising approach. However, it remains unclear, what triggers the CSF-1 
production and whether CSF-1 also plays a role in human melanoma. 
Here we investigated the role of CSF-1 in the context of anti-cytotoxic T-lymphocyte-
associated protein-4 (CTLA-4) therapy (e.i. ipilimumab) in melanoma patients. We showed 
increased serum levels of CSF-1, and that melanoma cells themselves produced CSF-1. 
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Interestingly, melanoma cells did so only when attacked by CTLs, or when exposed to the 
CTL-derived cytokines TNFα and IFNγ.   
Material and Methods 
1. Patient population and samples 
Human sample collection and use adhered to protocols approved by the Institutional Review 
and Privacy Board of the University Hospital of Lausanne (CHUV, Lausanne, Switzerland) 
(protocol N: 400/11-IPI-Biology) and the local ethics committee. All patients gave informed 
consent prior to study inclusion. Healthy volunteers or patients provided peripheral blood 
withdrawn by using tubes containing Li-heparin–coated beads (Sarstedt). Blood was 
centrifuged for 10 min at 210 × g for plasma preservation, followed by PBMC preparation by 
gradient centrifugation using Lymphoprep (Ficoll equivalent; Axis-Shield). All cells were used 
fresh or after cryopreservation. Viable cell recovery was consistently 85–100%. Patients in 
this study were diagnosed with metastatic melanoma and received a maximum of four cycles 
of 3 mg/kg ipilimumab intravenously every three week upon disease progression with at least 
one prior treatment. Blood samples were withdrawn at baseline, during treatment, 20 day 
after treatment, and then monthly for as long as 14 months after the last ipilimumab dose. 
2. Cell culture 
Melanoma cell lines were generated from metastasis or tumor-infiltrated lymph node 
specimens from HLA-A2+ patients with histologically proven metastatic melanoma and were 
a kind donation from Donata Rimoldi. All melanoma cell lines were MLANA-positive 
(confirmed by FACS) and had dbeen cultured less than 6 months at the time of the 
experiments (<P26). Autologous or HLA-matched MLANA-specific CD8+ T cell clones 
(CTLs) were isolated from melanoma patient blood and amplified by restimulation with PHA, 
irradiated feeder cells, and hrIL-2 (10).  The material originated from the following individuals: 
Melanoma patients listed in Figure 2A (melanoma cell lines), LAU1015 and LAU1185 
(MLANA-specific CTLs), LAU5048 (yellow fever-specific CTLs), and healthy donors 
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(monocytes). 
The complete Medium used was RPMI 1640 - GlutaMAXTM-I, complemented with 10% heat-
inactivated FCS, 1% non-essential amino acids (Gibco), 1% l-glutamine (Gibco), Hepes (10 
mM), and 10,000 U/ml of penicillin/streptomycin (Gibco). Monocytes were enriched from 
whole blood by negative selection using the Rosette Sep (STEMCELL Technologies) (5) and 
cultured in RPMI 1640 - GlutaMAXTM-I plus 10% fetal bovine serum (FBS), 4 mM L-glutamine 
with 100 ng/ml recombinant human (rhu)-CSF-1, or rhuGM-CSF for M2 or M1 macrophages, 
respectively (5). Melanoma culture supernatant was prepared in the same medium without 
additional CSF-1 or GM-CSF. 
3. Flow cytometry 
Data acquisition was performed with a Gallios flow cytometer (Beckman Coulter, 3-laser 
configuration) and the data were processed with FlowJo (Tree Star Inc., v9.7.7). The anti-
human antibodies used were anti-CSF-1R (PE, clone 12-3A3-1B10, eBioscience) and the 
matched isotype control was rat IgG2a, kappa (PE, clone 12-4321-42, eBioscience). 
4. ELISA 
The CSF-1 concentration in culture supernatant and serum samples of ipilimumab-treated 
patients was determined using the human M-CSF Quantikine ELISA kit (R&D Systems) 
according to the kit instructions. The IFNγ concentration was measured by ELISA with anti-
human IFNγ antibodies from Invitrogen (capture antibody: Cat. no. AHC4432; detection 
antibody: Cat. no. AHC4539). 
5. mRNA analysis 
mRNA was extracted from melanoma cells using the Pico Pure™ RNA isolation kit (Arcturus) 
according to the kit instructions and CSF-1 mRNA levels were determined with the 
NanoString nCounter™ technology at the iGE3Genomics platform, University of Geneva. 
The data analysis was done by Charlotte Soneson at the SIB. 
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6. IHC staining and quantification 
IHC was performed on consecutive 4-µm paraffin sections from complete excisions of 8 
primary melanoma and 13 cutaneous melanoma metastasis lesions from 15 patients. The 
tissue samples were acquired before inclusion of these patients in the ipilimumab clinical 
trial. The following primary antibodies were used: rabbit polyclonal anti-CSF-1 (Antigenix 
America), mouse monoclonal anti-CSF-1R (clone 29 pRED, Roche Penzberg), mouse 
monoclonal anti-CD8 (Ventana) and mouse monoclonal anti-CD163 (clone MRQ-26, 
Ventana). Slides were placed on a BenchMark XT slide stainer (Ventana; Roche), for 
deparaffinization, endogenous peroxidase quenching, and epitope retrieval. UltraView 
Universal DAB Detection Kit (Ventana) was used. All stains included a negative control with 
a matched antibody isotype, whereas staining of tonsillar sections served as positive controls 
for all antibodies. 
Stained slides were scanned in a batch format by using the Vectra multispectral imaging 
system (Perkin-Elmer), and lower power field images of the entire tissue were first collected. 
Then, an average of 4 high power fields (HPF) (20x) was chosen in tumor regions with high 
and low infiltrating CD8+ cells respectively (Figure S1). The same regions were selected for 
CSF-1, CD163 and CSF-1R staining. The selected 20× images were subsequently acquired 
and processed by using inForm tissue finder software (PerkinElmer). For unmixing of the 
images and analysis, the spectral libraries of hematoxylin and DAB were generated. For 
CSF-1 and CD8 staining, the HPFs selected were first segmented using the counterstained-
based cell segmentation algorithm and the numbers of positive cells were then calculated 
through nuclei threshold analysis. For CSF-1R and CD163 staining, the HPFs were 
segmented using the object-based cell segmentation algorithm and the numbers of positive 
cells were also calculated through nuclei threshold analysis. Thresholds used to determine 
the cutoff for all four antibodies stains were set visually and approved by a trained 
pathologist. 
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7. Statistics 
Correlation coefficients were computed using Spearman's non-parametric test or with linear 
regression. The non-parametric unpaired Mann–Whitney U test was used to assess 
statistical significance of differences between two data sets, and the non-parametric 
Wilcoxon sign rank test was used for paired samples. Data show the mean ± standard 
deviation of replicates, if not otherwise indicated. For all statistical analyses, asterisks 
indicate *P ≤ 0.05 ; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. Statistical tests in Figure 2 were 
done by David Barras (SIB, Lausanne, Switzerland). 
Results 
We analyzed serum samples from 15 patients with AJCC stage IV or unresectable stage III 
malignant melanoma. 12 healthy blood donors served as controls. Interestingly, in untreated 
melanoma patients, CSF-1 concentrations were statistically significantly increased as 
compared to healthy controls, demonstrating that metastatic melanoma triggers the 
production of CSF-1 (Figure 1A). In contrast, the comparison of patient’s CSF-1 values 
before and after treatment with ipilimumab showed no difference (Figure 1B). However, a 
positive correlation trend was seen between baseline CSF-1 and lactate dehydrogenase 
(LDH) concentration in the serum of ipilimumab-treated patients (Figure 1C), suggesting that 
CSF-1 is increased with progressive disease.  
We determined whether melanoma cells in vitro might contribute to the increased systemic 
CSF-1 levels observed in the blood of melanoma patients.  CSF-1 remained low or 
undetectable in supernatants from melanoma cell cultures  (Figure 2B). However, melanoma 
cells do not act in isolation in vivo but rather in interaction with the TME. Hence, we 
postulated that the immune microenvironment, particularly CTLs, could directly influence and 
induce melanoma cells to secrete CSF-1. Indeed, we found increased CSF-1 concentrations 
in co-cultures of melanoma cell lines with melanoma-specific CTLs, which was confirmed in 
all four cell lines tested. Co-cultures with yellow-fever-specific CTLs did not trigger melanoma 
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CSF-1 secretion, indicating that CTLs must be antigen-specific to trigger CSF-1 secretion by 
melanoma cells.  
We subsequently assessed if the induction of CSF-1 secretion was dependent on a direct 
contact between CTLs and melanoma cells. This was not the case, since TNFα and IFNγ, 
two cytokines that are secreted by activated CTLs induced CSF-1 secretion by six different 
melanoma cell lines in absence of melanoma-specific CTLs (Figure 2C). These results 
indicate that CTL-derived cytokines alone are sufficient to trigger CSF-1 secretion in 
melanoma cells without the need of a direct cell-cell contact. 
To establish the kinetics of this interaction, we then analyzed melanoma cells treated for 
different durations up to three days and using three different CTLs to melanoma cell ratios 
(Figure 2D and E). The more CTLs per tumor cells were seeded, the more IFNγ and CSF-1 
was found in the supernatant. The highest IFNγ concentration in the co-culture was 
measured at 24h whereas the CSF-1 concentration still increased at 72h thus compatible 
with the notion that IFNγ induces CSF-1 secretion. TNFa concentrations in the co-culture 
remained low or undetectable supporting the hypothesis that IFNg is the main trigger for 
CSF1 secretion (data not shown).  
To determine whether CSF-1 protein expression was regulated at the transcriptional level, 
we measured CSF-1 mRNA in melanoma cells after 24h of the above-mentioned different 
treatments. The results confirmed our findings at the protein level, since we found strong 
increases of CSF-1 mRNA in all four tested cell lines when cultured with melanoma-specific 
CTLs or the two cytokines TNFα and IFNγ, but not in presence of negative control CTLs 
(Figure 2F). These data show that the rapid and strong secretion of CSF-1 by melanoma 
cells is transcriptionally regulated. 
Melanoma-derived CSF-1 might either act pro-tumorigenically in a direct manner, by 
autocrine signaling, or indirectly, via a third cell type in the tumor microenvironment. To test 
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whether CSF-1 secreted by melanoma cells could potentially signal back into melanoma 
cells via CSF-1R, we analyzed the expression of CSF-1R on six different melanoma cell 
lines, untreated or cultured in the presence of TNFα and/or IFNγ. No CSF-1R could be 
detected on the melanoma cell lines under any of the tested conditions consistent with the 
idea that CSF-1 might not mediate autocrine signaling on melanoma cells (Figure S2). 
To determine whether CSF-1 triggering by melanoma antigen-specific CTLs or CTLs derived 
cytokines may also occur in vivo in the TME, we quantified the expression of CD8, CSF-1, 
CSF-1R and CD163 in primary tumors and metastases from cutaneous melanoma patients. 
We found that tumor regions of high density of tumor-infiltrating CD8+ T cells showed higher 
CSF-1+, CSF-1R+ and CD163+ cells (Figure 3A and 3C-F) compared to regions of low 
density of tumor-infiltrating CD8+ T cells within the same tumor (Figure 3G-J). Interestingly, 
these positive correlations were also observed when comparing different patients, i.e. the 
ones with high tumor-infiltrating CD8+ T cells to those with low tumor-infiltrating CD8+ T cells 
(Figure 3B).  
Since the presence of activated T cells was associated with increased CSF-1 expression in 
the TME, we determined whether a similar association might also be detectable at the 
systemic level. Therefore we analyzed CSF-1 concentrations and T cell frequencies in the 
blood of patients after ipilimumab therapy. Indeed, CSF-1 concentrations correlated 
statistically significantly with the percentage of effector memory (EM) CD8+ T cells (Figure 
1A), and inversely with the percentage of effector memory RA (EMRA) CD8+ T cells (Figure 
1B), a population of T cells that arise in the absence of antigen (11). The concentrations of 
CSF-1 also correlated significantly with ICOS+ CD8+ T cells (Figure 4C). These cells have 
been shown to correlate with clinical outcome of patients treated with anti-CTLA-4 antibodies 
(reference). Finally, the concentrations of CSF-1 correlated negatively with Granzyme B+ 
CD8+ T cells (Figure 4D). Although difficult to interpret, these findings may suggest that the T 
cells are Granzyme low because of increased killing activity. Overall, our results indicate that 
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specific and functional anti-tumor CD8+ T cell responses trigger the secretion of CSF-1 by 
melanoma cells locally and systematically.  
Discussion 
In this study we demonstrated that melanoma patients have increased CSF-1 serum 
concentrations when compared to healthy donors. Exposure of melanoma cell lines to 
melanoma-specific CTLs or CTL-derived cytokines triggered their expression of CSF-1. This 
suggests that melanoma cells can contribute to the increased systemic CSF-1 levels and that 
this CSF-1 secretion is induced by T cell-derived IFNγ. In line with this observation, T cell-
infiltrated tumor regions contained increased levels of CSF-1 and of CD163+ macrophages. 
Moreover, at the systemic level, increased levels of CSF-1 in patient serum correlated with 
an elevated frequency of CD8 effector memory T cells, a type of T cell that is increased in 
presence of its target antigen. In addition, CD8+ ICOS+ T cells and CD8+ GrzB+ T cells also 
showed correlations with CSF-1 plasma concentrations of melanoma patients. Taken 
together these findings suggest a model in which IFNγ is secreted by melanoma-specific T 
cells upon recognition of their target cells and then induces CSF-1 in neighboring melanoma 
cells. Then, the melanoma cell-derived CSF-1 leads to macrophage recruitment and 
differentiation.  
The latter part of this hypothesis remains to be proven. Two recent reports have analyzed the 
influence of tumor-conditioned medium on macrophages, but their results are not conclusive. 
Solinas et al. found that the conditioned medium of only two out of 16 different cancer cell 
lines influenced monocyte differentiation towards the M2 type and these two pancreatic 
cancer cell lines showed CSF-1 concentrations similar to the concentrations in the 
supernatant of T cell- or cytokine-treated melanoma cells here (12). Three of the non-active 
supernatants in this study were also tested for CSF-1 concentration and showed 
undetectable CSF-1 levels. When CSF-1 was depleted from the supernatant or CSF-1R was 
blocked on monocytes, its differentiation activity was reduced or entirely abolished, 
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suggesting that CSF-1 is the responsible molecule in the cancer cell supernatant for the 
differentiation of monocytes. In contrast, Wang et al. found that upon culture with melanoma-
conditioned medium human monocytes expressed both M1 and M2 markers and neutralizing 
CSF-1 in the melanoma-conditioned medium did not influence the monocyte differentiation 
(13). To date it remains unclear whether melanoma derived factors influence human 
macrophages in a pro- or anti-tumorigenic manner. To shed light on the melanoma cell 
influence on macrophages in the context of immunotherapy, we now plan to culture human 
blood monocytes with supernatant of melanoma cells that had been treated with melanoma-
specific T cells or T cell-derived cytokines.  
In conclusion, our results support the development of melanoma therapy combining CSF-1R 
blockade with T cell immunotherapy. A clinical trial is currently recruiting patients with 
different tumor types, to study the combination of the CSF-1R kinase inhibitor PLX3397 and 
the anti-PD-1 antibody Pembrolizumab (NCT02452424).  
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Figure legend 
Figure 1. CSF-1 concentration is increased in the blood of metastatic melanoma 
patients compared to healthy donors, and correlates with LDH levels. A) CSF-1 
concentrations in sera of healthy donors (n=12) and in patients at baseline, i.e. before 
starting ipilimumab treatment (n=15). Mann-Whitney test. Error bars represent S.E.M B) 
Concentrations of CSF-1 before and after ipilimumab treatment (n=12); Wilcoxon test C) 
Linear regression of lactate deshydrogenase (LDH) concentrations in relation with CSF-1 
concentrations measured at baseline in the serum of melanoma patients. Statistically 
significant differences are highlighted in bold when p values were < 0.05. (Ipi): ipilimumab 
Figure 2. Melanoma cells produce CSF-1 when attacked by Melan-A-specific CTLs but 
not by irrelevant CTLs and this induction is mediated by TNFα and IFN. A) Melanoma 
cell lines were generated from surgery specimens of melanoma patients. B, C and D) CSF-1 
protein concentrations and E) IFNγ protein concentrations in supernatants of melanoma cells 
cultured as indicated for (B) 24h, (C) 48h or up to (D and E) 72h. The co-cultures were 
seeded at the indicated CTL to melanoma cell ratio (x-axis), except from B, where a 1:1 ratio 
was seeded. D) Log2 CSF-1 mRNA expression of melanoma cells after 24h of the indicated 
treatment (n=3). Statistical tests: One-way Anova (B, F) and two-way Anova (C - E); *** P < 
0.001, ** P < 0.01. 
Figure 3. Tumor infiltrating CD8+ T cells are positively associated with CSF-1 
expression and with an enhancement of CSF-1R+ and CD163+ cells in melanoma 
tissues. A) Spearman correlation of CD8 with CSF-1 (left panel), CSF-1R (middle panel) 
and CD163+ cells/mm2 (right panel) calculated per area. B) Spearman correlation of CD8 
with CSF-1 (left panel), CSF-1R (middle panel) and CD163+ cells/mm2 (right panel) 
calculated per patient. Representative images of (C) CD8, (D) CSF-1, (E) CSF-1R and (F) 
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CD163 staining in a tumor region with high CD8+ T cell infiltration and (G) CD8, (H) CSF-1, 
(I) CSF-1R and (J) CD163 staining in a tumor region with low CD8+ T cell infiltration. 
Statistically significant differences are highlighted in bold, when p values were < 0.05. 
Figure 4. CSF-1 serum levels correlated positively with effector memory (EM) CD8+ T 
cells and negatively with effector memory CD45RA+ (EMRA) CD8+ T cells in blood of 
melanoma patients. Linear regression of average CSF-1 concentration in relation with 
average (A) EM, (B) EMRA, (C) ICOS and (D) Granzyme B CD8+ T cell concentrations 
measured in the blood of patients during ipilimumab treatment. (EM): effector memory; 
(EMRA): effector memory CD45RA+ 
Supplementary Figure S1. High and low tumor-infiltrating CD8+ T cell regions defined 
in melanoma patient tissues using Vectra system (Perkin Elmer) 
Supplementary Figure S2. No CSF-1R expression could be detected by flow cytometry on 
untreated or cytokine-treated melanoma cell lines. Six melanoma cell lines were left 
untreated (black non-solid line) or treated with TNFα and/or IFNγ for two days (red solid line). 
The peak with grey fill depicts the isotype control. Untreated monocytes enriched from 
human PBMCs were used as positive control.  
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CONCLUSIONS AND PERSPECTIVES 
This thesis provides multiple insights into the relationships between human melanoma cells 
and their environment. 
In the first and primary objective of this thesis, our novel approach using modern imaging 
tools allowed us to study unusually large tissue areas and quantify the major TME 
components, providing novel data on potential roles of lymphatic vessels and immune cells in 
melanoma pathophysiology. However, our approach remained largely descriptive, and 
provided only limited information on the underlying mechanisms. Being fully aware of these 
limitations, we have proceeded by complementing our studies with collaborations (still 
ongoing) to tackle the local and systemic impact of lymphatic vessels on T cells. In strong 
concerted efforts, we have set in action sophisticated clinical investigation protocols, allowing 
us to obtain a variety of different tissues and fluids from melanoma patients, as described in 
more detail below. 
Tumor-associated lymphatic vessels and their respective draining LNs are associated with 
the modification of the immune profile of the TME. The next step will be to determine how 
lymphatic vessels induce these changes. Many studies have identified alterations in both 
local and regional immune functions in mouse melanoma, which contribute to the expansion 
and metastasis formation. This immune modulation appears to be driven by factors derived 
from the tumor (e.g. VEGF-C, TGF-β) and the lymphatic vessels (CCL21/CCL19). We will 
therefore quantify CCL21 in various patient tissues in order to try to find links between 
VEGF-C and lymphatic vessels. We will also quantify VEGF-C and CCL21 in patient blood 
using ELISA. We hope that the analysis of in situ and systemic expression of these two key 
molecules will further our understanding on their cross-talk in the progression of human 
melanoma. 
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In order to recapitulate in vivo interactions, one must be able to analyze specific cell 
populations within the context of their heterogeneous tissue microenvironment. IHC 
techniques facilitate detection of in situ expression of specific cellular and molecular 
parameters. However, this technique is limited by the number of markers that can be co-
analysed. It is, therefore, difficult to fully characterize the activation/maturation status of 
specific immune cell populations. Furthermore, fresh clinical tissue samples suitable for 
fluorescence-activated cell sorting (FACS) analysis are often difficult to obtain. Alternatively, 
Laser Capture Microdissection (LCM) can be used to address both questions simultaneously: 
in situ localisation and the quantification of expression of multiple molecular entities via real-
time quantitative polymerase chain reaction (qRT-PCR), including properties that are directly 
indicative of cellular functions. LCM technology can harvest the cells of interest directly or 
can isolate specific cells by cutting away unwanted cells to give histologically pure and 
enriched cell populations. We will use LCM to further investigate FFPE tissues and quantify 
the expression of VEGF-C, TGF-β, CCL21 and CCL19, together with other genes that shape 
the TME  (primary tumor, non metastatic and metastatic LNs) in addition to those markers 
already described in objective 1. We hope to obtain insightful data on immune cells as well 
as the surrounding TME of these patients and understand more precisely the local impact of 
lymphatic vessels on the TME. 
Another step towards better defining the local anti-tumor immune response within the tissues 
of these patients would be to accurately characterize the phenotype and the functionality of 
tumor-infiltrating T cells. We have previously collected T cells from tumors of these patients 
and assessed their phenotype and functionality directly ex vivo using multiparameter flow 
cytometry. However, the number of samples for which we had matching tissues analyzed in 
this study was not sufficient for a meaningful evaluation. 
To overcome this limitation, we developed two novel protocols of clinical investigation, with 
the aim to obtain and study several different TME components directly ex vivo upon surgical 
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resection. Firstly, we are currently recruiting patients with primary melanoma (who have not 
received any treatment prior to surgery) and are collecting blood samples and primary 
tumors (fresh tissue and frozen tissues). We will then repeat the experiments described in 
objective 1. As the phenotype and functionality of tumor-infiltrating T cells, as well as 
transcriptome information on tumor and LECs has not been assessed in the LUD 00-018 
study patients (because of the lack of fresh and frozen primary tissues), this protocol will 
allow us to complete this missing information. Thus far, 5 patients in total have been enrolled 
in this study. 
Secondly, for more profound characterization of the TME and the lymphatic vessels, we have 
set-up a collaborative clinical investigation protocol. This protocol involves dedicated 
pathologists, surgeons, clinicians and researchers. A unique aspect of this protocol is the 
new and precise in vivo sampling method used directly in the operating theater. Apart from 
the collection of those tissues described above in protocol one, afferent lymphatic vessels 
and lymph fluid are collected during the SLNs procedure and LN dissection. We are 
determining the composition of the afferent lymph in terms of chemokines, growth factors 
and cytokines using proteomics, and looking at differences between patients with positive 
SLNs and patients with negative SLNs. We are also doing molecular and gene profiling on 
lymphatic vessels and LN tissues. Finally, we will perform IHC (with the same markers 
described in objective 1) on SLN tissues that will not be used for diagnosis. At present, we 
have already enrolled 116 melanoma patients. 
This project joins clinicians and two parallel research laboratories focusing on preclinical 
(Melody Swartz group) and clinical melanoma research (Daniel Speiser group). The potential 
of this collaboration is to translate, from studies in mouse models of an intractable human 
cancer, new knowledge on disease mechanisms with a particular focus on better 
understanding the TME and the associated lymphatic microenvironment and potentially 
identifying targets for novel therapies. 
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In conclusion, the study of immune modulation in cancer is complex and no single method is 
sufficient to cover all aspects. In this thesis, we explored important questions to improve 
understanding and treatment of melanoma by employing diverse methods and biological 
specimens. Such an approach fosters better understanding of the cellular and molecular 
interactions between the different components of the TME and their roles in local and 
systemic immune modulation that drives melanoma formation and progression. Finally, this 
work emphasized the importance of integrative collaborative work between clinicians, 
pathologists and laboratory researchers to develop novel and effective therapies for 
melanoma patients. 
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